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ABSTRACT  
Individuals may be infected with Hepatitis C Virus (HCV) and the Human 
Immunodeficiency Virus (HIV) due to shared routes of transmission. HCV is curable with 8-12 
weeks of direct-acting antiviral (DAA) therapy. However, those with HIV infection must take 
antiretroviral medications (ARV) chronically to suppress viral replication. ARVs and DAAs 
have overlapping clinical pharmacology and are therefore subject to drug-drug interactions. The 
consequences of an unexpected drug interaction with antiviral therapy can be significant and 
include toxicities, therapeutic failure, and/or the development of viral resistance.  
A highly effective and well-tolerated treatment for HCV is ledipasvir/sofosbuvir 
(LDV/SOF; Harvoni®, Gilead Sciences, Foster City, CA). LDV/SOF increases the plasma 
concentrations of the HIV drug, tenofovir. Tenofovir, when given as the tenofovir disoproxil 
fumarate (TDF) prodrug, has been associated with concentration-dependent nephrotoxicity. The 
mechanism for this drug interaction is not entirely clear. It is also unclear whether the increase in 
tenofovir concentrations with LDV/SOF increases the risk of nephrotoxicity in HIV-infected 
patients on TDF-based ARV therapy.  
The focus of this thesis was to study the interaction between tenofovir and LDV/SOF. 
Specifically, the magnitude of the effect of LDV/SOF on tenofovir concentrations in plasma and 
concentrations of the active form of tenofovir, tenofovir diphosphate (TFV-DP), in cells was 
determined in HIV/HCV coinfected persons through two clinical studies. LDV/SOF was found 
to increase tenofovir in plasma by 2-fold, TFV-DP in peripheral blood mononuclear cells by 2.8-
fold, and TFV-DP in dried blood spots by 7- to 18-fold. Patients on an ARV regimen that 
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included a boosting agent (ritonavir or cobicistat) had a smaller increase in TFV-DP (by 36.5%) 
with LDV/SOF. A potential mechanism for the interaction was identified. Concentrations of 
tenofovir monoester, an intermediate in the conversion of the TDF prodrug to tenofovir, were 
increased 5-fold when patients received LDV/SOF relative to TDF alone. Lastly, whether this 
drug interaction appeared to increase the risk of tenofovir-associated nephrotoxicity was 
determined. LDV/SOF trended towards increasing concentrations two proximal tubulopathy 
biomarkers, urinary retinol binding protein adjusted for creatinine (RBPCr) and urinary beta-2 
microglobulin adjusted for creatinine (β2MGCr). The increase was greater in those on ritonavir-
boosted atazanavir compared with ritonavir-boosted darunavir. Those on ritonavir-boosted 
atazanavir had 70% higher RBPCr with LDV/SOF and 200% higher β2MGCr. 
These data indicate the presence of a drug interaction with LDV/SOF and TDF which 
results, at least in part, from increased tenofovir monoester delivery to cells. The interaction may 
cause proximal tubulopathy, a risk that appears greater in those on ritonavir-boosted atazanavir.  
The form and content of this abstract are approved. I recommend its publication. 
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CHAPTER I 
OVERVIEW, FRAMEWORK, PREMISE  
Overview 
 In the past 5 years, several new drugs have received regulatory approval for the treatment 
of Hepatitis C virus (HCV). These new treatments, called direct acting antivirals (DAAs), are 
administered orally, are well-tolerated, and cure roughly 90% of those treated with 8 or 12 weeks 
of therapy.1 Prior to the introduction of DAAs, many patient populations were ineligible for 
therapy, unable to tolerate treatment, or were treated, but not cured. These limitations created 
barriers to treatment for many patients. DAAs eliminated these barriers, but new treatment 
considerations exist. One important consideration in the use of DAAs is the identification and 
management of potential drug-drug interactions. This is of particular importance for individuals 
who are co-infected with the human immunodeficiency virus (HIV). HCV and HIV are blood 
borne infections, and thus, individuals may be infected with both viruses due to shared routes of 
transmission. Individuals with HIV infection take antiretroviral (ARV) medications to 
chronically suppress viral replication. ARV agents and DAAs have overlapping clinical 
pharmacology and are therefore subject to drug-drug interactions.2 The consequences of an 
unexpected drug interaction with antiviral therapy are significant. High exposures may result in 
toxicities and low exposures may result in therapeutic failure and the development of viral 
resistance, which may make current and future therapies less effective.  
 A highly effective and well-tolerated treatment for HCV is ledipasvir/sofosbuvir 
(LDV/SOF; Harvoni®, Gilead Sciences, Foster City, CA). LDV/SOF is administered as one pill 
once daily. It has a low potential for drug interactions, but is not devoid of interactions. 
LDV/SOF has been shown to increase the plasma concentrations of the HIV drug, tenofovir. 
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Tenofovir is associated with concentration-dependent nephrotoxicity. The mechanism for this 
drug interaction is not entirely clear. It is also unclear whether the increase in tenofovir 
concentrations with LDV/SOF increases the risk of renal toxicity in HIV-infected patients on 
tenofovir-based antiretroviral therapy who receive 12 weeks of LDV/SOF for the treatment of 
HCV.  
The focus of this thesis was to study the interaction between tenofovir and LDV/SOF. 
Specifically, the magnitude of the effect of LDV/SOF on tenofovir concentrations in plasma and 
concentrations of the active form of tenofovir, tenofovir diphosphate (TFV-DP), in cells was 
determined. Concentrations of tenofovir monoester, an intermediate in the conversion of TDF to 
tenofovir, were determined before and after LDV/SOF treatment to shed light on a potential 
mechanism for the interaction. Lastly, the relationship between tenofovir and TFV-DP 
concentrations and markers of renal tubular toxicity was modeled to determine the 
pharmacokinetic-dynamic consequences of this drug interaction.     
Hepatitis C Virus 
 HCV is a single-stranded RNA flavivirus that infects the liver. HCV is transmitted 
through injection drug use, the reuse or inadequate sterilization of medical equipment, and the 
transfusion of unscreened blood or blood products. Sexual transmission is limited to high-risk 
sexual practices with significant blood exchange. Mother to child transmission occurs at a rate of 
~5%. Following initial HCV infection, 80% of people do not exhibit any symptoms. The vast 
majority of individuals infected with HCV, about 85%, will fail to clear the virus naturally and 
will develop chronic infection, which may progress to cirrhosis.3 Approximately 6% of cirrhotic 
individuals will develop symptoms of decompensated liver disease (e.g., ascites, hepatic 
encephalopathy, and/or variceal bleeding) each year and 4% will develop hepatocellular 
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carcinoma. These long-term complications carry a high risk of mortality and generally occur 
more than 20 years after infection.4 
Globally, approximately 71 million people have chronic HCV, for a global prevalence of 
1.0%.5 Central Asia (1.9%-6.4%), Egypt (6.3%), Gabon (7.0%), Romania (2.5%), and Russia 
(3.3%) have the highest prevalence of this disease. Only 20% (or 14 million) are aware of their 
diagnosis.3 There are approximately 400,000 HCV-related deaths annually worldwide.3  
In the United States, there are approximately 3.5 million people living with HCV, for a 
prevalence of 0.9%.6-8 Three quarters of those living with HCV are “baby boomers” born between 
1945 and 1965. Recent data suggest the number of new HCV infections has tripled since 2012, 
reaching a 15-year high of 33,900 new HCV cases in 2015.9  The majority of new infections are 
in those 20-29 years of age who inject(ed) drugs. This increase is attributed to the heroin epidemic.  
Genetic Heterogeneity of HCV 
HCV exhibits remarkable within- and between-subject genetic heterogeneity, which is a 
major obstacle to the development of a universal preventative vaccine. Six HCV genotypes have 
been identified.10 HCV strains belonging to different genotypes differ at 30-35% of nucleotide 
sites.11 Within each genotype, HCV is further classified into subtypes that differ at <15% of 
nucleotide sites. Amongst genotypes, transmissibility does not seem to differ, whereas the rate of 
disease progression and response to treatment with current therapies does differ. Globally, 
genotype 1 is most prevalent 11, followed by genotype 3. Genotypes 2, 4, and 6 together account 
for 25% of those living with HCV. Within the U.S., 75% of HCV isolates are genotype 1a or 1b, 
and the remainder are primarily genotype 2 or 3.12  
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The HCV Genome and Life Cycle 
The HCV genome consists of a positive-sense single-stranded RNA, ~9600 nucleotides 
long, which encodes three structural proteins (core, E1, and E2), the ion channel protein p7, and 
six non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B).13 Figure 114 shows the 
life-cycle of HCV. HCV replicates entirely within the cytoplasm; it does not establish latency; and, 
it is curable (i.e., can be eradicated). Cure of HCV is synonymous with achieving a sustained 
virologic response (SVR). SVR is defined as having no measurable HCV RNA in the blood 
following the cessation of treatment. With current therapies, SVR is assessed 12 weeks following 
treatment cessation. Achieving SVR decreases the progression of liver disease and reduces liver-
related and all-cause mortality.15,16   
HCV Drug Targets  
For many years, HCV was treated with a prolonged regimen of subcutaneously-
administered interferon α or pegylated interferon α (PegIFN α) with or without the purine 
nucleoside analog ribavirin. SVR rates with this therapy were low (40-60%) and tolerability was 
poor. Now several antivirals that directly target various steps in the HCV lifecycle (so called 
“direct acting antivirals” or DAAs) are the mainstay of HCV treatment. DAAs are administered 
orally, have few side effects, are taken for a period of 8 or 12 weeks, and achieve SVR rates of at 
least 90% in most patient populations. Use of PegIFN α for the treatment of HCV has been replaced 
by DAAs, though ribavirin is still used in combination with DAAs to improve SVR rates in certain 
clinical scenarios.  
Detailed knowledge of the HCV life cycle and the structures of HCV proteins has permitted 
development of targeted inhibitors of HCV replication and revolutionized pharmacotherapy of 
HCV infection. Available DAAs target three major sites in the HCV lifecycle: the NS3 protease, 
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the NS5B polymerase, and NS5A.17-19 Inhibition of the NS3 protease prevents the cleavage of the 
viral polyprotein and formation of the replication complex. The NS5B enzyme is essential for 
HCV replication as it catalyzes the synthesis of the complementary minus-strand RNA and 
subsequent genomic plus-strand RNA. There are two types of NS5B RNA-dependent RNA 
polymerase inhibitors: nucleotide and non-nucleoside inhibitors. The nucleotide inhibitors are 
active site inhibitors, whereas the non-nucleoside inhibitors are allosteric inhibitors. Another 
target, NS5A, encodes a protein that appears essential to the replication machinery of HCV and 
critical in the assembly of new infectious viral particles.20 However, the specific functions of this 
protein have not been established.  
HCV Treatment Approach 
  In 2011, the first DAAs, telaprevir and boceprevir, received regulatory approval. 
Telaprevir and boceprevir were NS3 protease inhibitors. They received regulatory approval for 
use in combination with PegIFN α and ribavirin. Although they increased SVR rates in treatment 
naïve patients by roughly 30%, they were associated with significant toxicities and unfavorable 
clinical pharmacology. In 2013, these drugs were replaced with the NS5B nucleotide polymerase 
inhibitor, sofosbuvir (SOF). SOF was initially approved for use in combination with PegIFN α 
and ribavirin, however it was primarily used off-label with the NS3 protease inhibitor, 
simeprevir. Simeprevir plus sofosbuvir was the first interferon-free DAA combination available 
for use in patients with genotype 1 HCV. In 2014, sofosbuvir was approved in a fixed dose 
combination tablet with the NS5A inhibitor, ledipasvir (LDV/SOF, Harvoni®, Gilead Sciences, 
Foster City, CA). LDV/SOF offered major advantages over prior treatments including one pill 
once daily administration, minimal drug interactions, and good tolerability. LDV/SOF in 
combination with ribavirin is also safe and effective in patients with decompensated liver disease 
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who were ineligible for interferon-based treatment and could not safely use 
simeprevir/sofosbuvir because of higher simeprevir exposures in those with advanced liver 
disease. LDV/SOF is FDA approved for the treatment of individuals with HCV genotypes 1, 4, 5 
and 6. In addition to LDV/SOF, several other efficacious and well-tolerated DAA combinations 
are now available as shown in Table 1.  
General Overview of Sofosbuvir Pharmacology 
Sofosbuvir (SOF) is a NS5B polymerase inhibitor. SOF is used in combination with other 
DAAs with or without ribavirin for the treatment of HCV. SOF is administered as a 
phosphoramidate pro-drug of the uridine nucleotide analog GS-331007 mono-phosphate.21 Once 
inside cells, SOF is hydrolyzed by cathepsin A, carboxylesterase 1, and histidine triad nucleotide 
binding protein 1 to GS-331007 monophosphate.21,22 GS-331007 monophosphate is then 
phosphorylated by uridine monophosphate-cytidine monophosphate kinase to the GS-331007 
diphosphate form, which is then phosphorylated by nucleotide diphosphate kinase to the 
triphosphate moiety (GS-461203).21,22 GS-461203 (also known as GS-331007 triphosphate) is 
the active form of SOF. When GS-461203 is incorporated into HCV RNA by the NS5B 
polymerase instead of the endogenous nucleotide base (uridine triphosphate), HCV replication is 
halted. The primary drug-related material circulating in plasma is GS-331007. GS-331007 is not 
taken up by cells. GS-331007 has no antiviral activity. Figure 2 shows the clinical pharmacology 
of SOF.  
The absolute bioavailability of SOF has not been determined, but is estimated to be at 
least 80% based on recovery of SOF and its primary metabolite, GS-331007, following 
administration of a radiolabeled dose.22 A high fat meal increases SOF area under the curve 
(AUC) by 67-91%, but the increase is not thought to increase the likelihood of toxicities based 
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on the wide therapeutic index of the drug.22  The drug is approved to be taken without regard to 
food. SOF is 61-65% protein bound, and is primarily (80%) renally excreted.23 The half-life of 
SOF in plasma is short, 0.4 hours. The half-life of the GS-331007 metabolite in plasma is 27 
hours. The half-life of GS-461203 in peripheral blood mononuclear cells and red blood cells was 
26 and 69 hours, respectively.24  
SOF AUC is increased 226% (90% CI 139%-367%) and 243% (90% CI 150%-396%) in 
patients with moderate and severe hepatic impairment (i.e., Child Pugh B and C), respectively, 
but GS-331007 AUC is unchanged, and no dose adjustment is needed for this population. In fact, 
SOF, in combination with other agents such as ribavirin and NS5A inhibitors, is the preferred 
treatment for individuals with decompensated cirrhosis. In contrast, SOF and GS-331007 
pharmacokinetics are affected by renal impairment, and use of this drug is limited in this 
population. SOF AUC is 161% (90% CI 109%-239%), 207% (90% CI 139%-307%), and 271% 
higher (90% CI 183%-402%) in mild (GFR > 50 and < 80 mL/min/1.73m2), moderate (GFR >30 
and < 50 mL/min/1.73m2) and severe (GFR < 30 mL/min/1.73m2) renal impairment, 
respectively, whereas GS-331007 AUC is increased 154% (90% CI 114% - 208%), 164% (90% 
CI 122%-222%) and 292% (90% CI 217% - 395%) in mild, moderate, and severe renal 
impairment respectively.22,25 Studies are ongoing to evaluate the safety and appropriate dosing of 
SOF in individuals with renal impairment.  
SOF is not a substrate, nor does it inhibit or induce any cytochrome P450 (CYP) enzymes 
and therefore has a low potential for drug interactions. However, SOF is a substrate for the efflux 
transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).25 Potent 
inducers of P-gp or BCRP (e.g., carbamazepine, rifampin or St. John’s wort) should not be used 
with SOF. When combined with amiodarone, patients receiving SOF with other DAAs have had 
26 
serious symptomatic bradycardia. The mechanism for this appears to be disrupted intracellular 
calcium handling and is pharmacodynamic rather than pharmacokinetic in nature.26 The 
combination should be avoided.27  
General Overview of Ledipasvir Pharmacology 
Ledipasvir (LDV) is an NS5A inhibitor. This compound is only available as part of a 
fixed dose combination tablet with SOF. The bioavailability of LDV in humans is unknown, but 
ranges from 30-50% in rats, monkey and dogs. LDV concentrations are similar when given 
fasted vs. with a moderate (600kcal) or high (1000kcal) fat meal. LDV is greater than 99.8% 
bound to human plasma proteins and LDV is primarily eliminated unchanged in the feces. 
Approximately 30% is metabolized, though the precise enzymes involved are uncertain. LDV is 
a substrate for and also inhibits P-gp and BCRP. LDV pharmacokinetics are not significantly 
altered by hepatic or renal impairment, but since the drug is coformulated with SOF, the same 
limitations on use in those with renal impairment apply.25 The half-life of LDV in plasma is 47 
hours.  
LDV relies on an acidic environment for optimal absorption, thus gastric acid modifiers 
should be used with caution. In one large cohort, use of proton pump inhibitors (PPI) was found 
to be an independent predictor of relapse to LDV/SOF treatment.28 If gastric acid modifiers must 
be used, temporal separation (two separate dosing times) is necessary with antacids (by 4 hours). 
Histamine-2 receptor antagonists (e.g., famotidine, ranitidine) and PPI (omeprazole, 
lansoprazole, etc.) doses should not exceed the equivalent of 40mg famotidine twice daily and 
20mg omeprazole once daily, respectively. The PPI must be administered simultaneously with 
LDV/SOF in the fasted state.29 Given that LDV inhibits P-gp and BCRP, LDV may increase the 
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concentrations of rosuvastatin (an organic anion transporting polypeptide 1B1 (OATP1B1) and 
BCRP substrate), thus this combination is not recommended.30  
HIV/Hepatitis C Coinfection 
Approximately one third of individuals living with the human immunodeficiency virus 
(HIV) are co-infected with the Hepatitis C virus (HCV) due to shared routes of transmission.31,32  
HIV accelerates the progression of HCV disease. Individuals with HIV coinfection have higher 
HCV RNA, a more rapid progression of fibrosis, and an increased frequency of liver 
decompensation and death.33-36 Due to the increased risks associated with HIV coinfection, 
treatment guidelines consider this patient population a “high priority” for HCV treatment.1,37 
HIV coinfected individuals were less likely to achieve SVR with PegIFN α plus RBV 
compared with HCV monoinfected individuals38, however this is not the case with newer DAAs.  
Multiple studies indicate similar SVR rates in trials of HIV coinfected individuals to those 
observed in trials of HCV monoinfected individuals.39  Thus, the primary consideration in 
treating HCV in individuals with HIV coinfection is avoidance of unfavorable drug interactions 
between DAAs and antiretroviral agents. Table 2 shows interactions between ARVs and DAAs. 
Drug Interactions with DAAs and ARVs 
 In Table 2, cells are shaded to indicate the safety of the ARV and DAA combination. 
Green indicates coadministration is safe; yellow indicates a dose change or additional monitoring 
is warranted; and red indicates the combination should be avoided. ARV regimens that include 
pharmacokinetic boosters (ritonavir or cobicistat) have the greatest potential for interaction with 
DAAs. DAA regimens that include an HCV protease inhibitor are particularly problematic with 
boosters. Thus, the ARV combinations that can be safely coadministered with the HCV protease 
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inhibitors are limited. DAA treatments that include SOF and an NS5A inhibitor (i.e., LDV/SOF 
or SOF/velpatasvir) have the lowest potential for interactions with ARV. However, LDV/SOF 
and SOF/velpatasvir are problematic with the HIV nucleotide reverse transcriptase inhibitor, 
tenofovir, when given as tenofovir disoproxil fumarate (TDF). Tenofovir causes concentration 
dependent nephrotoxicity.40-42 When given as TDF, LDV/SOF and SOF/velpatasvir may increase 
the risk of nephrotoxicity with certain concomitant antiretrovirals. LDV/SOF and 
SOF/velpatasvir appear less problematic with the newer tenofovir prodrug, tenofovir 
alafenamide (TAF).30,43  
SOF alone was studied with ritonavir-boosted darunavir, raltegravir, rilpivirine, and the 
fixed dose combination of TDF/emtricitabine/efavirenz, in healthy volunteers.44 There were 
minimal changes in the pharmacokinetics of the ARV, SOF, and GS-331007. Raltegravir AUC 
was reduced by 17% (90% CI 9%-41%) and tenofovir Cmax was increased by 25% (90% CI 
8%-45%) with no change in the tenofovir AUC. SOF and GS-331007 AUC were increased 37% 
(90% CI 16%-62%) and 19% (90% CI 13%-25%), respectively with ritonavir-boosted darunavir; 
while GS-331007 AUC and Cmax were reduced 17% (90% CI 9% to 25%) and 23% (90% CI 
16% to 30%), respectively with the fixed dose combination of TDF/emtricitabine/efavirenz. 
These changes are unlikely to have clinical relevance, but interactions must be considered with 
the DAAs that will be administered with SOF.  
LDV has been studied with several ARV agents. The CYP3A inducer, efavirenz, reduces 
LDV concentrations by 34% (90% CI -41% to -25%) and the pharmacokinetic enhancer 
cobicistat increases LDV concentrations by 79% (90% CI 64%-96%), but given the rather wide 
therapeutic index of LDV, these changes are not expected to have clinical relevance.30  The only 
potentially clinically significant interaction with LDV/SOF is with the HIV nucleotide analog, 
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tenofovir, when administered as TDF. LDV increases tenofovir exposures which may increase 
the risk of renal toxicity in patients with renal impairment or in those with normal renal function 
taking TDF with a ritonavir-boosted protease inhibitor or cobicistat.30 Figure 3 shows the 
exposures of tenofovir when given as TDF with various ARV both with and without LDV/SOF. 
As the figure indicates, in combination with ritonavir, which already increase tenofovir 
exposures, the addition of LDV/SOF may result in tenofovir exposures exceeding those with 
established renal safety data. Chapter II describes the clinical pharmacology and the renal 
toxicities associated with tenofovir. 
Premise for this Work 
 Tenofovir-based ARV regimens are available worldwide. TDF is a recommended 
component of initial HIV treatment in the United States Department of Health and Human 
Services45 and the World Health Organization guidelines for the treatment of HIV46. TDF is 
highly efficacious and well tolerated. TDF is available in developing countries at a cost as low as 
$3.60 per month.47 TDF has also recently become available generically in the United States. 
LDV/SOF is a recommended HCV treatment according to the American Association for 
the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA),1 European 
Association for the Study of the Liver37, and WHO treatment guidelines48. LDV/SOF has been 
sold to makers of generic drugs in developing countries in an effort to offer this treatment at a 
substantially lower price compared with the price in the United States.49 In India, LDV/SOF is 
$4 per pill.  
TDF and LDV/SOF will be administered concomitantly around the world. Thus, data are 
needed to determine the pharmacokinetics and safety of this combination in individuals with 
HIV/HCV coinfection. However, there is cautionary wording on use of this combination in the 
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AASLD/IDSA guidelines. At the time this thesis was conceived, the cautionary wording was as 
follows:   
“Because ledipasvir increases tenofovir levels, when given as tenofovir disoproxil fumarate 
(TDF), concomitant use mandates consideration of estimated glomerular filtration rate (eGFR) and 
should be avoided in those with eGFR below 60 mL/min. Because potentiation of this effect 
occurs when TDF is used with ritonavir-boosted or cobicistat-boosted regimens, ledipasvir should 
be avoided with this combination (pending further data) unless antiretroviral regimen cannot be 
changed and the urgency of treatment is high.” 
  
Although ARV regimens that do not contain ritonavir or cobicistat are available, there are 
risks associated with modifying ARV therapy in individuals who are stable, suppressed, and 
tolerating their current regimen. Additionally, one study found 40% of HIV/HCV coinfected 
patients undergoing evaluation for HCV treatment were unable to switch to an ARV regimen that 
did not contain an HIV protease inhibitor.50  
The overall goal of this work was to generate data on the pharmacokinetics and renal 
safety of tenofovir with LDV/SOF in HIV/HCV coinfected patients. Prior studies indicated 
LDV/SOF increased the plasma concentrations of tenofovir when given as TDF, but the 
mechanism for this interaction was unclear and the magnitude of the increase in tenofovir 
exposures differed based on concomitant ARVs. There are limited data on the effects of 
LDV/SOF on tenofovir pharmacokinetics in HIV/HCV coinfected individuals taking TDF with 
the pharmacokinetic enhancers ritonavir or cobicistat as part of their ARV therapy. Data are also 
lacking on the effects of LDV/SOF on the intracellular concentrations of the active form of 
tenofovir, tenofovir diphosphate (TFV-DP). It is also unknown whether LDV/SOF treatment 
causes changes in renal function or renal damage in patients on TDF. The following aims were 
developed to address these knowledge gaps:  
1. Determine the impact of LDV/SOF on plasma tenofovir and intracellular tenofovir 
diphosphate (TFV-DP) concentrations in HIV/HCV-coinfected patients receiving TDF.  
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2. Compare tenofovir disoproxil and tenofovir monoester concentrations in the plasma 
before and during LDV/SOF treatment in patients with HIV/HCV coinfection receiving 
TDF.   
3. Model the relationship between changes in tenofovir and tenofovir-diphosphate 
pharmacokinetics and renal function in HIV/HCV coinfected patients on TDF before, 
during and after treatment with LDV/SOF.  
Chapter II includes a detailed summary of tenofovir pharmacology, drug interaction 
potential, nephrotoxicity, and mechanisms for assessing tenofovir-induced nephrotoxicity, 
providing additional context for the aims, approach, and findings of this research.    
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Table 1  
FDA-Approved Direct Acting Antiviral Combinations for the Treatment of Hepatitis C Virus 
(2019). Components of the Fixed Dose Combination Products are Listed by Mechanism of 
Action. 
 Components of the Fixed Dose Combination Product 




NS5A Inhibitors NS5B Polymerase 
Inhibitors 
Epclusa®  Velpatasvir Sofosbuvir 
Harvoni®  Ledipasvir Sofosbuvir 
Viekira Pak® Ritonavir-boosted 
Paritaprevir 
Ombitasvir Dasabuvir 
Zepatier® Grazoprevir Elbasvir  
Mavyret® Glecaprevir Pibrentasvir  




Table 2  
Drug Interactions Between Preferred DAAs and Antiretroviral Drugs (modified from 
www.hcvguidelines.org, author J Kiser). When no drug interaction study has been performed, 
this is indicated as “ND” which stands for no data. Cells with “ND” are shaded based on the 































Atazanavir A A    
Boosted 
Darunavir A A 
   
Boosted 
Lopinavir  ND,






Doravirine  ND  ND ND 
Efavirenz     ND ND 
Rilpivirine       















C C   C 
Dolutegravir      ND 
Raltegravir      ND 





Abacavir  ND ND  ND 
Emtricitabine      




B, C B, C   C, D 
Tenofovir  
alafenamide D D ND 
 D 
ND, No data, A Caution with tenofovir disoproxil fumarate, B Increase in tenofovir depends on which additional 
concomitant antiretroviral agents are administered, C Avoid tenofovir disoproxil fumarate in patients with an eGFR <60 
mL/min; tenofovir concentrations may exceed those with established renal safety data in individuals on ritonavir- or 
cobicistat-containing regimens, D Studied as part of fixed-dose combinations with ledipasvir/sofosbuvir or 
sofosbuvir/velpatasvir plus TAF, emtricitabine, elvitegravir, and cobicistat.
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Figure 1. The Hepatitis C life cycle. Figure made by Jennifer Kiser, published in Goodman & 






Figure 2. Pharmacology of Sofobuvir, hCE1=carboxylesterase 1, CatA=cathepsin A, HINT-1, 
histidine triad nucleotide-binding protein 1, UMP-CMPK= uridine monophosphate-cytidine 
monophosphate kinase, NDPK=nucleoside diphosphate kinase, GS-461203 (also known as GS-
331007 triphosphate or 007-TP) is the active antiviral, NS5B=non-structural 5B polymerase. 
Figure made by Jennifer Kiser, published in Goodman & Gilman’s Pharmacologic Basis of 




Figure 3.  Mean (SD) tenofovir area under the concentration time curve (AUC) 
in plasma with various antiretroviral agents in the presence and absence of 
LDV/SOF in studies of healthy volunteers. The upper range of tenofovir 
exposures observed in healthy volunteers given the combination of LDV/SOF, 
tenofovir disoproxil fumarate, and a ritonavir-boosted protease inhibitor (either 
ritonavir-boosted atazanavir or darunavir) exceeds tenofovir exposures with 
established safety data. This figure courtesy of Gilead Sciences data on file. 
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CHAPTER II   
REVIEW OF THE LITERATURE 
Tenofovir  
Tenofovir Pharmacology 
 Tenofovir [(R)-9-(2-phosphonylmethoxypropyl)adenine] is an acyclic nucleoside 
phosphonate. The molecular weight of tenofovir is 287 kd. Tenofovir is ionized and polarized 
and therefore has low oral bioavailability (~13%).51 Formulating tenofovir as a bi-ester prodrug, 
tenofovir disoproxil fumarate (TDF), improved tenofovir bioavailability to 25% (fasted) and 
40% (fed). TDF has a molecular weight of 635.52 kd. TDF masks the two negative charges of 
tenofovir with the addition of isopropyloxycarbonyloxymethyl moieties. This increases the 
drug's lipophilicity, thus improving its membrane permeability, allowing for oral administration.  
Administration of TDF with a high fat meal (~ 700–1000 kcal containing 40–50% fat) 
increased tenofovir area under the concentration-time curve (AUC) and maximum concentration 
(Cmax) by 40% and 14%, respectively.52 Fatty food may reduce TDF hydrolysis by acting as an 
alternative substrate for endogenous lipases and esterases.53 Food also increases the time to 
maximum serum concentration (Tmax) from 1 hour in the fasted state to 2 hours.52 Tenofovir 
exposures with a light fat meal were similar to exposures when given in the fasted state.  
Tenofovir disoproxil (molecular weight 519 kd) is converted to tenofovir via diester 
hydrolysis. In Caco-2 cells, 76% of the total tenofovir disoproxil administered on the apical side 
appeared on the basolateral side as the monoester, indicating tenofovir disoproxil undergoes 
significant hydrolysis in the cell.54 Conversion to tenofovir may occur in the intestinal mucosa55, 
blood and/or liver54,56 as esterases are present in all of these cell and tissue types. 
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Early studies in Caco-2 cells indicated that tenofovir disoproxil was converted to the 
monoester when incubated with carboxylesterase (CES) and the monoester was then converted to 
tenofovir when incubated with a phosphodiesterase.54 In dog plasma and tissue homogenate, the 
monoester was the major degradation product and CES appeared to be the esterase involved in 
the initial hydrolysis.56 Subsequent studies indicated a variety of esterases - not just 
carboxylesterases and phosphodiesterases - can hydrolyze TDF to tenofovir. Strawberry extract 
and other ester mixtures inhibit TDF hydrolysis in intestinal extracts presumably through 
competition for esterases, though results are confounded in that some of these extracts and 
mixtures are also P-gp substrates.55,57 TDF is a P-gp substrate.58 Lipases also hydrolyze TDF, 
with a recent physiologic-based pharmacokinetic model showing a greater impact of lipase 
inhibitors on preventing TDF hydrolysis compared with P-gp or carboxylesterase inhibitors.51,53 
Substrate specificities of lipases and carboxylesterases show significant overlap.53 A study to 
evaluate generally recognized-as-safe (GRAS) excipients as potential inhibitors of TDF 
hydrolysis found that propylparaben (a carboxylesterase 2 substrate) increased apical to 
basolateral TDF transport by 22.8-fold, indicating the importance of CES2 in TDF hydrolysis.  
Carboxylesterase enzymes add water to an ester group producing a carboxylic acid and 
an alcohol. This makes the compounds more polar and promotes renal elimination. At least six 
carboxylesterase enzymes have been identified, with CES1 and CES2 being the most important 
pathways of drug metabolism. The most common drug substrates for carboxylesterase enzymes 
are ester prodrugs specifically designed to enhance oral bioavailability. These prodrugs must be 
hydrolyzed to their active carboxylic acid by hydrolysis after absorption from the gastrointestinal 
tract. Agents from a number of therapeutic classes including angiotensin-converting enzyme 
inhibitors, angiotensin-receptor blockers, antiplatelets, HMG-CoA reductase inhibitors, 
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antivirals, and central nervous system agents utilize carboxylesterases for activation.59 
Carboxylesterases lack substrate specificity, and drug substrates are susceptible to hydrolysis by 
either carboxylesterase. However, one usually serves as the major pathway of hydrolysis and is 
dependent on the structure of the ester. The CES1 enzyme prefers esters with a large, bulky acyl 
group and a small alcohol group, while CES2 has the opposite preference, small acyl group, but 
large alcohol group. Carboxylesterases are located in the cytoplasm and endoplasmic reticulum 
of numerous tissues including the liver, small intestine, kidney and lungs, but the greatest 
amounts are found in the liver and small intestine where they contribute to first pass metabolic 
hydrolysis of substrates. CES1 and CES2 are expressed in the liver, but levels of CES1 greatly 
exceed those of CES2.59 In the intestine, only high levels of CES2 are expressed.59 There are 
limited data on esterase expression/activity in plasma and cells. One study with C14-labeled TDF 
in dogs found the esterase activity in plasma, intestinal, and liver homogenate to be 7.8, 12.2 and 
43 IU/mL, respectively.60 Several compounds have been shown to inhibit carboxylesterases and 
some result in clinically significant interactions (e.g., ethanol and cocaine).61,62 Genetic variation 
in CES1 and CES2 have been described and studies have identified pharmacogenomic-kinetic 
and pharmacogenomic-dynamic associations for CES substrates. There are more data for CES1 
substrates compared with CES2, but findings to date are from small studies with conflicting 
results in some cases.63  
The mechanism(s) by which tenofovir enters cells has not been fully elucidated. TDF is 
presumed to enter via passive diffusion, whereas endocytosis and transporter-mediated uptake 
have been observed in vitro with tenofovir.64 In terms of the transporters responsible for 
tenofovir uptake, concentrative and equilibrative transporters, which are ubiquitously expressed, 
likely play a role. Tenofovir is also a substrate for the renal uptake transporters organic anion 
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transporter 1 and 3 (OAT1 and OAT3). OAT1 and OAT3 mediate the nephrotoxicity of 
tenofovir.   
Mechanism of Action and Intracellular Phosphorylation  
 Unlike the nucleoside analogs, which require three sequential phosphorylation steps to 
the active moiety, tenofovir is a nucleotide. It already contains a phosphonate group attached to 
the adenine base. This bypasses the initial, rate-limiting phosphorylation step and only two 
phosphorylation steps are needed to produce the active moiety, tenofovir diphosphate (TFV-DP). 
TFV-DP competes with endogenous deoxyadenosine 5’-triphosphate for incorporation into 
replicating virus.52 If TFV-DP is incorporated, it terminates chain elongation and interrupts DNA 
synthesis in the reverse transcriptase. Phosphorylation to tenofovir monophosphate is mediated 
by adenylate kinase 1 or 2 and formation of tenofovir diphosphate is mediated by nucleoside 
diphosphate kinase, creatine kinase, or pyruvate kinase. Conversion of TDF to tenofovir with 
subsequent intracellular phosphorylation to TFV-DP is shown in Figure 4. 
Tenofovir Pharmacokinetics 
 After administration of intravenous tenofovir, the volume of distribution is ~1.2 L/kg. 
Based on population pharmacokinetic modeling, the volume of distribution of tenofovir 
following a 300mg oral dose of TDF is 0.813 L/kg. Protein binding in vitro is less than 7%. The 
pharmacokinetics of tenofovir are dose-proportional and similar in HIV seronegative and 
seropositive individuals. Mean (SD) steady state tenofovir AUC and Cmax in plasma are 2.29 
(0.69) μg*hr/mL and 0.3 (0.09) μg/mL, respectively. Steady state TFV-DP concentrations in 
PBMCs range from 80 to 160 fmol/million cells with coefficients of variation of ~50%.65 The 
terminal half-life of tenofovir in plasma is 17 hours. The half-life of TFV-DP in cells is longer 
because this moiety is ionized and trapped. The half-life of TFV-DP in peripheral blood 
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mononuclear (PBMCs) and red blood cells (RBCs) is 6 days65 and 17-days, respectively. Eighty 
percent of an intravenous dose of tenofovir is recovered in the urine over 3-4 days. Tenofovir 
renal clearance (estimated between 161 and 194 mL/hr/kg) exceeds glomerular filtration so there 
is also a role for active tubular section.  
Compared with patients with normal renal function, those with creatinine clearance 
values of 30-49 mL/min and <30 mL/min had tenofovir AUCs 2.75-fold and 7.3-fold higher, 
respectively.52 Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of 
approximately 54%. Following a single 300 mg dose of TDF, a four-hour hemodialysis session 
removed approximately 10% of the administered dose.66 TDF doses should be reduced in 
patients with creatinine clearance values less than 50 mL/min. 
Drug Interactions with Tenofovir 
TDF has few drug interactions because tenofovir disoproxil and tenofovir are not 
substrates, inhibitors or inducers of CYP enzymes, but TDF is not devoid of interactions. TDF is 
a substrate for P-gp and BCRP. Tenofovir is a substrate for the uptake transporters OAT1 and 
OAT3 and the efflux multidrug resistance protein transporters MRP4, MRP7, and MRP8.42,67 In 
vitro studies also suggest the monoester is a P-gp substrate, but the apical to basolateral efflux 
ratio in Madin-Darby Canine Kidney (MDCK) monolayers is 2.1 for the monoester compared 
with 44.2 for TDF.53 Interactions may still occur at the level of membrane transporters, 
intracellular enzymes, and/or in the conversion of tenofovir disoproxil to tenofovir. Following is 
a description of notable drug interactions with TDF.   
Didanosine 
 TDF has been shown to increase concentrations of didanosine, another NRTI.52 Patients 
on this combination appeared to have a depletion of CD4 cells.68 A putative mechanism for this 
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interaction is inhibition of purine nucleoside phosphorylase (PNP) by tenofovir 
monophosphate.69 Inhibition of PNP leads to accumulation of deoxyribonucleotides, particularly 
deoxyguanosine triphosphate (dGTP), which results in a T-lymphocytopenia. Didanosine is no 
longer recommended as an antiretroviral treatment, so the likelihood of encountering this 
interaction in clinical practice is low, but the mechanism highlights the potential for intracellular 
interactions with nucleos(t)ide analogs.  
Protease Inhibitors 
 HIV protease inhibitors increase tenofovir exposures. This interaction has been attributed 
to the combined effects of P-gp inhibition (TDF is a P-gp substrate) and inhibition of esterase-
dependent degradation of TDF in an intestinal subcellular fraction.58 However, one study found a 
reduced renal clearance of tenofovir in patients on ritonavir-boosted lopinavir, suggesting that 
perhaps inhibition of a renal efflux transporter also plays a role in this drug interaction.70  
 Atazanavir exposures are reduced with TDF. The mechanism for this interaction is 
unclear. To mediate this effect, atazanavir is administered with a boosting dose of ritonavir when 
given with TDF.  
Sofosbuvir and Sofosbuvir-Containing HCV Treatment 
The geometric mean tenofovir plasma Cmax ratio (90% CI) when given as TDF with 
SOF vs. TDF alone is 1.25 (1.08, 1.45, n=16). A larger increase in tenofovir exposures is 
observed with LDV/SOF and SOF plus velpatasvir (SOF/VEL). LDV and VEL are NS5A 
inhibitors. Both compounds inhibit P-gp and BCRP. Tenofovir AUC, Cmax and Cmin are 
increased 35%, 47%, and 47% with LDV/SOF, respectively. Tenofovir AUC, Cmax, and Cmin 
are increased 40%, 46%, and 70% with SOF/VEL, respectively. Tenofovir plasma exposures are 
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higher when LDV/SOF or SOF/VEL are combined with ritonavir- or cobicstat-boosted 
antiretroviral regimens. Higher tenofovir concentrations may increase the risk of nephrotoxicity.    
Tenofovir-Associated Nephrotoxicity  
  Tenofovir is a highly efficacious and well-tolerated antiretroviral, but it use has been 
associated with nephrotoxicity. The incidence of tenofovir-induced nephrotoxicity varies 
widely.71,72 Rates of nephrotoxicity in clinical trials with TDF are lower than cohort studies 
presumably due to differences in assessment of renal function/toxicity, concomitant antiretroviral 
use and the patient populations.71,72 Patients in cohort studies were older, more treatment 
experienced, on didanosine or boosted protease inhibitors, and often had other comorbidities that 
contributed to declines in renal function.  
The most common nephrotoxic effect of tenofovir is damage to the proximal tubular 
cells.73 Active tubular secretion and reabsorption of salts, small molecules, and proteins occurs in 
the proximal tubule cells of the kidney.74 Evidence of tenofovir-induced kidney tubular 
dysfunction includes Fanconi syndrome, increased excretion of tubular proteins, 
hypophosphatemia, glycosuria, metabolic acidosis and hypokalemia.73 Diabetes insipidus, 
reductions in glomerular filtration, acute renal failure, and reductions in bone mineral density 
have also been observed.71-73  
The renal uptake transporter OAT1, and to a lesser extent OAT3, mediates the 
nephrotoxicity of tenofovir and the other structurally-related acyclic nucleoside phosphonates, 
adefovir and cidofovir.75 Overexpression of OAT1 and OAT3 transporters increases the 
cytotoxicity of tenofovir, adefovir, and cidofovir in vitro.75 However, the mechanisms by which 
tenofovir causes nephrotoxicity once it enters the renal proximal tubule cells is unclear.  
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Mitochondrial toxicity has been implicated as the cause of nephrotoxicity from tenofovir. 
NRTI triphosphates have affinity for human mitochondrial DNA polymerase gamma, though 
tenofovir has a much lower affinity for this enzyme compared with other NRTI triphosphates.76 
Kidney biopsies obtained in patients with tenofovir-associated nephrotoxicity revealed “toxic 
acute tubular necrosis, with distinctive proximal tubular eosinophilic inclusions representing 
giant mitochondria, depletion and dysmorphic changes”.73,77 The shortage in ATP production 
that results from inhibition of human mitochondrial DNA polymerase gamma is thought to cause 
acquired Fanconi syndrome.72 Fanconi syndrome is characterized by an inability for tubular cells 
to reabsorb ions and small molecules such as potassium, glucose, phosphate, uric acid, amino 
acids, and beta-2 microglobulin.72 Mitochondrial abnormalities may induce apoptosis of 
epithelial cells resulting in acute tubular necrosis.72 Hypophosphatemia may result from 
decreased proximal reabsorption of phosphate and decreased vitamin D activation.72 Tenofovir 
may also decrease aquaporin-2 expression which results in reduced water reabsorption and 
subsequently, nephrogenic diabetes insipidus.72  
Guidelines recommend an assessment of renal function (serum creatinine, estimated 
glomerular filtration rate, and urine dipstick) at HIV diagnosis. Serum creatinine, estimated 
glomerular filtration rate, phosphate, proteinuria, and glycosuria should be assessed twice a year 
in patients on TDF.78  
Measures of Renal Dysfunction  
Creatinine is a muscle metabolism end-product.79 Creatinine is primarily cleared by 
glomerular filtration in the kidney, but 10-20% also undergoes active tubular secretion.74,79 
Serum creatinine is a convenient endogenous marker for monitoring kidney function used in 
routine clinical practice.74 However, there are several shortcoming to use of this measure of renal 
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function. First, muscle mass, protein intake, proteinuria, race, and age can effect creatinine 
concentrations.73,79 Second, it is a late marker of kidney dysfunction and often is not elevated 
until glomerular filtration drops below 60 mL/min.72,79 Third, because there is a component of 
active tubular secretion, it overestimates glomerular filtration rate (GFR).79 Fourth, several 
drugs, including antiretroviral agents, inhibit renal transporters for which creatinine is a substrate 
including the multidrug and toxin extrusion 1 transporter (MATE1), MATE2-K, and organic 
cation transporter 2 (OCT2). Inhibition of these transporters causes an artificial increase in serum 
concentrations of creatinine. Clinically, this can be confused with renal impairment or renal 
toxicity. Creatinine and other current biomarkers of kidney disease become elevated late in the 
injury process and may miss opportunities to detect kidney injury earlier and intervene.79 Other 
biomarkers may detect subclinical but significant acute kidney injury that is missed by traditional 
gold standard methods.79 The FDA has approved use of a qualified set of biomarkers in 
preclinical assessments of nephrotoxicity80; indicating a move away from exclusive use of 
creatinine and towards a more targeted assessment of drug-induced kidney damage.79     
Various biomarkers of acute kidney injury have been investigated.79,81 Some are 
measured in serum such a neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and 
uric acid.81 Others are measured in urine. Urine biomarker categories include low-molecular 
weight proteins, enzymes of renal origin, protein products of genes, urinary cytokines and 
chemokines, and structural and functional proteins of the renal tubule.81 As described in the prior 
section, tenofovir primarily causes a proximal tubular toxicity. Thus, biomarkers for proximal 
tubule toxicity may detect early signs of tenofovir-induced nephrotoxicity. Table 3 from del 
Palacio et al.82 summarizes the main characteristics of urinary biomarkers used to assess tubular 
toxicity.  
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Low molecular weight proteins (< 40kDa), produced by most cells of the body and 
excreted into the bloodstream, are freely filtered by the glomerulus and almost completely 
reabsorbed by the proximal tubular cells.81 Increased urinary concentrations of these proteins 
may indicate proximal tubular damage. The low molecular weight proteins which have been best 
characterized for detecting lesions of proximal tubules are beta-2 microglobulin (β2MG) and 
retinol binding protein (RBP).79 β2MG and RBP offer high sensitivity in predicting tubular 
dysfunction in patients on TDF.83  
Beta-2 microglobulin (β2MG) is a low-molecular weight (11.8 kDa) protein with a 
similar structure to the CH3 domain of the immunoglobulin molecule.84 β2MG forms the 
invariant light chain portion of major histocompatibility complex class I molecules, which can be 
found on the membrane of all nucleated cells.84 β2MG is freely filtered by the glomerulus then 
reabsorbed and metabolized by the tubules with <1% appearing in the urine.79 Increased 
concentrations of β2MG in the urine are seen with nephrotoxic agents (e.g., radiocontrast), viral 
infections, and hypoxia from long surgeries.81,84 β2MG is one of the most studied biomarkers of 
TDF-related tubulopathy.85  
Retinol binding protein (RBP) is a 21 kDa protein synthesized by hepatocytes.82 RBP is 
involved in the transport of vitamin A in the blood. The C-terminally processed form is filtered 
by the glomerulus then reabsorbed by the renal proximal tubule cells. Even a minor reduction in 
renal tubule function may lead to increased excretion of RBP in urine. RBP is elevated as a result 
of renal impairment from heavy metals as well as patients with diabetic nephropathy.86    
Urinary biomarker results are sensitive to hydration status.80 To account for this, results 
are sometimes reported as a ratio to creatinine concentration.  
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TFV-DP in Dried Blood Spots Reflects TDF Adherence 
  The long cellular half-life of TFV-DP means concentrations reflect cumulative drug 
dosing or more long-term adherence to tenofovir-based ARV therapy.87-89 TFV-DP 
concentrations have proven invaluable for providing clinical context to study findings of 
TDF/emtricitabine for HIV prevention. TFV-DP are not subject to white-coat compliance 
because an individual with gaps in adherence will not be able to achieve the same concentrations 
as a person with consistent daily dosing. TFV-DP in dried blood spots (DBS), which are 
predominantly composed of red blood cells, is analogous to a hemoglobin A1C for assessing 
adherence to tenofovir-based ARV therapy. DBS are easy to collect, require minimal processing, 
and do not have the same stringent biohazard shipping requirements as other biological matrices. 
Tenofovir Alafenamide 
The renal and bone toxicities associated with TDF led to the development of a novel 
tenofovir prodrug, tenofovir alafenamide (TAF). TAF is an isopropylalaninyl monoamidate 
phenyl monoester prodrug of tenofovir.90 TAF is more stable in plasma and less is converted to 
tenofovir.90 Tenofovir plasma concentrations are 90% lower with TAF vs. TDF.90 TAF is 
efficiently delivered to PBMCs. TFV-DP concentrations are ~7-fold higher with TAF compared 
with TDF, TFV-DP mean (%CV) AUC was 21.4 µM *h (76.9) with 25mg TAF compared to 3.0 
µM *h (119.6) with TDF 300mg.90 TAF is not a substrate for OAT1 or OAT3.90 Thus, TAF has 
an improved renal safety profile compared with TDF in terms of smaller declines in creatinine 
clearance and lower β2MGCr and RBPCr ratios.91 The pharmacology of TAF relative to TDF is 
shown in Figure 5. 
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Summary  
 TAF is increasingly replacing TDF use in the United States due to its improved safety 
profile. However, TAF is not available worldwide and TDF is available as a generic drug. Thus, 
TDF will continue to form the backbone of antiretroviral therapy for millions of HIV-infected 
persons across the world, including individuals with HIV and Hepatitis C virus coinfection. TDF 
is likely to be used in combination with LDV/SOF and there are limited data on the 
pharmacokinetics and renal safety of this combination, especially in individuals also taking a 
ritonavir- or cobicistat-boosted HIV protease inhibitor. Through this thesis, the effect of 
LDV/SOF on tenofovir plasma and TFV-DP concentrations was determined in HIV/HCV 
coinfected individuals, including those on ritonavir- or cobicistat-boosted antiretroviral 
regimens, a possible mechanism for the interaction was identified, and the effect of the 
interaction on biomarkers of renal proximal tubulopathy (β2MGCr and RBPCr) was assessed.
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Table 3  
Main characteristics of urinary biomarkers assessing tubular toxicity (with modification from del 
Palacio, Romero, Casado AIDS Rev 2012;14:179-187) 




Early marker of tubular dysfunction, 
but influenced by serum β2MG and 
inflammation 
>200-500 mcg/L urinary β2MG 
after initiating TDF, no data on 
sensitivity/specificity 
Cystatin C Urinary levels may predict adverse 
outcome (renal replacement therapy 
requirement), but in HIV+ can be 
influences by inflammation 
Urinary cystatin C/urine 
creatinine ratio < 14 mcg/mmol 
showed a negative predictive 
value of 95.8% and a positive 
predictive value of 76.9% to 
rule out Fanconi syndrome 
Retinol Binding 
Protein (RBP) 
Full reabsorption in the proximal 
tubule via an ATP-dependent 
mechanism. ↑ urinary RBP to 
creatinine ratio is a marker of tubular 
transport alteration  
Urinary RBP / urine creatinine 





Tubular and glomerular damage. 
Early predictor of acute kidney 
injury, as an indirect diagnostic 
method of HIV-associated 
nephropathy 
Urinary NGAL / urine 
creatitine cutoff point of 121.5 





Derived from proximal tubular cells. 
Indicate tubular cell damage, severe 
cases of toxicity 
Urinary NAG / urine creatinine 




Α-GST specific for proximal tubule, 
correlated to acute tubular necrosis 
Not defined. No data on 
sensitivity/specificity. Urine 
GST higher in the tubular 
damage group 
Liver-type fatty acid 
binding protein (L-
FABP) 
Urine L-FABP is a sensitive 
indicator of acute and chronic 
tubulointerstitial injury 
Not defined. No data on 
sensitivity/specificity.  
Kidney injury 
molecule 1 (KIM-1) 
Marker of injury associated with 
renal tubular cell differentiation 









Urine IL-18 is a sensitive and 
specific marker of acute tubular 
necrosis and delayed graft function 
in the post-ischemic kidney 





Increases during renal inflammation, 
correlates with progression of acute 
kidney injury 










Figure 5. Pharmacology of TAF compared with TDF. TAF is an isopropylalaninyl monoamidate phenyl 
monoester prodrug of tenofovir. TAF is more stable in plasma and less is converted to tenofovir. Tenofovir 
plasma concentrations are 90% lower with TAF vs. TDF. TAF is efficiently delivered to PBMCs where 
TFV-DP concentrations are ~7-fold higher compared with TDF. TAF is not a substrate for OAT1 or OAT3. 
Figure courtesy of Gilead Sciences. 
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CHAPTER III   
HYPOTHESES, METHODS, ANALYSIS PLANS 
Hypotheses and Aims 
 Hypothesis 1. LDV/SOF increases concentrations of tenofovir in plasma, and tenofovir 
diphosphate in cells.  
 Aim 1. Determine the impact of LDV/SOF on plasma tenofovir, and intracellular 
tenofovir diphosphate (TFV-DP) concentrations in HIV/HCV-coinfected patients receiving TDF.  
 Strategy: Samples were used from two studies (ACTG 5327 and COMIRB 15-0123) 
involving HIV/Hepatitis C coinfected individuals on TDF-based antiretroviral therapy, 
undergoing Hepatitis C treatment with LDV/SOF. Tenofovir and TFV-DP concentrations were 
compared before and during LDV/SOF treatment.  
 Hypothesis 2. Plasma concentrations of tenofovir disoproxil and/or the tenofovir 
monoester are increased with SOF due to SOF’s inhibition of carboxylesterase 2.  
 Aim 2. Compare tenofovir disoproxil and tenofovir monoester concentrations in the 
plasma before and during LDV/SOF treatment in patients with HIV/HCV coinfection receiving 
TDF.  
 Strategy: Samples were used from one study (COMIRB 15-0123) of LDV/SOF 
treatment in HIV/HCV coinfected patients. These patients had plasma samples obtained prior to 
an observed dose of TDF, and at 1 and 4 hours post TDF dose before and 4 weeks after initiating 
LDV/SOF.  
 Hypothesis 3. The increase in tenofovir and tenofovir diphosphate concentrations with 
LDV/SOF treatment causes renal proximal tubule injury. This pharmacokinetic-dynamic 
relationship is quantifiable.  
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 Aim 3. Model the relationship between changes in tenofovir and tenofovir-diphosphate 
pharmacokinetics, and renal function in HIV/HCV coinfected patients on TDF before, during, 
and after treatment with LDV/SOF.  
 Strategy: Data from one study of LDV/SOF treatment in HIV/HCV coinfected 
individuals on TDF-containing antiretroviral therapy (COMIRB 15-0123) were used to address 
this aim. Ten patients had plasma samples obtained prior to an observed dose of TDF, and at 1 
and 4 hours post TDF dose, before and 4 weeks after initiating LDV/SOF.  
 Additional samples were obtained at convenient times post dose during LDV/SOF 
treatment. Urine samples were also collected to determine changes in biomarkers of renal 
proximal tubule damage (β2MGCr and RBPCr). The association between tenofovir plasma 
concentrations, and TFV-DP concentrations with markers of proximal tubulopathy were 
determined using mixed models.  
Rationale and Clinical Significance  
 Aim 1. Determine the impact of LDV/SOF on plasma tenofovir and intracellular 
tenofovir diphosphate (TFV-DP) concentrations in HIV/HCV-coinfected patients receiving TDF.  
In healthy volunteers, LDV/SOF raises tenofovir plasma concentrations, but the 
magnitude of the increase is dependent on concomitant antiretrovirals. There are also very 
limited data on the pharmacokinetics of tenofovir in patients receiving TDF with the 
pharmacokinetic enhancers ritonavir and cobicistat. There are no data on the effects of LDV/SOF 
on the intracellular concentrations of TFV-DP. This aim determined the effect of LDV/SOF on 
tenofovir AUC in plasma and TFV-DP concentrations in DBS.  
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 An increase in tenofovir concentrations in plasma may increase the risk of nephrotoxicity 
in patients undergoing HCV treatment with LDV/SOF. An increase in TFV-DP concentrations in 
DBS precludes the use of this analyte to determine adherence to TDF-based antiretroviral 
therapy during SOF-based HCV treatment. It also indicates that TFV-DP is elevated in other cell 
types having implications for both efficacy and toxicity.  
 Aim 2. Compare tenofovir disoproxil and tenofovir monoester concentrations in the 
plasma, before and during LDV/SOF treatment, in patients with HIV/HCV coinfection receiving 
TDF.  
Our preliminary data indicate that SOF causes an increase in TFV-DP concentrations in 
cells.92 As shown in Figure 6, TFV-DP was increased 4.3-fold (range 1.4-15.8-fold, p=0.0005) in 
DBS after 12 weeks of sofosbuvir and ribavirin treatment in 17 HIV-infected individuals with 
acute HCV. 
The increase was also observed in PBMCs, though not as pronounced. As shown in 
Figure 7, there was a 2.3-fold (range 1.09, 4.92) increase in TFV-DP in PBMCs.  
This was an unexpected finding and the mechanism is uncertain. In vitro, SOF inhibited 
the conversion of tenofovir disoproxil to tenofovir. This was attributed to potent and covalent 
inhibition of carboxylesterase-2 (CES2).93 Inhibition of CES2 in the intestine may result in 
increased tenofovir disoproxil or tenofovir monoester delivery to systemic circulation.93 More 
TDF was recovered in the presence of 1000μM SOF, in a separate experiment in Caco-2 cells 
(study AD-337-2001).94  
We hypothesized that inhibition of CES2 would result in higher tenofovir disoproxil 
and/or tenofovir monoester concentrations delivered systemically, which resulted in the observed 
increase in TFV-DP concentrations in cells. This aim determined if concentrations of tenofovir 
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disoproxil and the tenofovir monoester were higher, systemically, with LDV/SOF vs. without 
LDV/SOF. Figure 8 shows the proposed hypothesis for this Aim. 
If concentrations of tenofovir disoproxil and the tenofovir monoester are higher with 
LDV/SOF vs. without LDV/SOF, this may shed light on the mechanism for the observed 
increase in TFV-DP concentrations in DBS and PBMC. Tenofovir disoproxil and tenofovir 
monoester are more lipophilic than tenofovir, and therefore have greater cell penetration. These 
findings may direct future research into the mechanisms and the clinical implications of this new 
type of esterase-based drug interaction.  
 Aim 3. Model the relationship between changes in tenofovir and tenofovir-diphosphate 
pharmacokinetics with renal function during and after treatment with LDV/SOF.  
While a few small studies have failed to show a significant change in creatinine clearance 
or estimated glomerular filtration rate following LDV/SOF treatment in patients receiving TDF, 
there are very limited data on changes in proximal tubule biomarkers with this combination. The 
focus of this aim was to determine if there were changes in the proximal tubule biomarkers, 
β2MGCr and RBPCr, in patients on TDF-based antiretroviral therapy treated with LDV/SOF, 
whether these changes were associated with concentrations of tenofovir or TFV-DP, and lastly to 
quantify the relationship between tenofovir and/or TFV-DP with β2MGCr and RBPCr, and 
determine what demographic or clinical factors may influence this relationship.  
Methods  
Data from two studies were used to address the aims of this thesis. Both studies are 
described below with reference to the thesis aim(s) the study data were used to address, and the 
role of the student in these projects. A summary table follows the study descriptions.  
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ACTG 5327 
 Adult AIDS Clinical Trials Group (ACTG) study 532795, also known as “SWIFT-C,” was 
a multicenter, open-label, two-cohort trial of SOF-based HCV treatment in individuals with HIV 
and acute HCV infection. All participants provided written informed consent for study 
participation (NCT02128217). Acute HCV was defined as positive HCV RNA in patients with 
documented negative serology in the past 6 months, or positive HCV RNA plus a new alanine 
aminotransferase (ALT) elevation greater than 5 times the upper limit of normal. In Cohort 1, 17 
patients were treated with SOF and weight-based ribavirin (RBV) for 12 weeks. In Cohort 2, 27 
patients were treated with LDV/SOF for 8 weeks. The study design is shown in Figure 9. The 
cohorts were enrolled sequentially, and SVR rates in each cohort were compared to historical 
rates of SVR in HIV-infected patients that received PegIFN α and RBV.96 Jennifer Kiser is the 
protocol pharmacologist for this study.  
 The findings from Cohort 1 have been published.95 Briefly, 59% achieved SVR and the 
remainder failed treatment due to viral relapse. The SVR rate was much lower than anticipated, 
and SOF/RBV failed to achieve non-inferiority compared with historical rates of SVR with 
PegIFN α and RBV.96  
Plasma, PBMCs, and DBS were obtained from participants in Cohort 1 prior to 
SOF/RBV treatment, at weeks 1, 2, 4, 8, and 12 of SOF/RBV treatment, and 12 weeks after 
completing SOF/ribavirin treatment (EOT+12 visit). Fifteen of the 17 participants in Cohort 1 
were taking an antiretroviral regimen that included TDF.  
Per the protocol, since SOF/RBV failed to achieve non-inferiority, Cohort 2 proceeded to 
evaluate 8 weeks of LDV/SOF. Eligibility for Cohort 2 was the same as Cohort 1; except 
participants could not take gastric acid modifiers in Cohort 2 given LDV requires an acid 
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environment for optimal absorption. The pharmacokinetic sampling strategy was the same as 
Cohort 1 except PBMCs were not collected in Cohort 2. Twenty-two of the 27 participants in 
Cohort 2 were taking an antiretroviral regimen that included TDF.  
COMIRB 15-0123  
As described in Chapter I, “Premise for this Work,” the AASLD/IDSA HCV guidelines 
recommend avoiding LDV/SOF in patients taking TDF and a boosting agent (either ritonavir or 
cobicistat), since these individuals have a “double whammy” in terms of increased tenofovir 
exposures; both the boosting agent and LDV/SOF raise tenofovir levels. However, avoidance of 
this combination may not be possible or practical.  
Dr. Kiser designed a small study to evaluate plasma tenofovir and intracellular TFV-DP 
exposures in patients taking a ritonavir-boosted protease inhibitor and TDF undergoing 
LDV/SOF treatment for HCV (NCT02588287). See Appendix A for the IRB approval for this 
study. The primary aim was to determine the change in tenofovir plasma AUC before and after 
LDV/SOF. The secondary aims were to determine the change in intracellular TFV-DP 
concentrations, and the change in markers of renal proximal tubulopathy (β2MGCr and RBPCr). 
The study design is shown in Figure 10. Participants underwent 4-hour intensive 
pharmacokinetic visits before, and 4 weeks after initiating LDV/SOF treatment. Participants 
were fed a standardized breakfast on the day of the intensive pharmacokinetic visits, ARV doses 
were witnessed, and plasma samples were obtained before, and 1 and 4 hours after an observed 
dose of TDF. Jennifer Kiser was the principal investigator for this study.   
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Bioanalytical Methods  
Drug Quantification  
TFV-DP in peripheral blood mononuclear cells and dried blood spots, tenofovir in 
plasma, and tenofovir monoester in plasma were measured using validated liquid 
chromatography tandem mass spectrometry methods in the Colorado Antiviral Pharmacology 
Laboratory (CAVP). 97-99 Jennifer Kiser co-directs the laboratory. Methods to measure tenofovir 
in plasma and TFV-DP in cells were developed and validated in the CAVP many years ago; 
however, the tenofovir monoester method was developed as part of this thesis. Given the 
monoester method was based on the tenofovir in plasma method, both of these methods are 
described below. 
TFV-DP in cells 
Methods to isolate and process PBMC and DBS and quantify TFV-DP in cells are 
described in Appendix E. No new methodology was developed in the course of this dissertation 
related to this assay.  
Tenofovir in plasma  
 Tenofovir in plasma is measured using a validated LC/MS/MS method.97 This method 
uses a stable labeled internal standard (13C in the adenine moiety; Iso-TFV), which is added 
(10μL) along with trifluoroacetic acid (TFA; 25 μL) to plasma samples (250μL) to produce a de-
proteinated extract after high-speed centrifugation. Extracts are directly injected into the 3% 
acetonitrile/1% acetic acid mobile phase stream flowing at 200 μL/min. A Synergi Polar-RP, 2.0 
x 150mm, reversed-phase analytical column is used to achieve chromatographic separation. 
Detection is achieved by ESI positive ionization tandem mass spectrometry. The 
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precursor/product transitions (m/z) in the positive ion mode are 288/176 and 293/181 ions for 
tenofovir and Iso-TFV, respectively. The assay is linear in the range of 10 ng/mL to 1500 ng/mL 
when 250μL is extracted. The lower limit of quantification is 10 ng/mL. The inter- and intra-day 
accuracy and precision are within ±20% at the lower limit of quantification, and ±15% at the 
other quality control levels.  
Tenofovir disoproxil and tenofovir monoester in plasma 
The possibility of quantifying the monoester intermediate was based on findings by Nye 
and colleagues. Nye et al. described detection of a “metabolite” of tenofovir which was 
presumed to be tenofovir monoester in human plasma up to 4 hours post-dose in healthy 
volunteers who received 14-days of TDF coformulated with emtricitabine and efavirenz 
(Atripla®, Gilead Sciences, Foster City, CA).100 This presumed monoester was detected in the 
course of developing an ultraperformance liquid chromatography mass spectrometry (UPLC-
MS) method for simultaneous measurement of these three HIV compounds in plasma. Whole 
blood was obtained from 16 participants at pre-dose and 2, 4, 8, and 12 hours post-observed 
dose. The monoester was detected in all 16 participants at 2 hours post-dose and in some 
participants at 4 hours post-dose. In one participant, the amount of monoester at 2 hours post-
dose exceeded the tenofovir present. The ion at m/z 404.1292 corresponded in elemental 
composition to the putative protonated monoester of tenofovir – [C14H23N5O7P]+ (mass error of -
10.6 ppm). The monoester fragmented extremely easily within a mass spectrometer ion source to 
form tenofovir. Investigators concluded that “considerable quantities” of the monoester were 
present in plasma up to 4 hours post-dose, though the actual quantities of the monoester were not 
reported as the group lacked the monoester reference standard. These findings disputed prior 
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reports that suggested TDF and the monoester are completely hydrolyzed, and that only tenofovir 
was detected systemically.  
 Based on the preliminary findings by Nye and colleagues, a new method was developed 
and validated for measurement of the tenofovir monoester for purposes of this thesis. The 
tenofovir monoester reference standard was located and purchased, allowing for the development 
and validation of a method to quantify this compound.  
First, TDF and the monoester reference standard were diluted, and then directly injected 
on to the Waters Xevo® TSQ Micro tandem quadrupole mass spectrometer system to determine 
if the analytes were detectable per the specifics provided by Nye et al. Next, plasma samples 
were spiked with TDF and the monoester and subjected to the trifluoroacetic acid-based protein 
precipitation method used for the CAVP parent tenofovir assay. Unfortuantely, tenofovir 
disoproxil was not detectable on the system when spiked with human plasma. Presumably, 
hydrolysis from the disoproxil moiety to the monoproxil/monoester moiety occurred 
immediately. Thus, plans to attempt to quantify this prodrug were abandoned and efforts focused 
exclusively on the tenofovir monoester.  
Six samples from a study Dr. Peter Anderson conducted in healthy volunteers receiving a 
single observed dose of TDF were used to provide preliminary evidence of expected TFV 
monoester concentrations. This study, called A-TEAM101, sampled individuals frequently after 
TDF administration (at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 10, 24, 48, and 72 hours post-dose) unlike 
COMIRB 15-0123 which only sampled participants at pre-dose, 1 and 4 hours post dose. 
Samples from three individuals in 15-0123 were used to determine the expected concentrations 
with LDV/SOF. Together, data from these studies were used to determine the range of expected 
TFV monoester concentrations and the appropriate quantifiable range of the method. 
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An ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS-
MS) assay was developed for the determination of tenofovir-monoester in human plasma, and 
was validated for use with ethylenediaminetetraacetic acid (EDTA) plasma matrix. Plasma 
proteins were precipitated with trifluoroacetic acid followed by chromatographic separation 
performed on a Waters Acquity H-Class UPLC. Separation was achieved with a Waters Acquity 
HSS T3 (2.1 x 100mm, 1.8uM) reversed-phase UPLC column with gradient elution at 
0.5ml/min. The gradient went from 2% acetonitrile to 50% acetonitrile (0.1% formic acid) over 
3.0 minutes. Detection was achieved by ESI positive ionization tandem mass spectrometry on a 
Waters Xevo TQ-S Micro detector. Precursor/product transitions (m/z) in the positive ion mode 
were 404/176. Linearity of the method was in the range 0.1 ng/mL to 500 ng/mL using a 1/conc2 
weighted calibration curve. The assay had a minimum quantifiable limit of 0.1 ng/mL when 0.25 
mL of plasma was analyzed. Intra-day accuracy was within ±10.6% and precision ≤10.3%. The 
inter-assay accuracy was within 6.8% and precision ≤7.9%.   
Renal Biomarkers 
RBPCr  
Retinol binding protein (RBP) in urine was measured at the Mayo Clinic in Rochester, 
NY.102 A 5mL aliquot of frozen urine was sent. Creatinine was performed by the enzymatic 
method, which is based on the determination of sarcosine from creatinine with the aid of 
creatininase, creatinase, and sarcosine oxidase. The liberated hydrogen peroxide was measured 
via a modified Trinder reaction using a colorimetric indicator. Optimization of the buffer system 
and the colorimetric indicator enabled the creatinine concentration to be quantified both precisely 
and specifically (Package insert: Roche Diagnostics, Indianapolis IN, 2004).  
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In an immunochemical reaction, urinary RBP forms immune complexes with anti-retinol-
binding protein-specific antibodies coated onto polystyrene latex particles. The resulting latex 
bead-antigen-antibody complexes have enhanced light-scattering ability, which is detected with a 
nephelometer when a beam of light is passed through the sample. The intensity of the scattered 
light is proportional to the concentration of RBP in the sample. The result was evaluated by 
comparison with a standard of known RBP concentration (Package insert: Binding Site Human 
Urine Retinol Binding Protein Nephelometric Kit for use on the Dade-Behring BNII Analyzer).  
The reference value for RBP/Cr < 172 μg/g. 
β2MGCr  
Beta-2 microglobulin in urine was measured at ARUP Laboratories in Salt Lake City, 
UT. 103 A 3mL aliquot of frozen urine was sent. β2MG was determined using quantitative 
chemiluminescent immunoassay. The reference value was 0-300 μg/L per volume or if 
normalized to creatinine, 0-300 μg/g.  
Power Determinations and Analysis Plan 
Aim 1 
 Determine the impact of LDV/SOF on plasma tenofovir and intracellular tenofovir 
diphosphate (TFV-DP) concentrations in HIV/HCV-coinfected patients receiving TDF.  
Power and Sample Size Determination for Aim 1 
 In healthy volunteers, LDV/SOF increased tenofovir plasma AUC 35% when 
administered as TDF/emtricitabine/ritonavir-boosted atazanavir vs. TDF/emtricitabine/ritonavir-
boosted atazanavir alone. LDV/SOF increased tenofovir plasma AUC 50% when administered 
with TDF/emtricitabine/ritonavir-boosted darunavir vs. TDF/emtricitabine/ritonavir-boosted 
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darunavir alone. The study was powered to detect a greater than 40% increase in tenofovir AUC 
assuming that the coefficient of variation (CV) for tenofovir AUC was 30% (mean±SD tenofovir 
AUC of 2.29 ± 0.69 mcg*hr/mL in the TDF prescribing information66), within-subject 
correlation was 0.5, and the AUC reported on the original scale had a log-normal distribution. An 
increase of 40% was equivalent to 0.34 on the loge scale, and the variance of the change on the 
log scale was 0.087 (SD=0.30). With 11 participants, there is 90% power to detect a >40% 
increase as statistically significant in a within-subject analysis, in a 2-sided t-test on the log-
transformed AUC with 5% type I error.  
 TFV-DP concentrations in DBS were increased 4.3-fold in Cohort 1 of ACTG 5327 after 
12 weeks of SOF/ribavirin treatment.92 A similar or greater difference with LDV/SOF was 
expected. With 11 patients, there is >99.9% power to detect a 5-fold increase in TFV-DP 
concentrations even after making a conservative assumption that there is no correlation in 
concentrations with vs. without LDV/SOF. The power estimate is robust to increased variability, 
as there is greater than 99% power, even when the standard deviation is doubled in the power 
calculation.  
 Power and sample size determinations were performed using SAS v9.3.  
Analysis Strategy for Aim 1 
 
In ACTG 5327, TFV-DP concentrations in DBS were log-transformed and compared at 
each study visit to baseline (before LDV/SOF) using paired t-tests. The geometric mean ratio 
(GMR) and 90% confidence interval of TFV-DP in DBS at each study visit vs. baseline was 
determined. TFV concentrations in plasma were compared at week 8 of LDV/SOF treatment to 
baseline and EOT+12 to baseline using paired t-tests.  
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Data from ACTG 5327 and COMIRB 15-0123 were combined to determine demographic 
and clinic covariates that impact the magnitude of the TDF and LDV/SOF interaction. The 
associations between the covariates and the magnitude of the interaction with LDV/SOF were 
evaluated using mixed models.  
 Mixed models. Mixed models are the equivalent of linear regression for repeated 
measures. For Aim 1, there was interest in determining the demographic and clinical covariates 
that impacted the magnitude of the TDF and LDV/SOF interaction. The outcomes of interest for 
the models were tenofovir concentrations in plasma and TFV-DP concentrations in DBS. There 
were repeated measures for TFV and TFV-DP from both ACTG 5327 and COMIRB 15-0123. 
The primary predictor was receipt of LDV/SOF. LDV/SOF was tested as a dichotomous 
variable, as well as a variable that accounts for time on LDV/SOF (weeks*LDVSOF). The other 
covariates of interest were type of antiretroviral regimen (specifically receipt of a ritonavir or 
cobicistat booster), creatinine clearance, age, weight, race, sex, and study (ACTG 5327 vs. 15-
0123). An example of a mixed model for this analysis is: 
lnTFV-DP in DBSi = β0 + β1LDV/SOF + β2booster + β3CrCl + ϒi + εij 
 Pharmacokinetic data are often right skewed. An assumption of mixed effects models is 
that outcome variables are normally distributed as a function of the predictor. Consequently, 
natural log transformation of TFV-DP reduces skew and helps to satisfy this assumption. 
LDV/SOF, booster, and CrCl are the explanatory variables (fixed effects) for the model. The 
random effects are ϒi and εij. ϒi is between-person variability. ϒi is normally distributed and has 
a mean of zero and a variance of σB2. εij is the residual error, which is normally distributed and 
has a mean of zero and a variance of σw2. εij is the variation around each individual’s slope (or 
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the within-person variability). In this model, “i” represents the number of patients and “j” 
represents the number of observations.  
Aim 2 
Compare tenofovir disoproxil and tenofovir monoester concentrations in the plasma 
before and during LDV/SOF treatment in patients with HIV/HCV coinfection receiving TDF.  
Power and Sample Size Determination Aim 2 
There are no historical data on tenofovir monoester concentrations in humans taking 
TDF. Based on preliminary data from three subjects in COMIRB 15-0123, the mean (SD) 1 hour 
post-dose tenofovir monoester concentration with TDF alone (before LDV/SOF treatment) was 
157 ng/mL (71) and the mean (SD) 4 hour post-dose tenofovir monoester concentration with 
TDF alone was 0.52 ng/mL (0.32). With 10 subjects, there is 80% power to detect an increase in 
the 1 hour post-dose tenofovir monoester concentration, after initiating LDV/SOF to 228 ng/mL 
and to 0.84 ng/mL in the 4 hour post-dose tenofovir monoester concentration. Based on data 
from the three subjects, the mean (SD) 1 hour and 4 hour post TDF dose concentrations four 
weeks after initiating LDV/SOF were 331 (66) ng/mL and 3.37 (1.16) ng/mL, respectively.  
Analysis Strategy Aim 2 
Tenofovir disoproxil and tenofovir monoester concentrations in plasma were compared at 
1 hour and 4 hours post-dose, with vs. without LDV/SOF, from patients in COMIRB 15-0123 
using paired t-tests. Data were log transformed (as needed) to reduce skew.  
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Aim 3  
Model the relationship between changes in tenofovir and tenofovir-diphosphate 
pharmacokinetics and renal function in HIV/HCV coinfected patients on TDF before, during, 
and after treatment with LDV/SOF.  
Power and Sample Size Determination Aim 3 
Baseline β2MG and RBP measurements are available for 12 participants in COMIRB 15-
0123. Ten participants had paired data at baseline and after 4 weeks of LDV/SOF. With 10 
individuals, there is 80% power to detect a 2.5-fold increase in β2MGCr ratios with LDV/SOF, 
assuming the mean (SD) baseline β2MG was 198 (282) with TDF alone (alpha=0.05, 2-sided). 
With 10 individuals, there is 80% power to detect a 42% increase in RBPCr ratios with 
LDV/SOF, assuming the mean (SD) baseline URBP is 110 (46). Additional power is gained 
from repeated measures.  
Analysis Strategy for Aim 3 
The first step in the analysis plan for this aim was to graph β2MG and RBP before, 
during, and after LDV/SOF treatment to determine if the values appear to increase during 
LDV/SOF treatment. If these values appeared to increase in some or all of the patients, or there 
was great variability in the change in β2MG and RBP, then we would explore whether 
LDV/SOF treatment impacts β2MG and RBP. We would also determine if there appears to be a 
correlation between TFV concentrations in plasma or TFV-DP concentrations in DBS or 
PBMCs, and β2MG and RBP. If there appeared to be a pharmacokinetic-dynamic relationship, 
then that association was modeled using mixed effects modeling.  
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Table 4  
Summary of Studies used to Address Thesis Aims 













individuals with acute 
HCV treated with 
SOF/RBV for 12 
weeks (Cohort 1) or 
LDV/SOF for 8 
weeks (Cohort 2). 
Fifteen participants in 
Cohort 1 and 22 in 







Cohort 1 – plasma, PBMCs, 
DBS prior to SOF/RBV 
treatment, at weeks 1, 2, 4, 8, 
and 12 of SOF/RBV 
treatment, and 12 weeks after 
completing SOF/ribavirin 
treatment (EOT+12 visit). 
Cohort 2 – plasma prior to 
LDV/SOF treatment at at 
week 8 and EOT+12. DBS at 
weeks 1, 2, 4, and 8 of 
LDV/SOF treatment and 
weeks EOT 2, 4, 8, 10 and 12. 
All convenience samples.  
1 
15-0123 HIV/HCV coinfected 
individuals treated for 
12 weeks with 
LDV/SOF. 
12 PK: 
4-hour intensive PK visits 
before and 4 weeks after 
initiating LDV/SOF. Plasma 
samples obtained at pre-dose 
and 1- and 4-hours post-
observed dose during the 
intensive PK visits. Plasma, 
DBS and PBMCs collected 
prior to LDV/SOF treatment, 
at weeks 2, 4, 8, and 12 of 
LDV/SOF treatment and 
within one month of treatment 
discontinuation (all 
convenience samples).  
PD: 
Urinary beta-2 microglobulin 
and retinol binding protein 
before LDV/SOF and at 
weeks 2, 4, 8, and 12 of 
treatment and SVR12.  




Figure 6. TFV-DP concentrations in Dried Blood Spots in HIV-Infected Individuals with Acute 
Hepatitis C Virus on TDF-Based Antiretroviral Therapy treated with Sofosbuvir and Weight-
Based Ribavirin (SOF/RBV). Geometric mean TFV-DP concentration (%CV) is shown at study 
entry, following 12 weeks of SOF/RBV, and 12 weeks following the end of SOF/RBV treatment 
EOT + 12). Geometric means were compared between study entry and after 12 weeks of 




Figure 7. TFV-DP concentrations in Peripheral Blood Mononuclear Cells in HIV-Infected 
Individuals with Acute Hepatitis C Virus on TDF-Based Antiretroviral Therapy treated with 
Sofosbuvir and Weight-Based Ribavirin (SOF/RBV). Geometric mean TFV-DP concentration 
(%CV) is shown at study entry, following 12 weeks of SOF/RBV, and 12 weeks following the 
end of SOF/RBV treatment (EOT + 12). Geometric means were compared between study entry 




Figure 8. Proposed hypothesis for enhanced delivery of TDF or TFV-monoester to cells based on 
inhibition of CES2 by SOF. Dashed lines indicate hypothetical mechanism of inhibition of TDF 
hydrolysis by sofosbuvir. SOF: sofosbuvir; TDF: tenofovir disoproxil fumarate; TFV-monoester: 
tenofovir-monoester; TFV: tenofovir; TFV-MP: tenofovir-monophosphate; TFV-DP: tenofovir-
diphosphate. The number of arrows for TDF, TFV-monoester, and TFV indicates degree of 




Figure 9. Study Design ACTG 5327. Cohorts enrolled sequentially. SVR rates were compared in 
each Cohort to historical data in patients receiving PegIFN α and RBV. The study was not 








Figure 10. Study design for COMIRB 15-0123. Green triangles indicate time points for 
pharmacokinetic sampling. Open green triangles represent mini-intensive pharmacokinetic visits. 
Closed green triangles represent convenience or sparse pharmacokinetic sampling. The red 




CHAPTER IV  
RESULTS 
Aim 1 
 Determine the impact of LDV/SOF on plasma tenofovir and intracellular tenofovir 
diphosphate (TFV-DP) concentrations in HIV/HCV-coinfected patients receiving TDF. 
ACTG 5327 
Twenty seven HIV-infected male participants entered Cohort 2 of ACTG 5327 (SWIFT-
C) and all 27 completed 8 weeks of LDV/SOF treatment for acute HCV. All 27 were on ARV 
therapy and 22 were taking TDF as part of their ARV regimen. Demographics for these 22 
participants are shown in Table 5.  
At study entry, the geometric mean (CV%) TFV-DP concentrations in DBS was 1516 
(36) fmol/punch, which was similar to that for Cohort 1 (see Figure 6) and consistent with 
historical data in HIV-infected and uninfected individuals with high adherence.87,104,105 By week 
1 of LDV/SOF treatment, TFV-DP was 6.7-fold higher vs. entry (Figure 11). At WK 8 of 
LDV/SOF treatment, for the 20 participants with both entry and WK8 TFV-DP concentrations in 
DBS, the GMR TFV-DP was 17.8 (95% CI; 12.77, 24.86, p = <0.0001) compared with study 
entry. The geometric mean (CV%) at WK8 of TFV-DP was 26846 (49) fmol/punch.  
These data indicate that TFV-DP concentrations in DBS are higher with LDV/SOF vs. 
SOF/RBV. Unlike with SOF/RBV in Cohort 1, TFV concentrations in plasma were increased 
2.1-fold (95% CI (1.44, 2.91), p= 0.0005), at WK8 of LDV/SOF treatment with a geometric 
mean (CV%) of 155 (112) ng/mL (Figure 12).  
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Three participants in Cohort 2 switched from TDF to tenofovir alafenamide (TAF) at 
WK1, WK7 and WK15 of study, respectively, thus TFV-DP in DBS and TFV in plasma samples 
for these individuals were excluded from analyses following the switch. TFV-DP concentrations 
in DBS for these individuals are shown in Appendix F.   
These data clearly indicate that LDV/SOF increases TFV-DP concentrations in DBS and 
concentrations of TFV in plasma were increased, but to a lesser extent. With 22 participants, the 
ability to examine the effects of various covariates (especially the impact of boosted protease 
inhibitors) on the magnitude of the interaction is limited.  
COMIRB 15-0123 
Fourteen HIV-infected individuals with chronic HCV consented for participation in this 
study. Twelve enrolled and completed at least one pharmacokinetic visit. Demographics for these 
12 participants are shown in Table 6. Ten participants completed both the baseline and week 4 
mini-intensive pharmacokinetic sampling visits.  
As with ACTG 5327, an increase in TFV-DP concentrations with LDV/SOF was 
observed. In ACTG 5327, TFV-DP was obtained only in DBS. In this study, COMIRB 15-0123, 
TFV-DP was determined in PBMCs, RBCs, and DBS. As shown in Figure 13, the geometric 
mean TFV-DP ratio (95% CI) with vs. without LDV/SOF in PBMCs, RBCs, and DBS was 2.8 
(95% CI 1.71, 4.57), 10.96 (95% CI 5.96, 20.15), and 7.31 (95% CI 4.47, 11.95).   
The plasma concentrations of tenofovir at time 0 (pre-dose), 1 and 4 hours post-dose at 
the baseline (pre-LDV/SOF) and week 4 mini-intensive pharmacokinetic visits are shown in 
Table 7. Plasma concentrations of tenofovir at time 0 (pre-dose), 1, and 4 hours post-dose were 
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increased 1.34-fold ([95% CI 1.09, 1.65]; p=0.011), 1.83-fold ([95% CI 0.51, 6.54]; p=0.31), and 
1.43-fold ([95% CI 1.29, 1.58], p<0.0001), respectively, between week 4 versus baseline. 
Exploring Covariate Effects on the Interaction with LDV/SOF 
While the magnitude of the increase in tenofovir plasma concentrations with LDV/SOF 
was comparable in the two studies (2.1-fold higher in ACTG 5327 vs. 1.34-1.83-fold higher in 
COMIRB 15-0123), the magnitude of the increase in TFV-DP concentrations in DBS appeared 
lower in 15-0123. TFV-DP concentrations in DBS were increased 17.8-fold in ACTG 5327 after 
8 weeks of LDV/SOF vs. 7.31-fold at 4 weeks in COMIRB 15-0123. The increase was 12.2-fold 
at 8 weeks in this study. At week 8 of LDV/SOF, the geometric mean (%CV) TFV-DP 
concentration in DBS was 22,026 (48%) fmol/punch (n=7) in COMIRB 15-0123 vs. 26,846 
(49%) fmol/punch in ACTG 5327. The lower fold change may be the result of higher baseline 
levels in participants in COMIRB 15-0123. Indeed, TFV-DP concentrations were higher in 
COMIRB 15-0123 participants at baseline compared with ACTG 5327 participants at study 
entry, 2186 (54%) fmol/punch vs. 1516 (36%) fmol/punch, respectively. Ritonavir and cobicistat 
(pharmacokinetic enhancers or “boosters”) increase TFV-DP concentrations. All participants in 
15-0123 were taking ritonavir as part of their antiretroviral regimen vs. fewer than half (41%) in 
ACTG 5327.  
HCV treatment guidelines specifically caution about use of TDF with LDV/SOF in those 
on boosted regimens since boosted regimens are known to increase tenofovir concentrations. 
However, as previously mentioned, it may not be possible to switch a patient to an unboosted 
regimen. Table 8 shows, for ACTG 5327, the TFV-DP concentrations among those on a boosted 
vs. unboosted antiretroviral regimen at baseline and week 8 of LDV/SOF treatment. Boosted 
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includes the 9 participants on cobicistat or ritonavir vs. the unboosted group which includes 
participants not taking cobicistat or ritonavir.  
The absolute TFV-DP concentrations were higher at baseline in those on a boosted 
regimen. However, at week 8, there was no difference in the concentrations. Numerically, those 
on a booster had TFV-DP concentrations about 10,000 fmol/punch lower vs. unboosted patients, 
but this was not statistically significant and variability was higher with LDV/SOF.  
With only 22 participants in ACTG 5327, the ability to investigate the effect of covariates 
such as booster on the magnitude of this interaction is limited. Thus, these data were combined 
with data from COMIRB 15-0123 to further investigate the booster effect as well as the 
associations with other covariates and the magnitude of the interaction. Table 9 is similar to 
Table 8 but now includes additional participants on ritonavir-boosted antiretroviral regimens 
from COMIRB 15-0123 and also stratifies by type of booster. Participants in COMIRB 15-0123 
received 12 weeks of LDV/SOF, but for comparisons with ACTG 5327, the week 8 
concentrations were used. The majority of participants were on a ritonavir-booster as opposed to 
cobicistat. Including the COMIRB 15-0123 participants did not change the findings. Baseline 
TFV-DP concentrations in DBS were higher in those on a boosted regimen (2071 fmol/punch) 
compared with those on an unboosted regimen (1287 fmol/punch), but after 8 weeks of 
LDV/SOF, TFV-DP concentrations were statistically similar in the two groups, 21142 
fmol/punch and 30031 fmol/punch, respectively, p=0.14.  
Additional power may be gained with repeated measures, thus mixed models were used 
to further evaluate whether the magnitude of the interaction differed by concomitant booster use. 
Other covariates may also contribute such as renal function, weight, sex, age, race (black vs. 
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non-black), and receipt of a non-nucleoside reverse transcriptase inhibitor (NNRTI). These were 
also evaluated in the mixed models.   
Mixed Models to Explore the Effect of Covariates  
Mixed models were developed to evaluate the association between covariates and TFV-
DP in DBS and TFV concentrations in plasma. Data were combined for this analysis from both 
ACTG 5327 and COMIRB 15-0123. Tenofovir plasma concentrations (n=129) and TFV-DP 
concentrations in DBS (n=268) were used to develop these models. 
TFV-DP in DBS 
 Table 10 shows the univariate associations with TFV-DP. Only TFV plasma 
concentration, time on drug, and LDV/SOF were significantly associated with TFV-DP in DBS.  
TFV-DP in DBS increased 46% (95% CI 23-53%) for every 100 ng/mL increase in tenofovir 
plasma concentration (p<0.0001). For every week on LDV/SOF there is a 23% increase in TFV-
DP in DBS (p<0.0001). When participants received LDV/SOF, TFV-DP concentrations in DBS 
were ~4.9-fold higher overall (p<0.0001).  
 LDV/SOF and time on LDV/SOF are collinear, thus the variable with the smaller Akaike 
Information Criteria (AIC) was chosen for evaluation in multivariable models. The AIC for 
LDV/SOF was 674 and the AIC for time on LDV/SOF was 724, thus LDV/SOF was selected. 
TFV plasma concentration was included in multivariable models as well. Table 11 shows the 
multivariable models. Given the primary question was whether receipt of a booster (ritonavir or 
cobicistat) impacted the magnitude of the interaction, booster was included in a multivariable 
model. Model 3 tested the possibility of an interaction between LDV/SOF and booster. This 
interaction tests whether the effect of LDV/SOF differed between those on a boosted vs. 
unboosted regimen. The model that controlled for the interaction between LDV/SOF and booster 
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(Model 3) had the lowest AIC of the three. With the addition of LDV/SOF, TFV-DP in DBS is 
36.5% lower in those taking a ritonavir or cobicistat containing antiretroviral regimen compared 
to those taking an unboosted regimen (p<0.0001).  
TFV in Plasma  
A similar mixed model to that developed for TFV-DP in DBS was used for tenofovir in 
plasma. Time on LDV/SOF and LDV/SOF use (yes or no) were the only factors significantly 
associated with tenofovir concentrations in plasma (both p<0.0001). Time on LDV/SOF would 
not be expected to impact tenofovir plasma concentrations given the plasma tenofovir half-life is 
17 hours and thus steady state reached after approximately 4 days, but time on LDV/SOF was 
significantly associated with TFV plasma concentrations in univariate analysis. For every week 
on LDV/SOF, there was a 10% (6.9%, 12.7%, p<0.0001) increase in tenofovir plasma 
concentrations. When participants took LDV/SOF, tenofovir plasma concentrations were 
approximately doubled, 64 ng/mL (49, 90) vs. 128 ng/mL (92, 179), consistent with the simple 
paired t-test of pre vs. post LDV/SOF reported in Figure 12 and Table 7. No other covariates 
were significant in the model (all p≥0.2). When booster and the interaction of booster and 
LDV/SOF were included in multivariable models, booster and LDV/SOF*booster were not 
significant, p=0.3839 and p=0.5944, respectively and the AIC values similar (307.6 and 307.8, 
respectively) compared with the LDV/SOF alone model (307.9). Thus, the multivariable models 
for TFV in plasma do not appear to offer much beyond the univariate model with LDV/SOF.  
Summary of Findings for Aim 1 
 TFV-DP concentrations in DBS were increased 17.8-fold after 8 weeks of LDV/SOF in 
ACTG 5327 and 7.3-fold after 4 weeks of LDV/SOF in COMIRB 15-0123. TFV plasma levels 
and TFV-DP concentrations in PBMCs were also increased, but to a lesser extent (~2-fold and 
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2.8-fold, respectively). Though individuals taking an antiretroviral regimen that included a 
booster (either ritonavir or cobicistat) had higher TFV-DP concentrations in DBS at baseline 
(prior to initiating LDV/SOF), the increase in TFV-DP with the addition of LDV/SOF was 
36.5% less compared with the increase in those on unboosted regimens. A potential 
pharmacologic basis for the interaction is described in Aim 2 (below). 
Aim 2  
 Compare tenofovir disoproxil and tenofovir monoester concentrations in the plasma 
before and during LDV/SOF treatment in patients with HIV/HCV coinfection receiving TDF.   
Tenofovir Monoester Concentrations With and Without LDV/SOF 
Samples were available at pre-dose and 1 and 4 hours post dose for 10 participants in 
COMIRB 15-0123. The demographic characteristics of these 10 participants are shown in Table 
6. The TFV monoester concentrations with vs. without LDV/SOF are shown in Table 12 and 
Figure 14. 
TFV monoester was undetectable at pre-dose for all participants at all visits. The 
geometric mean TFV monoester concentration at 1 hour post-dose was highly variable and not 
different with vs. without LDV/SOF. It is highly likely based on A-TEAM results that some 
participants were in the absorption phase, while others were in the distribution phase and that this 
accounted for the significant variability. At 4 hours post-dose, TFV monoester concentrations 
were geometric mean ratio (90% CI) 5.02 (1.78, 14.16)-higher with LDV/SOF vs. without. As 
shown in Table 7, TFV plasma concentrations at time 0 (pre-dose), 1, and 4 hours post-dose 
were increased 1.34-fold ([95% CI 1.09, 1.65]; p=0.011), 1.83-fold ([95% CI 0.51, 6.54]; 
p=0.31), and 1.43-fold ([95% CI 1.29, 1.58], p<0.0001), respectively, with LDV/SOF versus 
baseline. The geometric mean TFV-DP ratio (95% CI) with vs. without LDV/SOF in PBMCs, 
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RBCs, and DBS was 2.8 (95% CI 1.71, 4.57), 10.96 (95% CI 5.96, 20.15), and 7.31 (95% CI 
4.47, 11.95).  
Summary of Findings for Aim 2 
Tenofovir monoester concentrations were 5-fold higher at 4 hours post-dose with 
LDV/SOF relative to TDF alone. Given the greater lipophilicity of the TFV monoester relative to 
TFV106, it is highly likely that the increased TFV-DP concentrations are the direct result of 
cellular loading of the TFV monoester (as shown in Figure 8). These findings support our 
hypothesis that TFV monoester concentrations are increased with LDV/SOF and provides 
valuable insight into the mechanism for this unexpected drug interaction.  
Aim 3  
 Model the relationship between changes in tenofovir and tenofovir-diphosphate 
pharmacokinetics and renal function in HIV/HCV coinfected patients on TDF before, during and 
after treatment with LDV/SOF.  
Markers of Renal Proximal Tubulopathy at Baseline (pre-LDV/SOF) 
 RBPCr and β2MGCr, markers of renal proximal tubulopathy, were obtained from the 12 
participants who completed at least one study visit for 15-0123 at baseline (pre-LDV/SOF), week 
4, week 8, week 12 of LDV/SOF treatment and at SVR12 assessment. Table 13 shows the 
baseline (pre-LDV/SOF) values for renal proximal tubulopathy biomarkers. As discussed in 
Chapter III, biomarker values were normalized for urinary creatinine to account for hydration 
status. At baseline, all but 1 participant had RBPCr and β2MGCr values within historical 
reference ranges. The reference range for β2MGCr is 0-300 μg/g and for RBPCr is 0-172 μg/g. 
The patient with elevated RBPCr and β2MGCr at baseline was a 51 year old Caucasian male 
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with a baseline CrCl of 76 mL/min taking TDF, emtricitabine, and ritonavir-boosted darunavir. 
He continued to have elevated RBPCr and β2MGCr at weeks 2 and 4 of LDV/SOF treatment, 
but was lost to follow-up after week 4.  
Exploring the Changes in RBPCr and β2MGCr with LDV/SOF  
Table 14 shows the change in RBPCr and β2MGCr from baseline to week 12 (end of 
LDV/SOF treatment). Only 6 participants (half the number at baseline) had week 12 renal 
biomarker data available. Of these 6 participants, 4 were on ritonavir-boosted darunavir and 2 
were on ritonavir-boosted atazanavir. Natural log transformed pre-LDV/SOF and week 12 
LDV/SOF renal measures were compared using paired t-tests. There were no statistically 
significant differences in the renal measures from baseline to week 12. This analysis does not 
account for repeated measures of the renal biomarkers.  
Figure 15 shows the individual RBPCr and β2MGCr ratios for the 12 study participants 
in COMIRB 15-0123. The graphs highlight the considerable variability between participants in 
these measures, but also that a few of the subjects tended to be high all the way across and a few 
tended to be low all the way across. This type of data lends itself well to a mixed models analysis 
because mixed models accommodate correlated data and they attempt to explain some of that 
variability.  Five of 12 participants had RBPCr > 172 mcg/g on 8 instances during the study 
period and five of 12 participants had β2MGCr > 300 mcg/g on 8 instances during the study 
period (4 participants overlapped). All but 2 of these instances of elevated RBPCr or β2MGCr 
occurred during LDV/SOF treatment.  
Correlations between PK Measures and Biomarkers 
 Prior to mixed models analysis, whether correlations existed between TFV concentrations 
in plasma and TFV-DP concentrations in cells with pharmacodynamic measures (urinary RBPCr 
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and β2MGCr) were explored. As shown in Figures 16 and 17, a trend towards modest, positive 
correlations with TFV in plasma and TFV-DP in DBS and PBMC with RBPCr and β2MGCr 
were observed. 
Mixed Models - Effects of LDV/SOF on RBPCr and β2MGCr 
Forty one tenofovir plasma concentrations, 42 TFV-DP concentrations in DBS, and 22 
TFV-DP concentrations in PBMCs were used to examine the association of these 
pharmacokinetic parameters with changes in markers of renal proximal tubulopathy (RBPCr and 
β2MGCr). Forty eight or 49 renal biomarker measures were available. RBPCr and β2MGCr were 
natural log-transformed for analysis to reduce skew. The effect of LDV/SOF was investigated 
two ways (1) a continuous measure - time on LDV/SOF and (2) a categorical measure - receipt 
of LDV/SOF (yes or no). Other covariates included in the model: TFV concentrations in plasma, 
TFV-DP in DBS and PBMCs, protease inhibitor (ATV/r vs. DRV/r), race (black vs. non-black), 
Hispanic (yes/no), age, and weight.  
Univariate and Multivariable Associations with RBPCr 
Univariate associations with RBPCr are shown in Table 15. The pharmacokinetic 
measures (tenofovir in plasma and TFV-DP in cells) were statistically associated with RBPCr. 
TFV-DP in PBMC was most strongly associated (p=0.0016), for every 100 fmol/106 cell 
increase in TFV-DP in PBMC there is an 8.6% increase in RPBCr. Time on LDV/SOF was not 
associated with LDV/SOF, but taking LDV/SOF trended towards significance. RBPCr 
concentrations were, on average, 28 µg/g higher when the participants were taking LDV/SOF 
(p=0.05). Interestingly, there was also a trend (p=0.07) towards participants on 
atazanavir/ritonavir having RBPCr concentrations that were 41 µg/g higher than those on 
darunavir/ritonavir. 
83 
 Covariates with a p<0.1 were included in multivariable models. Separate models were 
constructed for tenofovir in plasma, TFV-DP in DBS, and TFV-DP in PBMCs as shown in Table 
16. LDV/SOF was not significant in any of the multivariable models. However, concomitant 
HIV PI was associated with RBPCr in the plasma model and trended towards significance in the 
TFV-DP DBS model. After adjustment for LDV/SOF use and TFV plasma concentration, 
patients on ritonavir-boosted atazanavir had RBPCr concentrations about 50% higher than those 
on ritonavir-boosted darunavir (p=0.04). After adjustment for LDV/SOF use and TFV-DP in 
DBS, patients on ritonavir-boosted atazanavir had RBPCr concentrations about 36% higher than 
those on ritonavir-boosted darunavir (p=0.06). TFV-DP in PBMCs remained significant after 
adjustment for LDV/SOF and concomitant protease inhibitor. For every 100 fmol/106 cell 
increase in TFV-DP in PBMCs there was a 10.2% increase in RBPCr (p=0.008). Overall these 
data indicate that TFV-DP concentrations in PBMCs and receipt of atazanavir are associated 
with RBPCr, but not LDV/SOF. Interestingly, RBPCr concentrations were not higher in patients 
on atazanavir at baseline (prior to receipt of LDV/SOF) as shown in Table 13, but trends were 
apparent when all measures were included (Figure 18). Although the dots in Figure 18 include 
repeated measures from the same individuals, the parameter estimates, corresponding 95% 
confidence intervals, and p-values are based on mixed models analysis which accounts for 
repeated measures. This may suggest the presence of an interaction.  
An interaction term can be used to test whether the effect of LDV/SOF on RBPCr differs 
between darunavir vs. atazanavir. For plasma TFV and TFV-DP in DBS, models with the 
interaction term had lower AIC values. The AIC for the full model for TFV in plasma was 66.8 
with the interaction term vs. 69 with the reduced model without the interaction term. For TFV-
DP in DBS, the AIC for the full model was 79.9 vs. 82.7 for the reduced model. The interaction 
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term was not significant in the plasma model, but trended towards significance in the TFV-DP in 
DBS model (p=0.08). Table 17 shows the findings from the multivariable models including 
interaction terms. Including an interaction term in the PBMC model actually increased the AIC 
and the p-value was non-significant for the interaction term (p=0.39), thus this model is not 
included in Table 17.  
Univariate and Multivariable Associations with β2MGCr 
Univariate associations with β2MGCr are shown in Table 18. The findings are very 
similar to the RBPCr results. The pharmacokinetic measures (tenofovir in plasma and tenofovir 
diphosphate in cells) were statistically associated with β2MGCr. Time on LDV/SOF was not 
associated with LDV/SOF, but taking LDV/SOF was. β2MGCr concentrations were, on average, 
69 µg/g higher when the participants were taking LDV/SOF (p=0.06). Participants on 
atazanavir/ritonavir had β2MGCr concentrations that were roughly double those on 
darunavir/ritonavir, but this did not reach statistical significance (p=0.09).  
Covariates with a p<0.1 were included in multivariable models. Separate models were 
constructed for tenofovir in plasma, tenofovir diphosphate in DBS, and tenofovir diphosphate in 
PBMCs as shown in Table 19. In multivariable models for β2MGCr, only TFV concentration in 
plasma was significant. For every 100 ng/mL increase in TFV plasma concentration, β2MGCr 
increased 29% after adjustment for protease inhibitor and LDV/SOF (p=0.02). There was a trend 
for TFV-DP in both DBS (p=0.06) and PBMCs (p=0.09). Protease inhibitor trended towards 
significance (p=0.18 and p=0.16) for plasma TFV and TFV-DP in DBS, but was not significant 
in PBMCs.   
An interaction term can be used to test whether the effect of LDV/SOF on β2MGCr 
differs between darunavir vs. atazanavir. The interaction term was not significant for the PBMC 
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model and the AIC with the interaction term did not provide a better fit (64.8 with interaction vs. 
63.7 without), however the interaction term was significant for DBS and plasma tenofovir and 
these models are shown in Table 20. The AIC values for both plasma TFV (113.6 reduced, 108 
full) and TFV-DP in DBS (126.6 reduced, 120.5 full) were lower for the models that included 
the interaction terms.  
In summary, with the addition of LDV/SOF, there was a trend in univariate analyses 
towards a 28 µg/g increase in RBPCr and a 69 µg/g increase in β2MGCr. This association was 
mostly lost after controlling for concomitant protease inhibitor and TFV or TFV-DP 
concentration, although there was a signal indicating the effect of LDV/SOF on RBPCr and 
β2MGCr may be greater in those on atazanavir. The confidence interval for this association, 
however, was quite wide.  
Summary of Findings for Aim 3 
These data suggest LDV/SOF treatment in HIV/HCV coinfected individuals taking TDF 
plus ritonavir-boosted protease inhibitors may cause increases in markers of renal proximal 
tubulopathy in some patients, particularly in those taking ritonavir-boosted atazanavir.  
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Table 5  
Demographic Data for the 22 Participants in Cohort 2 of ACTG 5327 (SWIFT-C) on TDF 
 Cohort 2 (N=22) 





Hispanic, N (%) 
White, N (%) 
 
6   (27) 
16 (73) 
Baseline CLcr (mL/min): mean + SD 107.5 + 15.7 
Age (years): mean + SD 44.4 + 8.8 
Weight (kg): mean + SD 76.9 + 9.6 







8  (36) 
11 (50) 
9  (41) 
4  (18) 




Table 6  
Demographic Data for the 12 Participants Enrolled in COMIRB 15-0123 and the 10 Participants 
that Completed Baseline and Week 4 Mini-Intensive Pharmacokinetic Visits 
 N=12 enrolled  N=10 completed baseline and 
week 4 
Age (years),  
mean (SD, range)  
48.2 (9.4, 28-64) 48.2 (10.4, 28-64) 
Weight (kg),  
mean (SD, range) 
76.9 (20, 48-123) 72.1 (14.3, 48.2-92) 
CrCl (mL/min) 
Mean (SD, range) 
98.1 (28, 54-147) 98.7 (30, 54-147) 










Protease Inhibitor 8 on DRV/r 
4 on ATV/r 
7 on DRV/r 




Table 7  
Tenofovir (TFV) and Tenofovir-Diphosphate Concentrations at Baseline (pre-LDV/SOF) and 
week 4 of LDV/SOF. Data are reported as geometric mean (GM) and the corresponding 95% 
Confidence Interval 
 PK Measure Baseline GM [95% CI] Week 4 GM [95% CI] 
TFV C0h (ng/mL) 43.3 [21.3, 88.0] 58.1 [26.8, 125.7] 
TFV C1h (ng/mL) 198.6 [74.1, 532.4] 363.9 [222.0, 596.7] 
TFV C4h (ng/mL) 206.6 [177.5, 240.4] 295.5 [242.4, 360.1] 
TFV-DP PBMCs (fmol/106 cells) 80.2 [38.4, 167.5] 224.2 [117.6, 427.1] 
TFV-DP RBCs (fmol/106 cells) 129.5 [71.2, 235.6] 1419.9 [896.7, 2248.4] 




Table 8 Geometric mean (%CV, range) tenofovir diphosphate (TFV-DP) concentrations in 
fmol/punch at study entry vs. week 8 in those receiving a boosted antiretroviral regimen vs. an 
unboosted antiretroviral regimen in ACTG 5327. Number of patients with available samples are 
shown with n= for each time point. 
 Ritonavir or 
Cobicistat Boosted 
Unboosted p-value from 
unpaired t-test 
Pre-LDV/SOF 1922 (29%, 1132, 
2969), n=9 
1287 (32%, 867, 
2206), n=13 
p=0.0052 
Week 8 LDV/SOF 21699 (48%, 10221, 
41978), n=7 






Table 9 Geometric mean (%CV, range) Tenofovir Diphosphate (TFV-DP) Concentrations in 
Dried Blood Spots (DBS) in Participants from ACTG 5327 and COMIRB 15-0123 (Pooled) by 
Antiretroviral Regimen. Number of patients with available samples are shown with n= for each 
time point. 
 Pre-LDV/SOF Week 8 LDV/SOF 
Ritonavir or 
Cobicistat Boosted 
2071 (49%, 635, 5231), n=21 21142 (59%, 4528, 61493), n=16 
Ritonavir/boosted 
atazanavir 
1911 (38%, 965, 3022), n=7 23896 (62%, 4528, 18802), n=7 
Ritonavir-boosted 
darunavir  
2184 (57%, 635, 5231), n=10 17706 (55%, 8362, 36393), n=7 
Elvitegravir/cobicistat 2028 (35%, 1132, 2969), n=4 25655 (48%, 17981, 36605), n=2 
Unboosted 1287 (32%, 867, 2206), n=13 30031 (47%, 10312, 69239), n=13 






Table 10  
Univariate Associations with TFV-DP in DBS. The asterisk (*) indicates the percent change in 
TFV-DP for every 100 ng/mL increase in TFV concentration in plasma. Statistically significant 
covariates are bolded. 
Covariate Parameter Estimate (95% CI) P-value 
Weight 0.99 (0.97, 1.01) 0.3396 
Age 0.98 (0.96, 1.009) 0.2245 
CrCl 0.998 (0.99, 1.006) 0.6590 
No Booster 
RTV or cobi booster 
8696 (6075, 12447) 




8512 (6154, 11772) 
8198 (3793, 17721) 
0.8684 
Integrase No Booster 
Boosted 
NNRTI 
NNRTI + Integrase 
7028 (4261, 11592) 
8180 (6274, 10666) 
12215 (7937, 18798) 






7897 (5948, 10485) 
8171 (5312, 12572) 
15964 (4644, 54885) 




8344 (6635, 10494) 




8424 (6486, 10943) 




8179 (6243, 10716) 




7614 (4601, 12601) 
8895 (2605, 30376) 
0.6713 
TimeonDrug (weeks*LDVSOF) 1.23 (1.19, 1.27) <0.0001 
COMIRB 15-0123 
ACTG 5327 
8619 (5855, 12689) 




3617 (2810, 4654) 
17590 (11120, 27825) 
<0.0001 
TFV Concentration in Plasma 46.2 (23, 53)* <0.0001 
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Table 11  
Association Between Demographic and Clinical Covariates and TFV-DP DBS in Multivariable 
Models. The asterisk (*) indicates the percent change in x for every 1 unit increase in y. 




LDV/SOF and TFV 
 
TFV-DPDBS = e7.5 * 










TFV in plasma 
(per 100ng/mL ↑) 8.13 (-0.4, 17.4)* 0.0615 
Model 2 
LDV/SOF and TFV 
and Booster 
 
TFV-DPDBS = e7.5 *  











TFV in plasma 
(per 100ng/mL ↑) 8 (-0.5, 17.3)* 0.0664 
Booster (RTV or 
cobi) 8.5 (-24.5, 55.6)* 0.6566 
Model 3 




TFV-DPDBS = e7.2 * 












TFV in plasma 
(per 100ng/mL ↑) 9.9 (1.88, 18.6)* 0.0153 




72.0 (14.6, 158))* 




Table 12  
Tenofovir Monoester Concentrations in 10 HIV/HCV Coinfected Individuals Before (Visit 1) 
and After (Visit 2) Initiation of LDV/SOF. 




Visit 2 vs. 1 












1.72 [0.36, 8.18] 






Table 13  








Median (IQR) tenofovir 
troughs in plasma 
66 (36, 78) 66 (48,76) 43 (9, 82) 
Median (IQR) TFV-DP in 
DBS  
2754 (1343, 3190) 2754 (1343, 3862) 2606 (1897, 3009)
Median (IQR) TFV-DP in 
PBMCs  
116 (66, 130) 106 (66, 139) 116 (84, 124) 
Median (IQR) CrCl, 
mL/min* 
90 (79, 123) 95 (77, 124) 90 (81, 105) 
Median (IQR) Protein:Cr 
ratio in urine 
0.09 (0.08, 0.14) 0.09 (0.08, 0.12) 0.11 (0.07, 0.15) 
Median (IQR) Beta-2 
Microglobulin/volume 
(mcg/L) 
141 (108, 248) 139 (98, 249) 141 (135, 329) 
Median (IQR) Beta-2 
Microglobulin:Cr (mcg/g) 
110 (100, 120) 110 (102, 119) 108 (96, 150) 
Median (IQR) Retinol 
Binding Protein (mcg/L) 
182 (87, 221) 186 (58, 221) 179 (140, 232) 
Median (IQR) Retinol 
Binding Protein:Cr (mcg/g) 




Table 14  
RBPCr and β2MGCr at Baseline (prior to LDV/SOF) and week 12 of LDV/SOF treatment. P 
values determined using paired t-tests of natural log transformed values. 
Pre-LDV/SOF 
(N=12) 
Week 12 (N=6) p-value 
Median (IQR) CrCl, mL/min* 90 (79, 123) 102 (78, 124) 0.2 
Median (IQR) Protein:Cr ratio in 
urine 
0.09 (0.08, 0.14) 0.1 (0.07, 0.14) 0.7 
Median (IQR) Beta-2 
Microglobulin/volume (mcg/L) 
141 (108, 248) 152 (95, 249) 0.5 
Median (IQR) Beta-2 
Microglobulin:Cr (mcg/g) 
110 (100, 120) 110 (75, 163) 0.2 
Median (IQR) Retinol Binding 
Protein (mcg/L) 
182 (87, 221) 196 (104, 281) 0.4 
Median (IQR) Retinol Binding 
Protein:Cr (mcg/g) 




Table 15  
Univariate Associations with RBPCr. The parameter estimates and corresponding 95% 
confidence intervals are shown. The asterisk (*) indicates the percent change in RBPCr for every 
100 unit increase in x. P-values <0.1 are bolded. 
Covariate Parameter Estimate (95% CI) P-value 
Weight 1.0025 (0.99, 1.02) 0.6990 
Age 1.0045 (0.98, 1.03) 0.6945 
CrCl 0.998 (0.99, 1.00) 0.4944 
Males 
Females 
116 (91.2, 147.9) 




115 (88.4, 151) 




114 (87.7, 149.1) 




102.5 (81.5, 134.3) 
144.4 (109.9, 200.3) 
0.072 
TimeonDrug (weeks*LDVSOF) 1.0088 (0.98, 1.04) 0.5089 
No LDV/SOF 
LDV/SOF 
97.3 (73.7, 121.5) 
125 (99.5, 164) 
0.0553 
TFV Concentration in Plasma 18.5 (3, 30)* 0.0190 
TFV-DP in DBS 0.13 (0.1, 0.2)* 0.0289 




Table 16  
Multivariable Models for RBPCr. The parameter estimates and corresponding 95% confidence 
intervals are shown. P-values <0.1 are bolded. The asterisk (*) indicates the percent change in 
RBPCr for every unit increase in x. 





TFV in Plasma 
 
RBPCr = e4.4 * e0.08LDV/SOF * 






85 (63.7, 114.6) 
 
92.8 (69, 124) 
0.6356 
Atazanavir 40 (15, 66)* 0.0409 
TFV 
(per 100ng/mL ↑)
13.9 (-2.7, 33)* 0.1003 
Model 2 
TFV-DP in DBS 
 
RBPCr = e4.5 * e-0.015LDV/SOF + 






89 (66, 120) 
 
90 (60, 127.5) 
0.9429 
Atazanavir 42 (-1.26, 104)* 0.0580 
 
TFV-DP in DBS 0.11 (-0.4, 0.23)* 0.1491 
Model 3 
TFV-DP in PBMC 
 
RBPCr = e4.5 * e-0.05LDV/SOF * 






92.7 (69, 124.5) 
 
88.2 (63, 124.5) 
0.5837 
Atazanavir 1.7 (-38, 67)* 0.9403 
TFV-DP in 
PBMC 




Table 17  
Multivariable Models with Interaction for LDV/SOF*PI for RBPCr. The parameter estimates 
and corresponding 95% confidence intervals are shown. P-values <0.1 are bolded. The asterisk 
(*) indicates the percent change in RBPCr for every 100 unit increase in x. 




TFV in Plasma 
 
RBPCr = e4.6 * e-
0.07LDV/SOF * e0.1022TFV 
* e-0.02304ATV * 
e0.5355LDV/SOF * ATV 
Intercept No LDV/SOF 
Intercept LDV/SOF 
97.9 (70, 137) 
91.6 (68.9, 121.9) 
0.7332 
TFV (per 100 ng/mL ↑) 10.7 (-5.4, 29.6)* 0.1921 
No LDV/SOF + 
atazanavir 
LDV/SOF + atazanavir 
-2.3 (-44, 70.6)* 
66.9 (-13.7, 238)* 
0.1189 
Model 2 
TFV-DP in DBS 
 
RBPCr = e4.6 * e-
0.1482LDV/SOF * 
e0.00081TFV-DPDBS * e-
0.03ATV * e0.58LDV/SOF * 
ATV 
Intercept No LDV/SOF 
Intercept LDV/SOF 
102 (73.5, 141.5) 
87.9 (61.5, 125.8) 
0.5018 
TFV-DP in DBS  
(per 100fmol/106 cell ↑) 
0.08 (-0.068, 0.23)* 0.2747 
No LDV/SOF + 
atazanavir 
LDV/SOF + atazanavir  
-3.32 (-45, 70)* 





Table 18  
Univariate Associations with β2MGCr. The parameter estimates and corresponding 95% 
confidence intervals are shown. The asterisk (*) indicates the percent change in β2MGCr for 
every 100 unit increase in x. P-values <0.1 are bolded. 
Covariate Parameter Estimate (95% CI) P-value 
Weight 1.004 (0.97, 1.03) 0.9790 
Age 1.009 (0.96, 1.06) 0.7396 
CrCl 0.99 (0.98, 1.003) 0.1428 
Male 
Female 
178.4 (102.3, 311) 




191 (105, 348) 




156.3 (86.5, 282.5) 




133 (81, 220) 
286 (139, 587) 
0.0866 
TimeonDrug (weeks*LDVSOF) 1.02 (.097, 1.06) 0.4476 
No LDV/SOF 
LDV/SOF 
136 (79, 232) 
205 (123, 341) 
0.0613 
TFV Concentration in Plasma 35 (13, 57)* 0.0033 
TFV-DP in DBS 0.26 (0. 07, 0.45)* 0.0083 






Table 19  
Multivariable Models for β2MGCr. The parameter estimates and corresponding 95% confidence 
intervals are shown. P-values <0.1 are bolded. The asterisk (*) indicates the percent change in 
β2MGCr for every 100 unit increase in x. 




TFV in Plasma 
 
β2MGCr = e4.5 * 
e0.2LDV/SOF *  






90.2 (47, 173.1) 
 
110.4 (56.2, 216.9) 
0.4593 
Atazanavir 92 (-27.7, 409.8)* 0.1816 
TFV (per 100 ng/mL 
↑) 
29 (4, 54)* 0.0226 
Model 2 
TFV-DP in DBS 
 








98.8 (51.9, 188) 
 
95.7 (43.1, 212.6) 
0.9294 
Atazanavir 98.2 (-25, 423.7)* 0.1602 
TFV-DP in DBS 
(per 100 fmol/106 
cell ↑) 
0.3 (0.018, 0.5)* 0.0657 
Model 3 
TFV-DP in PBMC 
 
β2MGCr = e4.7 *  
e0.1087LDV/SOF *  





111.3 (57.6, 215.2) 
 
124.1 (48.9, 315.2) 
0.7545 
Atazanavir -7.68 (-67.6, 162.8)* 0.8645 
TFV-DP in PBMC 
(per 100 fmol/106 
cell ↑) 
22 (-4, 44)* 0.0952 
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Table 20  
Multivariable Models with Interaction for LDV/SOF*PI for β2MGCr. The parameter estimates 
and corresponding 95% confidence intervals are shown. P-values <0.1 are bolded. The asterisk 
(*) indicates the percent change in β2MGCr for every 100 unit increase in x. 





TFV in Plasma 
 
β2MGCr = e4.8 * e-
.1116LDV/SOF * e0.2357TFV 
* e-0.05156ATV * 
e1.1632LDV/SOF * ATV 
Intercept No LDV/SOF 
Intercept LDV/SOF 
118.0 (60.4, 230.5) 
105.5 (55, 202.3) 
0.6996 
TFV (per 100ng/mL ↑) 26.6 (-0.4, 61)* 0.0539 
No LDV/SOF + atazanavir 
LDV/SOF + atazanavir 
-5 (-69.4, 194.5)* 
203.7 (14.6, 
792.3)*    
0.0280 
Model 2 
TFV-DP in DBS 
 




e1.2495LDV/SOF * ATV  
Intercept No LDV/SOF 
Intercept LDV/SOF 
129.5 (67.3, 249.3) 
95.7 (44.8, 204.3) 
0.3989 
TFV-DP in DBS (per 100 
fmol/106 cells ↑) 
0.19 (-0.07, 0.45)* 0.1469 
No LDV/SOF + atazanavir 
LDV/SOF + atazanavir 
-7.4% (-70, 186) 







Figure 11. Geometric mean (%CV) TFV-DP (fmol/punch) concentrations in DBS samples at 
study entry (before starting LDV/SOF), Weeks 1, 2, 4 and 8 of LDV/SOF treatment, and 2, 4, 8 
and 12 weeks after completing LDV/SOF treatment (EOT+2, EOT+4, EOT+8 and EOT+12). 





Figure 12. Geometric mean (%CV) TFV (ng/mL) concentrations in plasma samples at study 
entry (before starting LDV/SOF), after 8 weeks of LDV/SOF treatment, and 12 weeks after 
completing LDV/SOF treatment (EOT+12). The TFV concentrations were 2.1-fold higher at 




Figure 13. Natural log transformed TFV-DP (fmol/punch) concentrations in peripheral blood 
mononuclear cells (A), red blood cells (B), and dried blood spots (C) in the 10 individual participants in 
COMIRB 15-0123 before (baseline) and after 4 weeks of LDV/SOF. The geometric mean ratio of TFV-
DP concentrations with vs. without LDV/SOF and the corresponding 95% CI are shown. Concentrations 





Figure 14. Natural Logarithm Tenofovir Monoester Concentrations at 1 hour (A) and 4 hours (B) 
post-dose, Geometric Mean Ratios (95%CI) are shown for tenofovir monoester with vs. without 
LDV/SOF, p-values are from paired t-tests.   
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Figure 15. Changes in RBPCr and β2MGCr over time for each individual participant in 15-0123. 
The black lines indicate the upper limits of the reference ranges for RBPCr and β2MGCr. 
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Figure 16. Correlations between natural log transformed plasma tenofovir and tenofovir 
diphosphate in dried blood spots and peripheral blood mononuclear cells and natural log 






Figure 17. Correlations between natural log transformed plasma tenofovir and tenofovir 
diphosphate in dried blood spots and peripheral blood mononuclear cells and natural log 









CHAPTER V  
DISCUSSION 
Summary of Overall Findings 
Within the context of this thesis project, an unexpected cellular drug interaction between 
TDF and LDV/SOF was identified. TFV-DP in DBS was increased 17.8-fold after 8 weeks of 
LDV/SOF in ACTG 5327. These findings were confirmed and extended in COMIRB 15-0123 
where a 7.3-fold increase in TFV-DP in DBS and a 2.8-fold increase in TFV-DP in PBMCs after 
4 weeks of LDV/SOF was observed. Clinical data to support a proposed mechanism for the 
interaction were generated. A method to measure the intermediate in TDF to TFV hydrolysis, the 
TFV-monoester, was developed, then using this method, the tenofovir monoester was found to 
be 5-fold higher with the addition of LDV/SOF. Given the greater lipophilicity of the TFV-
monoester, there was likely increased delivery of the drug to cells, resulting in higher TFV-DP 
concentrations in the presence of LDV/SOF. The magnitude of the effect of LDV/SOF on TFV-
DP was found to be lower in those taking ritonavir or cobicistat as part of their antiretroviral 
regimen. This too was an unexpected finding given absolute tenofovir plasma concentrations are 
higher in those on boosted regimens vs. unboosted regimens. Lastly, the potential clinical impact 
of the interaction (increased risk for tenofovir-induced proximal tubulopathy) was explored. TFV 
and TFV-DP were positively associated with RBPCr and β2MGCr. LDV/SOF also trended 
towards being significant, increasing RBPCr and β2MGCr by 28 µg/g (p=0.06) and 69 µg/g 
(p=0.06), respectively. There was also a signal towards a greater increase in RBPCr and 
β2MGCr in those on atazanavir, though the confidence intervals were wide. Collectively, these 
data establish an interaction between LDV/SOF and TDF occurring at the level of TDF 
hydrolysis. At the cellular level, the magnitude of the interaction is less in those on an 
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antiretroviral regimen containing ritonavir or cobicistat. Although the clinical implications 
remain largely unknown, there does not appear to be an increased risk of overt proximal 
tubulopathy during the 8-12 weeks of LDV/SOF treatment, but additional renal monitoring may 
be indicated in those receiving an ARV regimen including TDF plus ritonavir-boosted 
atazanavir. Figure 19 provides a graphical summary of the overall findings. 
Aim 1   
Prior to the start of this work, the plasma levels of TFV, when given as TDF, were known 
to be increased with LDV/SOF. The magnitude of the increase in TFV was dependent on the 
concomitant antiretroviral agents administered with LDV/SOF and TDF, but ranged from 30%-
80%.107 The mechanism for the interaction was presumed to be inhibition of P-gp or BCRP by 
LDV. Absolute tenofovir exposures were highest when LDV/SOF was administered with TDF 
and ritonavir or cobicistat. When these boosting agents were administered with TDF and 
LDV/SOF, TFV exposures exceeded the range with established renal safety data. Thus, HCV 
treatment guidelines cautioned against the use of LDV/SOF with ARV regimens containing TDF 
and a boosting agent. In cases where the combination could not be avoided, increased renal 
monitoring was advised. COMIRB 15-0123 was designed to generate pharmacokinetic and 
safety data with this combination. Concurrent with COMIRB 15-0123, the ACTG undertook a 
study of SOF/RBV (first) and subsequently LDV/SOF for acute HCV in HIV-infected 
individuals. In both of these studies, DBS were obtained. An unexpectedly low SVR rate with 
SOF/RBV in Cohort 1 of ACTG 5327 prompted an evaluation of long term adherence to HCV 
treatment (using ribavirin plasma concentrations) and HIV treatment (using TFV-DP 
concentrations in DBS). Through these investigations, an unexpected interaction was observed 
between SOF/RBV and TDF, whereby TFV-DP concentrations were increased 4.3-fold and 2.3-
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fold in DBS and PBMC, respectively. Armed with the knowledge that TFV plasma exposures 
were increased with LDV/SOF and that SOF/RBV increased cellular TFV-DP concentrations, 
LDV/SOF was expected to increase TFV-DP concentrations, but not to the magnitude observed. 
After 8 weeks of LDV/SOF in Cohort 2 of ACTG 5327, plasma TFV concentrations were 
increased ~2-fold, which was similar to historical data, but TFV-DP in DBS was increased 17.8-
fold. The magnitude of this interaction precludes the use of TFV-DP in DBS as a measure of 
TDF adherence, but it also raised questions about the potential mechanism for this interaction 
and the clinical implications. TDF is associated with concentration-dependent nephrotoxicity, 
specifically renal proximal tubulopathy. It was unclear whether the interaction observed in DBS 
occurred in other cell types. Nucleos(t)ide analogs can also cause mitochondrial dysfunction if 
the drug triphosphate is incorporated into human mitochondrial DNA polymerase gamma rather 
than the endogenous base. TFV-DP has a low affinity for human mitochondrial DNA polymerase 
gamma, but higher cellular concentrations could conceivably increase the likelihood for 
incorporation of TFV-DP and increase the risk for mitochondrial toxicity. To save costs, PBMCs 
were not collected in Cohort 2 of ACTG 5327. Thus, it was not possible to determine if TFV-DP 
was increased in this cell type. However, within COMIRB 15-0123, PBMCs were obtained. 
Markers of renal proximal tubulopathy were also collected. After 4 weeks of LDV/SOF in 
COMIRB 15-0123, TFV-DP was increased 7.3-fold in DBS and 2.8-fold in PBMCs. Plasma 
concentrations were increased 43%-83% depending upon time post TDF-dose. These two 
independent clinical studies confirmed an unanticipated drug interaction between TDF and 
LDV/SOF, resulting in higher TFV-DP concentrations and COMIRB 15-0123 found the 
interaction occurred in PBMCs as well, but to a lesser extent.  
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The impact of clinical and demographic factors on the magnitude of the interaction was 
investigated. Previously, sex, black race, weight, and antiretroviral regimen were associated with 
TFV-DP in DBS in HIV-monoinfected individuals.108 Specifically, NNRTIs were associated 
with lower TFV-DP in DBS and boosters were associated with higher TFV-DP in DBS. 
Theoretically patients on boosters should have higher TFV-DP concentrations with LDV/SOF 
because both LDV and ritonavir and cobicistat increase plasma levels of TFV which would 
increase delivery of TFV to cells. HIV protease inhibitors are also taken with food, whereas 
NNRTI-based regimens are taken on an empty stomach, so there may be higher levels of TFV-
DP by virtue of competition with food for esterases with the HIV protease inhibitors, resulting in 
higher tenofovir monoester concentrations. In ACTG 5327, there were 9 patients on a boosted 
antiretroviral regimen and 13 patients on an unboosted regimen. Prior to LDV/SOF initiation, 
TFV-DP concentrations were higher in those on a boosted regimen. This was expected and 
consistent with historical data, but after 8 weeks of LDV/SOF, patients on a booster actually had 
lower TFV-DP levels. This difference was not statistically significant, but two patients (both on 
boosters) switched to TAF and were therefore excluded from the week 8 comparison, limiting 
power for this comparison. Given COMIRB 15-0123 included only patients on boosted 
regimens, data were pooled from both studies to enrich the number on boosted regimens and 
further investigate this relationship. Using mixed models, which accounted for repeated 
measures, the effect of LDV/SOF on TFV-DP was found to be 36.5% lower in those taking a 
booster. The mechanism for this is unclear. Though this work identified a potential mechanism 
for the interaction between TDF and SOF, it does not completely explain why the effect of 
LDV/SOF on TFV-DP was less in those on boosters. HIV protease inhibitors are known to 
inhibit TDF hydrolysis.58 They also inhibit several efflux transporters including P-gp, BCRP, and 
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several multidrug resistance proteins.70,109 An effect on phosphorylation or dephosphorylation 
enzymes is plausible as well. Perhaps there is some form of saturation of one of these processes 
by ritonavir or cobicistat, which mediates the interaction. Additional studies are needed to 
elucidate the mechanism for these findings. It is conceivable that patients on a boosted regimen 
were less adherent than those on an unboosted regimen, but the interaction with LDV/SOF 
precludes use of TFV-DP in DBS to assess TDF adherence.  
No effect of sex, black race, or body weight on TFV-DP in DBS was observed, which 
differs from prior findings in HIV monoinfected patients.108 However, this dataset is 
considerably smaller than the prior study. We had very few women (12%) and blacks (12%), so 
were limited in the ability to evaluate the effect of sex or black race on TFV-DP in DBS. ACTG 
5327 and COMIRB 15-0123 also included TFV-DP concentrations obtained before, during and 
after LDV/SOF treatment and it is likely that the interaction with LDV/SOF may have 
overwhelmed other effects.  
Plasma tenofovir levels appeared higher in COMIRB 15-0123 compared with ACTG 
5327. However, time post TDF dose was not controlled for in these analyses because these data 
were not available for all time points in COMIRB 15-0123 (only the pre- and 4 week post 
LDV/SOF visits). Thus, it is possible that samples were obtained closer to the end of the dosing 
interval in ACTG 5327 compared with closer to the time of recent TDF dosing in COMIRB 15-
0123. Besides LDV/SOF use, no other demographic or clinical factors were associated with TFV 
plasma concentrations. As with the TFV-DP model, this is surprising since prior studies have 
found factors such as renal function and weight to be associated with TFV plasma 
concentrations, but no effect was observed in this dataset. 
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In summary, TFV-DP concentrations in DBS were increased 17.8-fold after 8 weeks of 
LDV/SOF in ACTG 5327 and 7.3-fold after 4 weeks of LDV/SOF in COMIRB 15-0123. TFV 
plasma levels and TFV-DP concentrations in PBMCs were also increased, but to a lesser extent 
(~2-fold and 2.8-fold, respectively). Though individuals taking an antiretroviral regimen that 
included a booster (either ritonavir or cobicistat) had higher TFV-DP concentrations in DBS at 
baseline (prior to initiating LDV/SOF), the increase in TFV-DP with the addition of LDV/SOF 
was 36.5% less compared with the increase in those on unboosted regimens.  
Aim 2   
 Research conducted by Nye and colleagues in London100 and Shen and Yan at Rhode 
Island93 guided this thesis work towards a potential mechanism for the interaction between TDF 
and LDV/SOF. In the course of developing an analytical method, Nye and colleagues identified a 
compound (in plasma samples obtained from individuals taking TDF) with a mass to charge ratio 
corresponding in elemental composition to TFV monoester. This finding challenged prior 
literature which indicated that conversion of the prodrug of TDF to TFV was complete and rapid 
and only parent TFV was detected in human plasma in patients receiving TDF.52,110 This finding 
raised questions about the contribution of the TFV monoester, which was more lipophilic than 
parent TFV, to the cellular pharmacology of this drug. It has been generally accepted that TDF 
hydrolysis was mediated first by CES2, converting TDF to the TFV monoester, and then by an 
unspecified hepatic phosphodiesterase, converting the monoester to parent TFV.51,101 The 
evidence to support this assertion in the literature, however, is quite limited. Shen and Yan 
conducted a series of experiments which found SOF inhibited TDF hydrolysis via inhibition of 
CES2 in vitro. The analytical method for parent TFV already in use in the CAVP laboratory was 
extended to measure the TFV monoester. This method was used to investigate the effect of 
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LDV/SOF on TFV monoester in COMIRB 15-0123. This method was also used to define the 
monoester PK in a separate study (A-TEAM) which included intensive sampling of HIV 
seronegative individuals receiving TDF.101 The A-TEAM data provided context for the findings 
in COMIRB 15-0123. In COMIRB 15-0123, TFV monoester was measured at pre-dose, 1 and 4 
hours post-dose. Consistent with the short half-life for the monoester (26 minutes as defined in 
A-TEAM), TFV monoester was not detectable at pre-dose in any participant. At 1 hour post-
dose, TFV monoester was 1.72-fold higher when patients took LDV/SOF compared to baseline. 
This difference was not statistically significant, but data from A-TEAM would suggest at 1 hour 
post dose some participants were likely still in the absorption phase, while others were already in 
the distribution phase (A-TEAM Tmax 0.5 hours (0.25 – 2). At 4 hours post dose, TFV monoester 
concentrations were 5-fold higher with LDV/SOF compared to baseline. These data establish 
that the mechanism by which LDV/SOF increases TFV-DP is via inhibition of TDF hydrolysis, 
though the exact enzyme (e.g., CES2) that SOF inhibits cannot be confirmed with this work. A 
variety of esterases appear capable of hydrolyzing TDF51 and additional research would be 
needed to confirm the exact enzyme(s) affected. TFV monoester concentrations were higher in 
COMIRB 15-0123 compared with A-TEAM. TFV monoester at 1 hour post dose was 97.4 
ng/mL in COMIRB 15-0123 at baseline vs. 38.7 ng/mL in A-TEAM. TFV monoester at 4 hours 
post dose was 0.74 ng/mL in COMIRB 15-0123 vs. 0.17 ng/mL in A-TEAM. The difference in 
exposures may be due to food effects as A-TEAM participants were fasted and COMIRB 15-
0123 participants received a standardized meal. The presence of boosted protease inhibitors in 
COMIRB 15-0123 also likely contributed via P-gp and esterase inhibition. P-gp inhibition by 
ledipasvir may also have prevented the recycling of tenofovir disoproxil and/or monoester back 
to the gut where it is converted to tenofovir. There were also differences in the patient 
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populations, A-TEAM was HIV seronegative volunteers whereas COMIRB 15-0123 included 
HIV/HCV coinfected persons.   
In summary, tenofovir monoester concentrations were 5-fold higher at 4 hours post-dose 
with LDV/SOF relative to TDF alone. Given the greater lipophilicity of the TFV monoester 
relative to TFV106, it is highly likely that the increased TFV-DP concentrations are the direct 
result of cellular loading of the TFV monoester.  
Aim 3 
TDF use has been associated with nephrotoxicity, primarily renal proximal 
tubulopathy.111 Prior work attributed this tubulopathy to effects on mitochondria in the renal 
proximal tubule cells,112 but data are conflicting. Recent work with TDF and TAF found no 
effect of either compound on T-cell mitochondria.113 Tubulopathy appears to be regulated by 
OAT1 and MRP4 expression which effect TFV uptake and efflux.114  Tubulopathy has been 
positively associated with plasma TFV concentrations in patients taking TDF.41 There are fewer 
data on the associations of TFV-DP with TDF-associated nephrotoxicity. A natural question then 
for the field is whether the drug interaction observed with LDV/SOF and TDF increases the risk 
of nephrotoxicity.   
All patients in COMIRB 15-0123 had CrCl > 60 mL/min at study enrollment (median 
was 98 mL/min). There was no change in CrCl during LDV/SOF treatment (end of treatment 
median CrCl was 94 mL/min). Among the 12 patients that enrolled in COMIRB 15-0123, all but 
1 had RBPCr and β2MGCr measures within normal limits prior to initiating LDV/SOF. Despite 
the fact that had RBPCr and β2MGCr were quantified in many clinical studies with TAF, the 
absolute values were seldom reported and were typically reported as changes from baseline. This 
limits comparisons of our values to historical data. RBP and β2MG (without adjustment for 
118 
creatinine) were quantified in ION-4 and values observed in our HIV/HCV coinfected patients 
were higher for RBP (182 mcg/L vs. 147 mcg/L in ION-4), but lower for β2MG (141 mcg/L vs. 
240 mcg/L in ION-4).95 ION-4 also enrolled HIV/HCV coinfected individuals, but HIV protease 
inhibitor use was exclusionary. In addition to the one patient with elevated RBPCr and β2MGCr 
at baseline, five additional patients had an elevation of RBPCr and/or β2MGCr during LDV/SOF 
treatment. Three of these six patients were on atazanavir and three were on darunavir. When 
comparing baseline and end of treatment RBPCr and/or β2MGCr values, there were no 
statistically significant changes. However, this analysis did not account for repeated measures.   
In univariate mixed models analysis, the same covariates were associated with RBPCr 
and β2MGCr. TFV concentrations and TFV-DP concentrations were positively associated with 
RBPCr and/or β2MGCr. LDV/SOF and atazanavir trended towards increasing RBPCr and 
β2MGCr. In multivariable models for RBPCr, the effect of atazanavir and TFV-DP in PBMCs 
was retained and there was a trend for TFV in plasma (p=0.1). In multivariable models for 
β2MGCr, TFV in plasma and TFV-DP in DBS were retained and there was a trend for TFV-DP 
in PBMC (p=0.09) and atazanavir (p=0.16 and 0.18). An interaction term was included to 
explore whether the effect of LDV/SOF on RBPCr and β2MGCr differed by protease inhibitor. 
The effect of LDV/SOF on β2MGCr was greater in those on atazanavir. There was a trend for 
this effect observed in RBPCr.  
For interpretation of findings, one would expect a 10% increase in RBPCr with a 
doubling in TFV plasma concentrations. Given a baseline RBPCr of ~100 mcg/g which was the 
median for patients based on raw data and the intercept for the model, and an estimated 10% 
increase in RBPCr for every 100 ng/mL increase in TFV, this would be an increase to 110 
mcg/g. If the patient were also taking atazanavir and LDV/SOF there would be an additional 
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70% increase in RBPCr to 187 mcg/g. 187 mcg/g is higher than the upper limit of the reference 
range of 172 mcg/g. For interpretation of β2MGCr, given a baseline of ~110 mcg/g, and an 
estimated 27% increase in RBPCr for every 100mg/mL increase in TFV, this would be an 
increase to 139 mcg/g. If the patient were also taking atazanavir and LDV/SOF, there would be 
an additional 203% increase in RBPCr to 421 mcg/g. 421 mcg/g is higher than the upper limit of 
the reference range of 300 mcg/g. Thus, it is conceivable that some patients on atazanavir and 
TDF, particularly those with higher baseline TFV concentrations may have some proximal 
tubule injury with LDV/SOF.  
There is biologic plausibility for an effect of atazanavir on RBPCr and β2MGCr. 
Atazanavir is a more potent inhibitor of TDF hydrolysis and P-gp compared with darunavir in 
vivo.58 Thus, some of the effect of atazanvir on RBPCr and β2MGCr may be attributed to its 
effect on TFV and TFV-DP PK, however our model indicates atazanavir has an independent 
effect. Atazanavir has been associated with urolithiasis, acute interstitial nephritis, acute kidney 
injury, chronic kidney disease, and tubulopathy.115,116Atazanavir is often given with TDF, thus is 
it conceivable that direct effects of atazanavir on the proximal tubules are often masked by TDF. 
However, at least two retrospective analyses have identified an independent effect of atazanavir 
after controlling for TDF. Calza and colleagues found that among 235 HIV-infected individuals 
taking TDF/FTC, those taking ritonavir-boosted atazanavir had a 14.1% incidence of 
tubulopathy (defined as ≥2 of the following:  proteinuria, glycosuria, hypouricemia, 
hypophosphatemia, or hypokalemia on ≥1 occasion) at 12 months compared with 4.9% on 
efavirenz and 5.3% on ritonavir-boosted lopinavir.117 In the Aquitaine cohort, among 399 HIV-
infected individuals, the odds of proximal tubular dysfunction (defined as 2 of the following: 
phosphate diabetes, glucosuria, metabolic acidosis, β2MGCr > 300 mcg/g, or low serum uric 
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acid) were 1.28 per year of exposure (p=0.02) in patients receiving atazanavir after controlling 
for other antiretrovirals.118 
In summary, these data suggest LDV/SOF treatment in HIV/HCV coinfected individuals 
taking TDF plus ritonavir-boosted protease inhibitors may cause increases in markers of renal 
proximal tubulopathy in some patients, particularly in those taking ritonavir-boosted atazanavir. 
Limitations 
 There are limitations of the clinical studies and analyses used for this thesis that impact 
interpretation and generalizability of findings. Data were pooled from two separate studies to 
evaluate demographic and clinical factors that impact the magnitude of the LDV/SOF and TDF 
interaction. The patient populations in these two studies differed in ways that can be quantified 
(e.g., ACTG 5327 included patients with acute HCV whereas COMIRB 15-0123 included those 
with chronic HCV), but there may also have been differences that could not be quantified. A 
covariate for “study” was included in the analyses to account for these differences, but study was 
not significantly associated with TFV-DP in DBS or TFV in the mixed models.  
An important limitation for the plasma TFV model is that time post-dose was not 
controlled. Time post-dose data for TDF administration was not collected at all study visits in 
COMIRB 15-0123. Time post dose is relevant for plasma TFV (17 hour half-life), but not 
relevant for TFV-DP given the long (17 day) half-life.  
In ACTG 5327, the interaction plateaued faster than expected given the 17 day half-life 
of TFV-DP in DBS. The maximal effect had been achieved by week 4. Thus, the increase in 
TFV-DP concentrations were reported at week 4 in COMIRB 15-0123 to coincide with TFV 
monoester results. In retrospect, the magnitude of the interaction may have continued to increase 
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in COMIRB 15-0123, reaching a 11.2-fold increase in TFV-DP in DBS by week 8. However, 
three participants were lost from week 4 to week 8, so these drop outs may have contributed.   
The week 8 measures in ACTG 5327 and week 12 measures in COMIRB 15-0123 may 
have occurred after discontinuing LDV/SOF. The visit window for Week 8 in ACTG 5327 was –
7 days to +14 days. For COMIRB 15-0123, the visit window was +/- 7 days. This could bias 
estimates towards lower drug concentrations at these time points and supports the use of repeated 
measures analysis which lessens the importance of this single time point.   
The abbreviated sampling scheme for the mini-intensives in COMIRB 15-0123 was also 
a limitation. There was no plan at the outset of COMIRB 15-0123 to measure TFV monoester 
and the sampling strategy was not enriched for earlier time points in the dosing interval. Thus, 
the ability to characterize the monoester PK in COMIRB 15-0123 was quite limited given only 
the 1 and 4 hour post-dose measurements. The A-TEAM study results were therefore very 
helpful for providing context to the COMIRB 15-0123 findings.   
Pharmacokinetic-dynamic associations (in Aim 3) should be interpreted with caution. 
COMIRB 15-0123 was a small project initiated by Dr. Kiser. Twelve participants completed the 
first mini-intensive PK visit, but complete data were not available for all 12 participants through 
12 weeks. There was also greater variability in the renal biomarkers relative to prior literature 
estimates. Thus, power for this analysis was significantly limited and the lack of an overt effect 
of LDV/SOF on RBPCr and β2MGCr in this small study does not preclude the need for 
continued renal monitoring in patients on TDF with LDV/SOF.   
Future Directions 
It is unclear why those on a boosted ARV regimen had less of an increase in TFV-DP 
with LDV/SOF. It would be prudent to confirm these findings in a larger trial. If confirmed, a 
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series of in vitro studies coupled with physiologic-based pharmacokinetic modeling would 
provide insight into the mechanism for this observation.  
There was limited ability to investigate the clinical implications of this drug interaction 
due to the small sample size, loss to follow-up and highly variable RBPCr and β2MGCr 
measures. Additional data on the potential clinical implications for the interaction would require 
a larger number of patients.  
Future studies would need to reflect the current standard of care for treatment of HIV and 
HCV. Over the course of this thesis work, LDV/SOF use in the United States has been largely 
supplanted by pangenotypic DAAs including SOF/velpatasvir and glecaprevir/pibrentasvir. The 
pharmacology of velpatasvir is very similar to ledipasvir43, including the effects on tenofovir 
plasma exposures. HCV treatment guidelines have the same precautionary wording on use of 
SOF/velpatasvir with TDF and boosters as with LDV/SOF. Future studies should likely focus on 
the safety of TDF with SOF/VEL rather than LDV/SOF. However, given LDV/SOF is available 
for as little as $3 per pill in India, many patients will still receive LDV/SOF treatment globally.  
TAF use has replaced TDF use in the United States. If TAF becomes universally 
available, it is likely given the lower plasma exposures and lower rates of renal toxicity 
compared with TDF, that LDV/SOF or SOF/velpatasvir use would not increase the risk of 
nephrotoxicity.  
HIV protease inhibitors are no longer part of initial recommended treatment regimens 
according to United States treatment guidelines. While they are still used globally, integrase-
based therapies are likely to eventually replace the use of HIV protease inhibitors in many 
patient populations.  
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Dr. Kiser is currently conducting a study similar to COMIRB 15-0123 to determine the 
potential for TAF to interact with LDV/SOF in patients on boosted regimens. Based on the 
findings of this study, additional studies may be conducted with SOF/velpatasvir.  
The most promising avenues for future research are based on the findings in Aim 2 of this 
work. For many years, the conversion of TDF to TFV was thought to occur very rapidly and 
almost exclusively at the level of the gut/first pass metabolism. Thus, the discovery that TFV 
monoester is in fact detectable systemically after administration of TDF and likely contributes 
significantly to the plasma levels of TFV and the cellular pharmacology of TDF is an important 
and novel finding. It suggests the field has likely overlooked the importance of interactions 
occurring at the level of nucleotide prodrug conversion for decades and additional studies are 
needed to (1) fully characterize the pathways of nucleotide prodrug conversion, (2) determine the 
impact of drug-drug interactions occurring at the level of nucleotide prodrug conversion on the 
cellular pharmacology of nucleotide analogs, and (3) define the pharmacogenetic-kinetic 
associations between genes involved in the hydrolysis of nucleotide prodrugs and the 
pharmacokinetics of hydrolysis intermediates, parent drug concentrations, and concentrations of 
the nucleotide triphosphate in cells. These studies should not be limited to TDF, but should occur 
for other nucleotide prodrugs including SOF and TAF. A list of carboxylesterase substrates and 
inhibitors is provided in Table 21. The table was adapted from 59,61,62. This list is not exhaustive, 




Table 21  




ACE inhibitors Clopidogrel 
Clopidogrel Ethanol 
Cocaine Isradipine 
Dabigatran etexilate Procainamide 
Fenofibrate   
Lovastatin  
Meperidine  
Methylphenidate   









Acetylsalicylic acid Ethanol 




Olmesartan medoxomil  
Prasugrel  










Figure 19. Summary of Thesis Findings. SOF=sofosbuvir, TFV-disoproxil=tenofovir disoproxil, 
TFV-monoester=tenofovir monoester, TFV=tenofovir, TFV-MP=tenofovir monophosphate, 
TFV=DP=tenofovir diphosphate, DBS=dried blood spots, PBMC=peripheral blood mononuclear 
cells, RPT=renal proximal tubule cells, RPBCr=retinol binding protein, β2MG=Beta-2 
microglobulin, ATV=atazanavir 
  
TFV-disoproxil TFV ↑~2-fold 
TFV-MP 
TFV-DP 
↑ depends on 
cell type (below) 
SOF
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Blood Cells (easily accessible) 
 
TFV-DP ↑7-18-fold in DBS 
(36.5% less in those on booster) 
 
TFV-DP ↑ 2.8 in the PBMCs 
Renal Proximal Tubule Cells (not easily accessible)
TFV-DP ↑? unknown / not measured 
RBPCr
↑~70% with ATV* 
β2MG 
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Abstract   
Roughly one third of individuals living with the human immunodeficiency virus (HIV) are co-infected 
with the Hepatitis C virus (HCV) due to shared routes of transmission. HIV accelerates the progression of 
HCV disease, thus coinfected individuals are at high priority for HCV treatment. Several new HCV 
therapies, called direct-acting antiviral agents (DAAs), are available that achieve cure rates of >90% in 
many patient populations including individuals with HIV. The primary consideration in treating HCV in 
HIV-infected persons is the potential for drug interactions. We describe the clinical pharmacology and 
drug interaction potential of the DAAs, review the interaction data with DAAs and antiretroviral agents, 
and identify the knowledge gaps in the pharmacologic aspects of treating HCV in individuals with HIV 
coinfection.  This review will focus on DAAs that have received regulatory approval in the United States 
and Europe and agents in late stages of clinical development.     
 
Introduction: 
Roughly one third of individuals living with the human immunodeficiency virus (HIV) are co-
infected with the Hepatitis C virus (HCV) due to shared routes of transmission.[1, 2]  HIV accelerates the 
progression of HCV disease. Individuals with HIV coinfection have higher HCV RNA, a more rapid 
progression of fibrosis, and an increased frequency of liver decompensation and death.[3-6]. Due to the 
increased risks associated with HIV coinfection, treatment guidelines consider this patient population a 
“high priority” for HCV treatment.[7, 8] 
There have been significant advances in the treatment of HCV in recent years.  Pegylated 
interferon alfa (PEG) and ribavirin (RBV) were the standard of care for this disease for decades, but 
several agents that directly target specific steps in the HCV lifecycle (Figure 1) have recently received 
regulatory approval.[9]  The approved direct acting antiviral agents (DAAs) inhibit three specific steps in 
the HCV lifecycle including the NS3/4A protease enzyme, NS5A protein, and the NS5B polymerase. 
Inhibition of the NS3 protease prevents the cleavage of the viral polyprotein and formation of the 
replication complex responsible for replicationof viral RNA. The NS5B enzyme is essential for HCV 
replication as it catalyzes the synthesis of the complementary minus-strand RNA and subsequent genomic 
plus-strand RNA. There are two types of NS5B RNA-dependent RNA polymerase inhibitors: nucleotide 
and non-nucleoside inhibitors. The nucleotide inhibitors are active site inhibitors, whereas the non-
nucleoside inhibitors are allosteric inhibitors. Another target, NS5A, encodes a protein that appears 
essential to the replication machinery of HCV and critical in the assembly of new infectious viral 
particles. However, the specific functions of this protein have not been established.  
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Relative to PEG plus RBV, DAAs are well-tolerated, administered for shorter treatment durations 
(e.g., 8 to 24 weeks), and ultimately achieve high rates of cure, otherwise known as a sustained virologic 
response, (SVR; >90%) in many patient populations. While RBV is still used in combination with DAAs 
in certain clinical scenarios, PEG is seldom used.  
HIV coinfected individuals were less likely to achieve SVR with PEG plus RBV compared with 
HCV monoinfected individuals [10], however this is not the case with newer DAAs.  Multiple studies 
indicate similar SVR rates in trials of HIV coinfected individuals to those observed in trials of HCV 
monoinfected individuals. [11]  Thus, the primary consideration in treating HCV in individuals with HIV 
coinfection is the potential for drug interactions between DAAs and antiretroviral agents.   
The purpose of this manuscript is to describe the clinical pharmacology and drug interaction 
potential of the DAAs, review the interaction data with DAAs and antiretroviral (ARV) agents, and to 
identify the knowledge gaps in the pharmacologic aspects of treating HCV in individuals with HIV 
coinfection.  This review will focus on DAAs that have received regulatory approval in the United States 
and Europe and those in late stages of clinical development.  The epidemiology of HCV infection and 
reinfection, disease progression and the efficacy of emerging HCV treatment strategies in persons 




Sofosbuvir (SOF) is a NS5B polymerase inhibitor. SOF is used in combination with RBV and/or 
with other DAAs for the treatment of HCV. SOF is administered as a phosphoramidate pro-drug of the 
uridine nucleotide analog GS-331007 mono-phosphate.[13] Once inside cells, SOF is hydrolyzed by 
cathepsin A and/or carboxyesterase 1 to GS-331007 monophosphate.[13, 14] GS-331007 monophosphate 
is then phosphorylated by uridine monophosphate-cytidine monophosphate kinase to the GS-331007 
diphosphate form, which is then phosphorylated by nucleotide diphosphate kinase to the triphosphate 
moiety (GS-461203).[13, 14] GS-461203 is the active form of SOF. When GS-461203 is incorporated 
into HCV RNA by the NS5B polymerase rather than the endogenous base, HCV replication is halted. The 
primary drug-related material circulating in plasma is GS-331007. GS-331007 has no antiviral activity.  
The absolute bioavailability of SOF has not been determined, but is estimated to be at least 80% 
based on recovery of SOF and its primary metabolite, GS-331007, following administration of a 
radiolabeled dose.[14] A high fat meal increases SOF area under the curve (AUC) by 67-91%, but the 
increase is not thought to increase the likelihood of toxicities based on the wide therapeutic index of the 
drug.[14]  SOF is 61-65% protein bound, and is primarily renally excreted.[15] For the pharmacokinetic 
properties of SOF refer to Table 1. SOF is not a substrate, nor does it inhibit or induce any cytochrome 
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P450 (CYP) enzymes and therefore has a low potential for drug interactions. However, SOF is a substrate 
for the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).[16] SOF 
area-under-the-concentration-time-curve (AUC) is increased 2.3-fold and 2.5-fold in patients with 
moderate and severe hepatic impairment (i.e., Child Pugh B and C), respectively, but GS-331007 AUC is 
unchanged, and no dose adjustment is needed for this population. In fact, SOF, in combination with other 
agents such as RBV and the NS5A inhibitors ledipasvir or daclatasvir, is the preferred treatment for 
individuals with decompensated cirrhosis. In contrast, SOF and GS-331007 pharmacokinetics are affected 
by renal impairment, and use of this drug is limited in this population. SOF AUC is 61%, 107%, and 
171% higher in mild (GFR > 50 and < 80 mL/min/1.73m2), moderate (GFR >30 and < 50 
mL/min/1.73m2) and severe (GFR < 30 mL/min/1.73m2) renal impairment, respectively, whereas GS-
331007 AUC is increased 55%, 88% and 451% in mild, moderate, severe renal impairment 
respectively.[14, 16] Studies are ongoing to evaluate the safety and appropriate dosing of SOF in 
individuals with renal impairment.  
 Given SOF is not a substrate, inhibitor, or inducer of CYP enzymes, it has a low potential for 
drug interactions. However, potent inducers of P-gp or BCRP (e.g., carbamazepine, rifampin or St. John’s 
wort) should not be used with SOF. When combined with amiodarone, patients receiving SOF with other 
various DAAs have had serious symptomatic bradycardia. Whether this represents an unexpected drug 
interaction is unclear[17], but the combination should be avoided if possible.   
SOF has been studied with several ARV agents (the fixed dose combination of tenofovir 
disoproxil fumarate (TDF)/emtricitabine/efavirenz, ritonavir-boosted darunavir, raltegravir and 
rilpivirine) in healthy volunteers.[18] There were minimal changes in the pharmacokinetics of the ARV, 
SOF, and GS-331007. Raltegravir AUC was reduced by 17% and tenofovir Cmax was increased by 25% 
with no change in the tenofovir AUC. SOF and GS-331007 AUC were increased 37% and 19%, 
respectively with ritonavir-boosted darunavir; while GS-331007 AUC and Cmax were reduced 17-23% 
with the fixed dose combination of TDF/emtricitabine/efavirenz. These changes are unlikely to have 
clinical relevance, but interactions must be considered with the DAAs given with SOF. Of note, ritonavir-
boosted tipranavir has not been studied with SOF, but given this protease inhibitor is a potent P-gp 
inducer, it is likely to reduce SOF exposures and is thus not recommended.[18] Figure 2 provides a 
summary of drug interactions with SOF and ARV. This table is updated regularly and available through 
the “Recommendations for Testing, Managing, and Treating Hepatitis C’ guidance at 
www.hcvguidelines.org.[7] 
A summary of the efficacy and safety of SOF, in combination with RBV, in HIV-coinfected 
individuals follows.. The efficacy and safety of SOF when combined with DAAs is reviewed in 
subsequent sections.  The PHOTON-1 study evaluated the use of SOF and weight based RBV (1000mg or 
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1200mg in divided doses) in treatment naive genotype 1, 2, and 3 patients as well as treatment 
experienced genotype 2 and 3 patients with HIV coinfection. This study enrolled 223 patients into 3 
treatment arms: 114 treatment naïve patients with genotype 1 treated for 24 weeks, 68 treatment naïve 
patients with genotypes 2 and 3 treated for 12 weeks, and 41 treatment experienced patients with 
genotypes 2 and 3 treated for 24 weeks. Of the 223 patients, 212 (95%) were receiving ARV with 
TDF/emtricitabine plus one of the following: efavirenz, ritonavir-boosted atazanavir, ritonavir-boosted 
darunavir, raltegravir or rilpivirine. Roughly 10% of patients had cirrhosis.  In the treatment-naive 
participants, the SVR rates were 76%, 88% and 67% for genotypes 1, 2 and 3, respectively. Among 
treatment-experienced participants who were treated for 24 weeks, 92% and 94% of individuals with 
genotypes 2 and 3, respectively achieved SVR. Overall this regimen was well tolerated with the most 
common adverse events being fatigue (37%), insomnia (17%), headache (13%), and nausea (16%). The 
most common abnormal laboratory values were declines in hemoglobin and elevations in direct bilirubin. 
Thirty-four patients (15%) had decreases in hemoglobin below 10 mg/dL with 3 patients experiencing 
decreases in hemoglobin to less than 8.5mg/dL. Forty-three patients (19%) required dose reduction of 
RBV.[19] The PHOTON-2 study also evaluated SOF and RBV in HIV-coinfected treatment naive 
patients with genotype 1-4 and treatment experienced patients with genotype 2 and 3. Of the 275 patients 
enrolled, 265 (96%) were receiving ARV treatment with the same ARVs as in PHOTON-1. In this study, 
19.6% had cirrhosis. In treatment naive patients, SVR rates were 85%, 89%, 91% and 84% for genotypes 
1, 2, 3 and 4 respectively, and in treatment experienced genotype 2 and 3 patients SVR rates were 83% 
and 86% respectively. Similar to PHOTON-1, the participants in PHOTON-2 experienced fatigue, 
insomnia, asthenia, headache, anemia, and increase in bilirubin. Twenty-six patients (9%) experienced 
hemoglobin less than 10mg/dL and one patient (<1%) had a hemoglobin level less than 8.5mg/dL. 
Among patients who completed treatment, 30 (11%) required reductions in RBV dose.[20]  
 
Daclatasvir 
Daclatasvir (DCV) is a HCV NS5A replication complex inhibitor that binds to the N-terminus of 
NS5A. DCV has been studied in combination with the HCV protease inhibitor, asunaprevir and a non-
nucleoside NS5B inhibitor, beclabuvir, but these drugs are not available in the United States. DCV has 
also been studied with the HCV protease inhibitor, simeprevir.[21] However, the primary use of DCV in 
the United States is in combination with SOF. DCV/SOF has regulatory approval for genotype 3 disease, 
in individuals with genotype 1 or 3 who are coinfected with HIV, and with or without RBV in individuals 
with genotype 1 or 3 infection with advanced liver disease.  
The absolute bioavailability of DCV is 67%. A high-fat, high calorie meal reduces DCV 
exposures by 23%, but a low fat meal has no effect. DCV is 99% protein bound and has minimal renal 
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excretion.[22] For the pharmacokinetic properties of DCV refer to Table 1. DCV is metabolized by 
CYP3A. However, DCV does not appear to inhibit or induce any CYP enzymes. DCV is a substrate for 
P-gp and DCV inhibits P-gp, BCRP, and OATP1B1/3.[22] Total exposures of DCV are 38% and 36% 
lower in patients with Child Pugh B and C decompensated cirrhosis, respectively, but unbound 
concentrations are unchanged. Thus, no dose adjustment is needed in patients with decompensated 
cirrhosis. DCV AUC in those with end stage renal disease (eGFR less than 15 mL/min/1.73m2 receiving 
hemodialysis), eGFR 30-59 mL/min/1.73m2, and eGFR 15-29 mL/min/1.73m2 were 1.27, 2.10, and 1.94-
fold higher, respectively compared to those with normal renal function, which is more than expected 
given only 7% of the drug is renally eliminated.[22]  The increase is hypothesized to relate to impaired 
hepatic metabolism as a consequence of uremic toxins or increases in parathyroid hormone, and/or 
cytokines in those with renal impairment, but given the wide therapeutic index of DCV, this change is 
unlikely to have clinical relevance. 
DCV is primarily a victim of drug interactions rather than a perpetrator, though it does increase 
digoxin (a P-gp substrate) by 27%, and rosuvastatin (OAT1B1 and BCRP substrate) by 58%. Due to 
DCV being highly reliant on CYP3A for its metabolism, dose adjustments of DCV are necessary in the 
presence of strong or moderate CYP3A inhibitors and moderate inducers. Ketoconazole (a potent 
CYP3A4 inhibitor) increases the AUC of DCV by 200% and multi-dose rifampin (a potent CYP3A4 
inducer) decreases the AUC of DCV by 79%.[22] Strong inducers are contraindicated with DCV.  
In terms of ARV, DCV was studied with ritonavir-boosted atazanavir, efavirenz and TDF in 
healthy volunteers. Ritonavir-boosted atazanavir increased DCV AUC by 2.1 fold; whereas efavirenz 
reduced DCV AUC by 32%. DCV dose modification from 60mg to 30mg with ritonavir-boosted 
atazanavir and 90mg with efavirenz were predicted to normalize AUC relative to the target exposure.[23, 
24] No interaction was observed with TDF.[24] A DCV dose reduction to 30mg was assumed to be 
appropriate for other ritonavir-boosted protease inhibitors given the interaction observed with ritonavir-
boosted atazanavir. However, the DCV AUC and Cmax with a 30mg dose were 33% and 23% lower with 
ritonavir-boosted lopinavir and darunavir, respectively vs. 60 mg of DCV.[25] Thus, no dose adjustment 
of DCV is necessary with ritonavir-boosted lopinavir or darunavir. DCV increases dolutegravir AUC and 
Cmax by approximately 33% and 29% respectively, but this increase is unlikely to have clinical 
implications.[26] Figure 2 provides a summary of drug interactions with DCV and ARV. This table is 
updated regularly and available through the “Recommendations for Testing, Managing, and Treating 
Hepatitis C’ guidance at www.hcvguidelines.org.[7] 
The combination of SOF and DCV, administered for 12 weeks, was evaluated in 151 HIV/HCV 
coinfected individuals in the ALLY-2 trial.[11] This study included treatment naive and treatment 
experienced patients with genotypes 1-4. Treatment naive patients received either 8 or 12 weeks of 
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treatment and the experienced patients received 12 weeks. Patients taking ritonavir-boosted atazanavir, 
lopinavir, or darunavir received 30mg once daily of DCV and those taking either efavirenz or nevirapine 
received 90 mg DCV daily. All others received the standard 60mg dose of DCV. Approximately 14% of 
patients in this trial had cirrhosis. The SVR rate for all genotypes was 97% following 12 weeks of 
treatment and 76% with 8 weeks of treatment. Fifty one subjects (25% of the study population) were 
taking ritonavir-boosted darunavir and slightly lower SVR rates were observed in these patients (93.3% 
when treated for 12 weeks and 66.4% when treated for 8 weeks). Nine of the 12 patients that experienced 
viral relapse in this study were receiving ritonavir-boosted darunavir. Patients received the reduced 
(30mg) DCV dose prior to the availability of pharmacokinetic data demonstrating the dose was 
suboptimal with ritonavir-boosted lopinavir and darunavir. Thus, low DCV exposures in those on 
ritonavir-boosted darunavir may have contributed to viral failure in this study. A higher proportion of 
patients on ritonavir-boosted darunavir received the 8-week treatment duration and this group had high 
baseline HCV RNA values which also contributed.[11, 27] The most common treatment related adverse 
events in this study were fatigue (17%), nausea (13%) and headache (11%). 
 
Ledipsavir 
Ledipasvir (LDV) is an inhibitor of NS5A and is only available co-formulated with SOF. 
SOF/LDV is approved for genotypes 1, 4, 5, and 6.  SOF/LDV is also approved for genotypes 1 and 4 
liver transplant recipients as well as genotype 1 infection with decompensated cirrhosis.[16] 
The bioavailability of LDV in humans is unknown, but ranges from 30-50% in rats, monkey and 
dogs. LDV concentrations are similar when given fasted vs. with a moderate (600kcal) or high (1000kcal) 
fat meal.  LDV is greater than 99.8% bound to human plasma proteins and LDV is primarily eliminated 
unchanged in the feces. For the pharmacokinetic properties of LDV refer to Table 1. Approximately 30% 
is metabolized, though the precise enzymes involved are uncertain. LDV is a substrate for and also 
inhibits P-gp and BCRP. LDV pharmacokinetics are not significantly altered by hepatic or renal 
impairment, but since the drug is coformulated with SOF, the same limitations on use in those with renal 
impairment apply.[16]  
LDV relies on an acidic environment for optimal absorption, thus gastric acid modifiers should be 
used with caution. In one large cohort, use of proton pump inhibitors (PPI) was found to be an 
independent predictor of relapse to LDV/SOF treatment.[28] If gastric acid modifiers must be used, 
temporal separation is necessary with antacids (by 4 hours) and histamine-2 receptor antagonists (e.g., 
famotidine, ranitidine) and PPI (omeprazole, lansoprazole, etc.) doses should not exceed the equivalent of 
40mg famotidine twice daily and 20mg omeprazole once daily, respectively. The PPI must be 
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administered simultaneously with LDV/SOF in the fasted state.[29] Given that LDV inhibits P-gp and 
BCRP, LDV may increase the concentrations of rosuvastatin (an OATP1B1 and BCRP substrate) so this 
combination is not recommended. Rosuvastatin AUC was increased by 699% with LDV, GS-9451 (an 
investigational protease inhibitor), and tegobuvir (an investigational non-nucleoside NS5B inhibitor)[30]. 
It is unknown whether LDV would cause this effect on rosuvastatin (or an increase of this same 
magnitude) in the absence of these other DAAs.[31] 
LDV has been studied with several ARV agents. The CYP3A inducer, efavirenz, reduces LDV 
concentrations by 30% and the pharmacokinetic enhancer cobicistat increases LDV concentrations by 2-
fold, but given the rather wide therapeutic index of LDV, these changes are not expected to have clinical 
relevance.[32]  LDV increases tenofovir exposures which may increase the risk of renal toxicity in HIV-
infected individuals taking TDF with a ritonavir-boosted protease inhibitor or cobicistat.[33] A new 
formulation of tenofovir, tenofovir alafenamide (TAF), may be used in place of TDF given the tenofovir 
concentrations are 5-fold lower than with TDF.[34] Figure 2 provides a summary of drug interactions 
with LDV and ARV. This table is updated regularly and available through the “Recommendations for 
Testing, Managing, and Treating Hepatitis C’ guidance at www.hcvguidelines.org.[7] 
SOF/LDV has been studied in two separate trials of HIV/HCV co-infected individuals.  The 
ERADICATE trial evaluated 50 non-cirrhotic HIV/HCV co-infected individuals with HCV genotype 1. 
In this study, forty-nine subjects (98%) achieved SVR12 and one patient relapsed four weeks after 
completing treatment.[35] The ION-4 trial evaluated SOF/LDV for 12 weeks in 335 patients with HIV 
coinfection. Participants were primarily (97.6%) genotype 1. Eight patients had HCV genotype 4. Fifty-
five percent of patients were treatment experienced, 34% were black and 20% had cirrhosis and all 
patients were receiving ARV comprised of TDF/emtricitabine plus efavirenz, raltegravir or rilpivirine. 
Ritonavir-boosted protease inhibitors were excluded. SVR rates were 96% for genotype 1 and 100% for 
genotype 4. Among the patients did not achieve SVR, 1 patient died after 4 weeks of treatment, 2 had 
HCV breakthrough during treatment that was associated with suspected poor adherence and 10 had an 
HCV relapse. Of the 10 patients with a virologic relapse, all were black, 6 were treatment experienced, 3 
had cirrhosis, 1 was treatment experienced and cirrhotic, 7 had the unfavorable IL28B TT allele, and 8 
received efavirenz.[36] LDV exposures (determined through population pharmacokinetic modeling) were 
similar however in the individuals on efavirenz compared with individuals on other ARV.   
 
Simeprevir 
Simeprevir (SIM) is an inhibitor of the HCV NS3 protease. SIM is indicated in combination with 
SOF for the treatment of HCV-infected individuals with genotype 1 or 4 infection. This combination 
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represented the first interferon-free treatment with DAAs for individuals with genotype 1 disease, but its 
use has been largely replaced by less expensive combinations of DAAs. 
The mean absolute bioavailability of SIM is 62%. A 533 kcal meal and 928 kcal meal increase 
SIM AUC by 69% and 61%, respectively. Thus, it is recommended to take with food. SIM is 99.9% 
protein bound, primarily to albumin and less than 1% of SIM is renally cleared.[37] For the 
pharmacokinetic properties of SIM refer to Table 1. SIM is metabolized by CYP3A and is a substrate for 
P-gp, MRP2, BCRP, OATP1B1/3, and OATP2B1. SIM is also a mild inhibitor of CYP1A2 and intestinal 
CYP3A, OATP1B1, NTCP, P-gp, MRP2, and BSEP. SIM exposures are increased 2.4-fold and 5.2-fold 
in patients with Child Pugh B and C hepatic impairment respectively. There have been reports of hepatic 
decompensation, hepatic failure, and death in patients with advanced liver disease receiving SIM, 
consequently, it should be avoided in patients with decompensated cirrhosis. There is an 82% increase in 
exposure of SIM in those with eGFR < 30 mL/min/1.73 m2 presumably due to the same mechanism(s) 
previously described for DCV.[37] Since SIM is used with SOF, the same limitations on use in those with 
eGFR less than 30 mL/min/1.73 m2 apply. 
In terms of SIM’s ability to act as a perpetrator in drug interactions, SIM increases the AUC of 
oral midazolam (a CYP3A substrate) by 45%, digoxin (a P-gp substrate) by 39%, and rosuvastatin (an 
OATP1B1 and BCRP substrate) by 2.8-fold in healthy volunteers.[38] While these are significant 
changes in the AUC, coadministration is still appropriate with close monitoring for adverse effects. The 
rosuvastatin dose should not exceed 5mg with initiation of SIM. As a victim, SIM is altered by moderate 
or strong inducers and inhibitors of CYP3A. Multi-dose rifampin, a potent CYP3A inducer, reduces SIM 
AUC by 48% and thus coadministration is not recommended. While no effect of cyclosporine on SIM 
exposures was apparent in a drug interaction study in healthy volunteers, SIM exposures were 6-fold 
higher in those on cyclosporine vs. historical values in individuals receiving SIM, DCV, and RBV 
treatment post liver-transplant. Given this increase in SIM exposures, coadministration with cyclosporine 
is not recommended.[37] Cyclosporine inhibits OATP1B1, P-gp and CYP3A so any or all of these 
mechanisms may have contributed to the interaction observed.  
Due to the effects of potent CYP3A inhibitors and inducers, ARV options are more limited with 
SIM. Efavirenz reduces SIM AUC by 71%.[38] SIM exposures are increased 2.6-fold by ritonavir-
boosted darunavir, even after an empiric dose reduction of SIM from 150mg to 50mg.  Thus, ritonavir or 
cobicistat boosted HIV protease inhibitors and efavirenz are not recommended with SIM. Rilpivirine, 
raltegravir and TDF can be safely used with SIM. Figure 2 provides a summary of drug interactions with 
SIM and ARV. This table is updated regularly and available through the “Recommendations for Testing, 
Managing, and Treating Hepatitis C’ guidance at www.hcvguidelines.org.[7] 
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To date there are no formal studies of SIM/SOF in HIV-coinfected individuals. In 310 non-
cirrhotic HCV-monoinfected individuals receiving 12 weeks of SIM/SOF, SVR was achieved in 97% of 
treatment naïve and experienced patients.[39]  The SVR rate was 83% for 103 cirrhotic HCV-
monoinfected individuals receiving 12 weeks of SIM/SOF, thus extending treatment duration to 24 weeks 
is necessary for cirrhotic patients.[40]  
 
Velpatasvir 
Velpatasvir (VEL) is an investigational NS5A inhibitor.[41] This drug is being developed as a 
fixed-dose combination tablet with SOF. It is expected to receive regulatory approval in June 2016.  
VEL absorption is pH-dependent and gastric acid modifiers are problematic with this agent. If a 
proton pump inhibitor is required with VEL, it is recommended to take these agents simultaneously with 
food and not to exceeded 20mg equivalent of omeprazole.[42] There does not appear to be an appreciable 
food effect with VEL.[43] VEL is predominantly excreted in feces as parent and metabolite and <1% of 
the dose is excreted in urine. For the pharmacokinetic properties of VEL refer to Table 1. VEL is 
metabolized by CYP3A4, 2C8, and 2B6, but has not been shown to inhibit any CYP enzymes. VEL is a 
substrate for P-gp, a weak inhibitor of P-gp, BCRP, and OATP1B1/1B3 but does not induce any 
transporters.[44] VEL AUC is 17% lower in patients with moderate hepatic impairment, but this is likely 
a protein binding affect and unbound levels are unchanged. VEL AUC is increased 14% in those with 
severe hepatic impairment[45]. In patients with severe renal impairment (eGFR less than 30mL/min/1.73 
m2), the AUC of VEL was increased by 50%.[46] Since VEL is used with SOF, the same limitations on 
use in those with eGFR less than 30 mL/min/1.73 m2 apply. 
In terms of VEL’s ability to act as a perpetrator in interactions, pravastatin (an OATP1B1 
substrate) AUC increased 35% and rosuvastatin (an OATP1B1 and BCRP substrate) AUC increased 
approximately 170% when coadministered with VEL in healthy volunteers. While no pravastatin dose 
adjustment is needed, the rosuvastatin dose should not exceed 10mg with VEL. Digoxin (a P-gp 
substrate) AUC increased 34%. Digoxin concentrations should be monitored during VEL treatment and 
doses adjusted as needed. In terms of its ability to act a victim in interactions, single-dose rifampin (an 
OATP1B1 inhibitor) increased VEL AUC by 47%. VEL AUC increased 103% with a single dose of 
cyclosporine (a mixed OATP/P-gp/MRP2 inhibitor). Ketoconazole (CYP3A inhibitor) increased VEL 
AUC by 70%. When coadministered with multiple doses of rifampin (a potent CYP3A inducer), VEL 
AUC was reduced by approximately 82%.[44] Rifampin, cyclosporine, and ketoconazole should be 
avoided with VEL.  
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Drug interaction studies with SOF/VEL and the following ARV have been performed in healthy 
volunteers: TDF/emtricitabine /efavirenz, TDF/emtricitabine/rilpivirine, dolutegravir, raltegravir, 
elvitegravir/cobicistat/emtricitabine/TAF, TDF/emtricitabine and ritonavir-boosted atazanavir, 
TDF/emtricitabine and ritonavir-boosted darunavir and emtrictiabine/TDF and ritonavir-boosted 
lopinavir. VEL AUC was reduced 50% with TDF/emtricitabine /efavirenz. SOF/VEL increased tenofovir 
exposures by  
40-81%.[47] VEL AUC was increased by 2.4 fold with atazanavir/r, VEL AUC was also increased 20-
30% in the presence of cobicistat-containing regimens. When TDF was administered with SOF/VEL there 
is a 20-40% increase in TFV AUC. [47 As with LDV, this could be problematic in individuals receiving 
TDF with other agents that raise tenofovir exposures, but TAF is an alternative to TDF in this scenario.  
A study of SOF/VEL in HCV/HIV coinfected patients is currently underway (NCT02480712).  
SOF/VEL for 12 weeks was studied in 740 HCV-monoinfected individuals with genotypes 1, 2, 4, 5, and 
6. Nineteen percent of the study participants were cirrhotic and 32% had failed prior HCV treatment. The 
overall SVR rate was 99%, with rates of 98%, 100%, 100%, 97% and 100% for genotypes 1, 2, 4, 5 and 6 
respectively.[48] The ASTRAL-2 study compared SOF/VEL for 12 weeks with SOF/RBV (the current 
standard of care for genotype 2) for 12 weeks in 266 HCV-monoinfected individuals with genotype 2. 
SVR was significantly higher (p=0.018) with SOF/VEL relative to SOF/RBV.[49] ASTRAL-3 compared 
12 weeks of SOF/VEL to 24 weeks of SOF plus RBV in 552 HCV-monoinfected individuals with HCV 
genotype 3. Approximately 30% of participants were cirrhotic and 26% treatment experienced in each 
arm. SVR in the SOF/VEL group was 95% vs. 80% in participants that received SOF and RBV.[50] 
SOF/VEL with and without RBV was evaluated in 267 HCV-monoinfected individuals, genotypes 1-6 
with Child-Pugh class B decompensated cirrhosis.[51]  SVR rates were 83% for SOF/VEL for 12 weeks, 
94% with SOF/VEL plus RBV for 12 weeks and 86% SOF/VEL for 24 weeks.  
 
Grazoprevir/Elbasvir 
Grazoprevir and elbasvir (GZR/EBR) are inhibitors of the NS3 and NS5A viral enzymes, 
respectively. GZR/EBR is available as a once daily co-formulated tablet that is approved for treatment of 
HCV genotypes 1 or 4 infection in adults.[52] The typical treatment duration is 12 weeks. However, 
individuals with genotype 1a infection and pre-existing NS5A viral variants receive GZR/EBR in 
combination with RBV for 16 weeks.  
The bioavailability of EBR is 30%. GZR bioavailability ranges from 10-40%. Administration of 
GZR/EBR with a high-fat (900 kcal, 500 kcal from fat) meal to healthy subjects results in decreases in 
EBR AUC and Cmax of approximately 11% and 15%, respectively, and increases in GZR AUC and 
Cmax of approximately 1.5-fold and 2.8-fold, respectively.[52] GZR is at least 98% protein bound and 
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EBR is more than 99% bound.[52] GZR and EBR are hepatically metabolized and less than 1% of GZR 
and EBR are renally eliminated. For the pharmacokinetic properties of GZR/EBR refer to Table 1. GZR is 
a substrate for CYP3A4, P-gp and OATP1B. GZR is also known to be an inhibitor of CYP3A4, UGT1A1 
and BCRP. EBR is a substrate for CYP3A4 and P-gp and an inhibitor of BCRP and P-gp. GZR exposures 
are increased 62% in those with mild (Child-Pugh A) and 388% in those with moderate (Child Pugh B) 
hepatic impairment relative to those with no hepatic impairment. GZR/EBR is contraindicated in Child-
Pugh B or C decompensated cirrhosis. Of note, EBR with a reduced dose of GZR (50mg) was evaluated 
in a study of 30 individuals with decompensated cirrhosis with good efficacy and tolerability [53], but a 
50mg GZR formulation is not available commercially. Total concentrations of EBR are 24% and 14% 
lower in patients with mild and moderate hepatic insufficiency, respectively. As with some of the other 
hepatically-metabolized DAAs, GZR/EBR AUCs are increased by 65% and 86%, respectively in those 
with eGFR < 30 mL/min/1.73 m2 not receiving dialysis. This increase is not expected to have clinical 
relevance however and in fact this regimen has demonstrated good efficacy and tolerability in 226 HCV-
infected individuals with renal impairment.[54] GZR and EBR pharmacokinetics in individuals with 
ESRD on hemodialysis are comparable to individuals without hepatic impairment, presumably because 
dialysis clears the uremia, parathyroid hormone, or cytokines which contribute to impaired hepatic 
metabolism.  
In terms of being perpetrators in drug interactions, pravastatin (OATP1B1 substrate) and 
rosuvastatin (OATP1B1 and BCRP substrate) exposures are increased 33% and 126%, respectively by 
GZR/EBR[52]. While no adjustment of pravastatin is necessary, the rosuvastatin dose should not exceed 
10mg daily with GZR/EBR. In terms of being victims of drug interactions, OATP1B1 inhibitors 
significantly raise GZR exposures. Single dose rifampin (OATP1B1 inhibitor) raises GZR AUC by 8-10 
fold and cyclosporine (OATP/P-gp/MRP2 inhibitor) raises the GZR AUC by 15-fold. Thus, 
coadministration of GZR/EBR with rifampin or cyclosporine is not recommended. GZR is also 
susceptible to potent CYP3A inhibitors. Ketoconazole (CYP3A4 inhibitor) increases GZR AUC by 3-
fold.[55, 56] EBR is also a victim of drug interactions when administered with ketoconazole (CYP3A4 
inhibitor) the EBR AUC increases by 80%.[52] Coadministration of GZR/EBR with ketoconazole is not 
recommended.  
Given the propensity for OATP1B1 and CYP3A mediated interactions, ritonavir or cobicistat-
boosted protease inhibitors and efavirenz cannot be used with GZR/EBR. In healthy volunteers, GZR and 
EBR are increased 10.6-fold and 4.76-fold, respectively by ritonavir-boosted atazanavir, 7.5-fold and 
1.66-fold, respectively by ritonavir-boosted darunavir, and 12.86-fold and 3.71-fold, respectively by 
ritonavir-boosted lopinavir. GZR and EBR are reduced 83% and 54%, respectively with efavirenz.[52, 
57] Tenofovir is increased 34% by EBR. Integrase inhibitors and rilpivirine do not interact with 
154 
GZR/EBR.  Figure 2 provides a summary of drug interactions with GZR/EBR and ARV. This table is 
updated regularly and available through the “Recommendations for Testing, Managing, and Treating 
Hepatitis C’ guidance at www.hcvguidelines.org.[7] 
GZR/EBR was evaluated in 218 treatment-naive patients with chronic HCV genotype 1, 4, or 6 
infection and HIV co-infection. This was a non-randomized, phase 3, open-label, single-arm trial and 
16% of participants were cirrhotic. All patients in this study received GZR 100 mg plus EBR 50 mg in a 
fixed dose combination for 12 weeks.  In this study 211 of the 218 patients were receiving ARV 
consisting of abacavir/lamivudine or TDF/emtricitabine with either raltegravir, dolutegravir, or rilpivirine. 
SVR was achieved by 96% of patients in this study.[58] The C-WORTHY trial included 59 treatment-
naïve, non-cirrhotic individuals with genotype 1 HCV and HIV coinfection. These patients received GZR 
100mg plus EBR 50mg for 12 weeks with or without RBV, while continuing on their ARV regimen with 
dual nucleoside or nucleotide reverse transcriptase inhibitors and raltegravir. SVR rates were 97% and 
87% with and without RBV respectively.[59]  
 
PrOD/PrO 
Ombitasvir is a potent NS5A inhibitor, paritaprevir is a potent NS3 protease inhibitor and 
dasabuvir is a non-nucleoside NS5B polymerase inhibitor.[60]  This combination (PrOD) is used for the 
treatment of HCV genotype 1. PrOD is administered for 12 weeks to patients with genotype 1b regardless 
of cirrhosis status. However, in individuals with genotype 1a, RBV is used with PrOD. Non-cirrhotic 
individuals with genotype 1a receive 12 weeks of treatment and cirrhotic individuals receive 24 weeks of 
PrOD plus RBV.  Ritonavir-boosted paritaprevir and ombitasvir (PrO) is used with RBV, but without 
dasabuvir, for 12 weeks for the treatment of individuals with genotype 4 disease.[60, 61] Ritonavir is used 
in this combination to pharmacokinetically enhance or “boost” the exposures of paritaprevir via inhibition 
of CYP3A. Ritonavir has no HCV activity. Ritonavir, paritaprevir and ombitasvir are co-formulated.[60]  
The absolute bioavailability of ombitasvir, paritaprevir, and ritonavir is unknown. The absolute 
bioavailability of dasabuvir is approximately 70%. Moderate and high fat meals increase exposures of all 
four components and the treatment is approved for administration with a meal. Protein binding is high for 
all four drugs: ombitasvir 99.9%, paritaprevir 97 to 98.6%, ritonavir greater than 99%, and dasabuvir 
greater than 99.5%.[60]  See Table 1 for additional information on the pharmacokinetic properties of 
these agents. Paritaprevir is a substrate for CYP3A4 and to a lesser extent CYP3A5, it also inhibits CYP 
2C8. Paritaprevir is also a substrate for the transporters P-gp, OATP1B1 and BCRP and inhibits P-gp, 
OATP1B1/1B3 and BCRP. Ombitasvir is not a substrate for any CYP enzymes but is a substrate for P-gp. 
Ombitasvir inhibits CYP2C8 and UGT1A1, but does not induce or inhibit any transporters. Dasabuvir is 
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metabolized by CYP2C8 and CYP3A and inhibits UGT1A1. Dasabuvir is a substrate for P-gp and has 
also been shown to inhibit BCRP.[61] Paritaprevir exposures are increased 62% and 945% in individuals 
with Child Pugh B and C cirrhosis, respectively. There were reports of hepatic decompensation, hepatic 
failure, and death in patients with advanced liver disease receiving PrOD. Thus, it should be avoided in 
patients with decompensated cirrhosis. Ombitasvir pharmacokinetics are not significantly altered in renal 
impairment, but paritaprevir, dasabuvir, and ritonavir exposures are increased with worsening renal 
function. This is presumed to be due to impairment of hepatic metabolism with poor renal function. PrOD 
has been studied in non-cirrhotic HCV-infected individuals with eGFR < 30 mL/min/1.73 m2, with good 
efficacy.[62] PrOD is a potential treatment option for individuals with genotype 1b disease and renal 
impairment, but RBV is difficult to tolerate so PrOD may not be ideal for individuals with genotype 1a.   
In terms of acting as perpetrators of interactions, omeprazole (a CYP2C19 substrate) AUC is 
reduced 38% by PrOD. Rosuvastatin (substrate for OATP1B1 and BCRP) and pravastatin (substrate for 
OATP1B1) exposures are increased 159% and 82%, respectively.[63]Low doses of pravastatin and 
rosuvastatin should be used while on PrOD. PrOD increases ketoconazole AUC by 2-fold and this 
combination is contraindicated. Ethinyl-estradiol containing oral contraceptives should be avoided with 
PrOD or PrO because liver enzyme elevations were noted in a drug-drug interaction study of this 
combination in healthy volunteers. Progestin-containing oral contraceptives may be used.[63] PrOD and 
PrO are contraindicated with drugs that are highly dependent on CYP3A for clearance, moderate or strong 
inducers of CYP3A, and strong inducers or inhibitors of CYP2C8.In terms of acting as victims of 
interactions, ketoconazole (a CYP3A inhibitor) increases ombitasvir, paritaprevir, and dasabuvir by 17%, 
98%, and 42%, respectively. Gemfibrozil (a potent CYP2C8 inhibitor) increases dasabuvir exposures by 
11-fold. Carbamazepine (CYP3A and P-gp inducer) reduces ombitasvir, paritaprevir, and dasabuvir by 
31%, 70% and 70%, respectively. Many interactions are similar with PrO and PrOD[64], but not all. 
Refer to the product labeling and www.hep-druginteractions.org for up-to-date information on drug 
interactions with PrOD and PrO. 
PrOD has been studied with several ARV agents. Atazanavir (300mg once daily) can be given 
with PrOD, but it should be administered simultaneously with the ritonavir-boosted paritaprevir and 
ombitasvir. The separate ritonavir booster is not needed since PrOD contains a booster. In healthy 
volunteers, PrOD reduced darunavir trough concentrations by 48% with once daily ritonavir-boosted 
darunavir and 43% with twice daily ritonavir-boosted darunavir. An ongoing study (NCT01939197) is 
evaluating the efficacy of PrOD with ritonavir-boosted darunavir. Until these data are available, this 
combination should be avoided. Without dasabuvir however (i.e., PrO), the decrease in darunavir troughs 
is not as pronounced. Since lopinavir is already co-formulated with ritonavir, it cannot be used with PrOD 
which also contains ritonavir. Rilpivirine AUC is increased 225% by PrOD.[60] This is concerning due to 
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potential QTc prolongation with increased rilpivirine exposures, thus the combination should be avoided. 
A study of efavirenz and PrOD in healthy volunteers was prematurely discontinued due to toxicities. 
Dolutegravir can be used with PrOD. The dolutegravir exposures are increased, but are still within the 
therapeutic range for the drug.[65]  Figure 2 provides a summary of drug interactions with PrOD and PrO 
and ARV. This table is updated regularly and available through the “Recommendations for Testing, 
Managing, and Treating Hepatitis C’ guidance at www.hcvguidelines.org.[7] 
Part 1a of the TURQUOISE-I trial included 63 treatment-naïve patients (19% cirrhotic) with HIV 
coinfection who received either 12 or 24 weeks of PrOD plus RBV.[66] All patients received dual 
nucleos(t)ide therapy with raltegravir or ritonavir-boosted atazanavir. SVR rates were 94% and 91% with 
12 and 24 weeks of treatment, respectively.[66]  
 
Ribavirin 
Ribavirin (RBV) is a purine nucleoside analog. Oral RBV is used in combination with DAAs for 
the treatment of chronic HCV infection in certain scenarios including in combination with SOF for genotype 
2 disease, with SOF/LDV or SOF and DCV in the setting of decompensated cirrhosis, with PrO or PrOD 
in patients with genotype 1a or 4 disease, or in combination with GZR/EBR in individuals with baseline 
NS5A resistance mutations. RBV dosing is typically weight based. Individuals weighing less than 75kg 
receive 1000mg daily and those weighing at least 75kg receive 1200mg daily. The dose is often divided 
and given twice daily. The efficacy and safety of RBV when combined with various DAAs was summarized 
in prior sections. Host cell enzymes phosphorylate RBV to mono-, di-, and tri-phosphate derivatives. The 
exact mechanism(s) of action of RBV and/or its phosphorylated derivatives in vivo are unknown, but 
several immunomodulatory and antiviral effects have been observed in vitro including (1) inhibiting the 
HCV RNA-dependent RNA polymerase, (2) depleting guanosine triphosphate (and thus nucleic acid 
synthesis in general) through inhibition of inosine monophosphate dehydrogenase, (3) enhancing viral 
mutagenesis, (4) converting the T-helper cell phenotype from 2 to 1, (4) inducing interferon stimulated 
genes, and (5) modulating natural killer cell response.[67, 68]  
The absolute bioavailability of RBV is 64%. RBV concentrations are increased with a high fat meal 
and decreased with purine-rich foods such as margarine, tuna, ham, or whole milk.[69, 70] RBV is not 
protein bound, and 61% is recovered in the urine. RBV is a substrate for the nucleoside uptake transporters 
(ENT1, CNT2, and CNT3) and thus widely distributed throughout the body. RBV is not dose adjusted for 
hepatic impairment, but for renal impairment the dose of RBV must be reduced. RBV is given in alternating 
daily doses of 200 mg and 400 mg in individuals with an eGFR of 30-50 mL/min/1.73 m2, and 200 mg 
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orally once daily for individuals with an eGFR less than 30 mL/min/1.73 m2 or receiving hemodialysis.[70] 
Despite these dose reductions, many individuals with renal impairment develop hemolytic anemia.  
RBV has minimal drug interactions, but should not be used with the HIV nucleoside analog, 
didanosine. RBV increases formation of the triphosphorylated form of didanosine which raises the risk of 
mitochondrial toxicity.[71] Zidovudine and RBV both cause anemia and thus, this combination should also 
be avoided.  
 
Conclusions 
As with HCV monoinfected persons, the vast majority of individuals with HIV and HCV 
coinfection can achieve SVR with all oral DAAs. The primary consideration in treating this population is 
identification and management of drug interactions. In general, current therapies have well-characterized 
pharmacology and manageable drug interaction profiles, but opportunities remain to determine optimal 
doses and combinations of the DAAs in individuals with HIV coinfection. A comprehensive 
understanding of the pharmacology and interaction potential of DAAs allows for informed and improved 
use of these agents.  
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Figure 1.  The HCV lifecycle. Reprinted with permission from [9] 
(A) The virus gains entry by receptor-mediated endocytosis. (B) Fusion and uncoating occur and the HCV 
genomic RNA is released from the nucleocapsid into the cytoplasm. (C) Translation into a single large 
polyprotein occurs in the endoplasmic reticulum. (D) This polyprotein is then cleaved by viral and host 
proteases into 10 mature HCV proteins, including structural proteins (HCV core protein and envelope 
proteins E1 and E2) and non-structural proteins (P7, NS4A, NS4B, NS5A, and NS5B). (E) These viral 
and host proteins form a membrane bound replication-complex. (F) Transcription takes place, dependent 
upon the RNA helicase (RNA-dependent RNA polymerase or NS5B polymerase) where the positive-
strand RNA serves as a template for transcription. (G) Virion assembly occurs in the Golgi apparatus 
when viral glycoproteins combine with newly produced RNA. (H) Virion maturation, budding and release 
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Synopsis (max of 250 words):  250 
Background: The nucleotide analogs, tenofovir and sofosbuvir, are considered to have a low potential for 
drug interactions. 
Objective: To determine the effect of SOF-based Hepatitis C virus (HCV) treatment on plasma 
concentrations of tenofovir and cellular concentrations of tenofovir-diphosphate.  
Methods: HIV-infected participants with acute HCV were treated for 12 wks with sofosbuvir + ribavirin 
in Cohort 1 or 8 wks with ledipasvir/sofosbuvir in Cohort 2 of AIDS Clinical Trials Group study 5327. 
Only participants taking tenofovir disoproxil fumarate  were included in this analysis. Tenofovir in 
plasma, tenofovir-diphosphate in dried blood spots  and tenofovir-diphosphate in peripheral blood 
mononuclear cells (PBMCs) were measured pre-HCV therapy and longitudinally during the study using 
validated LC/MS-MS.  
Results: Fifteen and 22 men completed Cohorts 1 and 2, respectively. In Cohort 1, tenofovir- diphosphate 
was 4.3-fold higher (95% CI GMR (2.46, 7.67); p=0.0001) in DBS and 2.3-fold higher (95% CI (1.09, 
4.92); p=0.03) in PBMCs following 12 wks of sofosbuvir+ribavirin versus study entry. Tenofovir in 
plasma was unchanged. In Cohort 2, tenofovir-diphosphate was 17.8-fold higher (95% CI (12.77, 24.86); 
p<0.0001) in dried blood spots after 8 wks of ledipasvir/sofosbuvir versus study entry. Tenofovir plasma 
concentrations were 2.1-fold higher (95% CI (1.44, 2.91), p=0.0005). Despite the increase in cellular 
tenofovir-diphosphate concentrations, only a small decline in CLcr (6-7%) was observed in both cohorts 
between study entry and end of treatment.  
Conclusion: These data indicate an unexpected drug interaction with tenofovir disoproxil fumarate and 





Globally, an estimated 2.3 million are coinfected with the HIV and Hepatitis C virus (HCV) due to shared 
routes of transmission.1 Prison inmates, men who have sex with men, and persons who inject drugs are 
most affected.1 HIV accelerates the progression of liver disease in individuals coinfected with HCV.2, 3 
Thus, treatment is imperative to reduce the complications of chronic liver disease in this population. In 
the pegylated interferon and ribavirin era, treatment of HCV in the acute phase resulted in higher rates of 
sustained virologic response (SVR) with a shortened course of therapy compared with treating individuals 
with chronic infection.4-7 However, there are limited data on the optimal use of contemporary all-oral, 
direct acting antiviral agents (DAAs) in individuals with acute HCV.    
AIDS Clinical Trials Group study 5327 (“SWIFT-C”, NCT02128217) was an open-label, two-cohort 
clinical trial of sofosbuvir based treatment of acute HCV in individuals with chronic HIV-1 infection.8, 9 
Cohort 1 of SWIFT-C assessed the safety and efficacy of 12 weeks of 400 mg of sofosbuvir in 
combination with weight-based ribavirin. Cohort 2 assessed the safety and efficacy of 8 weeks of 90mg of 
ledipasvir in combination with 400mg of sofosbuvir. The sustained virologic response rate was 100% in 
Cohort 2 of SWIFT-C, but only 59% in Cohort 1.10 The high rate of relapse in Cohort 1 was unexpected 
and we suspected suboptimal ribavirin adherence contributed to this outcome. Although pill counts and 
participant recall suggested good ribavirin adherence, as previously reported, we found that individuals 
that relapsed after treatment with sofosbuvir+ribavirin had lower ribavirin plasma concentrations during 
treatment.10, 11 Ribavirin has a long-half-life in plasma (~9 days)12, and thus ribavirin concentrations in 
plasma reflect, in part, cumulative drug dosing and long-term adherence to this drug. Thus, the lower 
ribavirin plasma concentrations in patients that relapsed in Cohort 1 of SWIFT-C likely reflected 
suboptimal adherence to ribavirin, given the patients who achieved SVR had levels comparable to 
historical data.10, 11  Though there are no historical data establishing the ribavirin exposures observed with 
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perfect adherence, mean ribavirin plasma concentrations in SWIFT-C participants that relapsed were 
lower than those observed in prior studies of sofosbuvir+ribavirin.13, 14 
Suboptimal adherence to medications leads to inadequate response to treatment and increased healthcare 
costs.15 The World Health Organization estimates that 50%-60% of individuals are non-adherent to the 
medications they have been prescribed to treat chronic illnesses.16 Suboptimal adherence to antiretroviral 
therapy leads to drug resistance, an increase in AIDS-related illnesses and death, and higher rates of HIV 
transmission.17-19 Adherence is also an issue for illnesses with a finite treatment duration. Consider 
tuberculosis where 16% to 49% of individuals do not complete treatment.20 There is evidence of 
suboptimal adherence in clinical trials of direct acting antivirals, despite the fact that HCV treatment is 
only 8 to 24 weeks in duration.21-28 Traditional tools to assess adherence (e.g., refill records, pill counts, 
self-report) have significant shortcomings and typically over-estimate adherence.29 Pharmacokinetic-
based adherence measures provide objective evidence of drug ingestion.30 For compounds with short half-
lives, the information gained is qualitative (i.e., was a dose taken recently) but compounds with longer 
half-lives provide information on cumulative drug dosing and a more quantitative measure of drug taking 
behavior.31  
Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine 
monophosphate and is initially converted to tenofovir by diester hydrolysis in the gut, liver, and plasma.32, 
33 Tenofovir is taken up by cells32, then phosphorylated by cellular kinases to the active form of the drug, 
tenofovir-diphosphate. Tenofovir diphosphate competes with deoxyadenosine 5'-triphosphate (dATP) for 
incorporation into replicating viral DNA. If tenofovir-diphosphate is incorporated into the viral DNA, 
rather than dATP, chain termination occurs.34 The tenofovir-diphosphate half-life in peripheral blood 
mononuclear cells (PBMCs) is 3-7 days35 36, 37  and in red blood cells it is 17 days.38 Thus, like ribavirin 
concentrations in plasma, tenofovir-diphosphate concentrations in cells can be used to assess cumulative 
drug exposure and long-term averaged adherence.38 Concentrations of tenofovir-diphosphate in dried 
blood spots, which contain approximately 12 million red blood cells, are correlated with the risk of 
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acquiring HIV in studies of tenofovir disoproxil fumarate and emtricitabine for HIV prevention.39, 40 
Plasma concentrations of tenofovir have also been used for assessing adherence, but the plasma half-life 
of tenofovir is approximately 10-15 hours34 and thus tenofovir concentrations in plasma reflect only 
recent dosing.  
Given that we found lower ribavirin levels in participants that failed treatment with sofosbuvir+ribavirin  
in Cohort 1 of SWIFT-C10, 11, which suggested suboptimal adherence to ribavirin, the primary aim of this 
analysis was to evaluate whether similar trends were evident for antiretroviral adherence (using 
established methods38) among SWIFT-C participants by comparing tenofovir-diphosphate concentrations 
in dried blood spots before, during, and after sofosbuvir+ribavirin treatment. In the course of this analysis, 
we identified an unexpected drug interaction between tenofovir disoproxil fumarate and sofosbuvir. Thus, 
we also compared tenofovir-diphosphate in PBMCs and tenofovir in plasma before, during, and after 






Participants ≥18 years old with chronic HIV-1 infection and documented confirmation of acute HCV 
infection within 6 months prior to entry were recruited from eight different AIDS Clinical Trials Group 
sites in the United States. Acute HCV was defined as10:  (1) new HCV RNA in patients with documented 
negative serology in past 6 months or (2) in those with no documented serology in past 6 months, positive 
HCV RNA plus a new ALT elevation (>5xULN) with normal ALT in past 12 months or >10xULN with 
no measured ALT in past 12 months, as well as exclusion of other causes of acute hepatitis. Participants 
were not required to be taking antiretroviral therapy, but those receiving antiretroviral therapy were 
required to be stable on a regimen for at least 8 weeks with an HIV-1 RNA less than 50 copies/mL and 
CD4+ T cell count greater than 200 cells/mm3.  Participants’ adherence was assessed using a 4-day recall 
and by pill count. 
For Cohort 1 participants, plasma, dried blood spots, and PBMCs were analyzed at entry, week 12 of 
sofosbuvir+ribavirin treatment (WK12) and 12 weeks following the end of sofosbuvir+ribavirin treatment 
(EOT+12). In Cohort 2 participants, plasma samples were analyzed for each participant at entry, WK8 of 
ledipasivr/sofosbuvir treatment and EOT+12 and dried blood spot samples were analyzed from each 
participant at entry, WK1, WK2, WK4 and WK 8 of ledipasvir/sofosbuvir treatment as well as EOT+2, 
EOT+4, EOT+8 and EOT+12. PBMC were not collected in cohort 2. All pharmacology samples were 
collected at convenience times post dose.  
Tenofovir-diphosphate concentrations in a 3mm dried blood spot punch and in PBMCs were analyzed 
using a validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) method.41 The dynamic 
range of the assay was 25–6000 fmol/sample for tenofovir-diphosphate in dried blood spots and 2.50-
2000 fmol/sample for PBMCs.41 Accuracy was ≤ ± 15% from nominal and precision was  ≤15% CV. 
Lack of assay interference between analytes was confirmed. Plasma tenofovir concentrations were also 
analyzed using a validated LC/MS-MS method, the dynamic range of the assay was 10-1500 ng/mL.42  
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Tenofovir and tenofovir-diphosphate concentrations were log transformed and compared between study 
visits using paired t-tests.  
Results: 
Study Patients: 
Seventeen HIV-infected male participants entered Cohort 1 of SWIFT-C and all 17 completed 12 weeks 
of sofosbuvir+ribavirin treatment for acute HCV. All 17 were on antiretroviral therapy and 15 were 
taking tenofovir disoproxil fumarate as part of their antiretroviral regimen. Among these 15, 11 were 
Hispanic, 4 Non-Hispanic White with a mean (+SD) age of 44.3 (+9.5) years and weight of 76.5 (+10.3) 
kg. Complete demographic information can be found in Table I.  
Twenty seven HIV-infected male participants entered Cohort 2 of SWIFT-C and all 27 completed 8 
weeks of ledipasvir/sofosbuvir treatment for acute HCV. All 27 were on antiretroviral therapy and 22 
were taking tenofovir disoproxil fumarate as part of their antiretroviral regimen. Among these 22, 6 were 
Hispanic, 16 Non-Hispanic White with a mean (+ SD) age of 44.4 (+ 8.8) years and weight of 76.9 (+ 9.6) 
kg. Complete demographic information can be found in Table I. 
Tenofovir-Diphosphate and Tenofovir Concentrations: 
In Cohort 1, at study entry, the geometric mean (CV%) tenofovir-diphosphate concentration in dried 
blood spots was 1687 (31) fmol/punch; consistent with historical data in HIV-infected and uninfected 
individuals with high adherence.30, 31, 38, 43 However, at WK12 of sofosbuvir+ribavirin treatment, the 
geometric mean (CV%) tenofovir-diphosphate in dried blood spots was 6607 (74) fmol/punch. In the 12 
participants with both entry and WK12 tenofovir-diphosphate concentrations in dried blood spots, the 
geometric mean ratio (GMR) for tenofovir-diphosphate was 4.3 versus entry (95% CI; 2.46, 7.67, 
p=0.0001). By EOT+12, tenofovir-diphosphate in dried blood spots had declined and the geometric mean 
(CV%) was 2101 (36) fmol/punch (p=0.0072) (Figure 1a). Tenofovir-diphosphate concentrations were 
also determined in PBMCs. At entry, WK12 and EOT+12, geometric mean (CV%) tenofovir-diphosphate 
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concentrations in PBMCs were 79 (48), 149 (91) and 81 (52) fmol/106 cells, respectively. The tenofovir-
diphosphate concentrations pre sofosbuvir+ribavirin in PBMCs were similar to historical data in HIV-
infected individuals with high adherence,30, 38 but for the 10 participants with both entry and WK12 
concentrations, the tenofovir-diphosphate concentrations in PBMCs were 2.3-fold higher at WK12 (95% 
CI; 1.09, 4.92, p=0.03) (Figure 1b). Despite the increased levels of tenofovir-diphosphate in PBMC and 
red blood cells, tenofovir concentrations in plasma were similar to historical data and unchanged across 
visits (p=0.83). At entry, WK12 and EOT+12, geometric mean (CV%) tenofovir concentrations were 98 
(63), 96 (57), and 94 (76) ng/mL, respectively (Figure 1c). 
In Cohort 2, at study entry, the geometric mean (CV%) tenofovir-diphosphate concentrations in dried 
blood spots were 1516 (36) fmol/punch, which was similar to that for Cohort 1 and consistent with 
historical data in HIV-infected and uninfected individuals with high adherence.30, 38, 43 By week 1 of 
ledipasvir/sofosbuvir treatment, tenofovir-diphosphate concentrations were 6.7-fold higher versus entry 
(Figure 2a). At WK 8 of ledipasvir/sofosbuvir treatment, for the 20 participants with both entry and WK8 
tenofovir-diphosphate concentrations in dried blood spots, the GMR tenofovir-diphosphate was 17.8 
(95% CI; 12.77, 24.86, p = <0.0001) compared with study entry. The geometric mean (CV%) at WK8 of 
tenofovir-diphosphate was 26846 (49) fmol/punch. Tenofovir concentrations in plasma were increased 
2.1-fold (95% CI (1.44, 2.91), p= 0.0005), at WK8 of ledipasvir/sofosbuvir treatment with a geometric 
mean (CV%) of 155 (112) ng/mL (Figure 2b). Three participants in Cohort 2 switched from tenofovir 
disoproxil fumarate to tenofovir alafenamide at WK1, WK7 and WK15 of study, respectively, thus 
tenofovir-diphosphate in dried blood spots and tenofovir in plasma samples for these individuals were 
excluded from analyses following the switch.  
Prior data in healthy volunteers suggested administering  ledipasvir/sofosbuvir concomitantly with a 
boosted antiretroviral regimen and tenofovir disoproxil fumarate could result in tenofovir exposures that 
exceed the range with established renal safety data.44 In this study, Cohort 1 participants who were taking 
either ritonavir or cobicistat for pharmacokinetic boosting did not have higher tenofovir-diphosphate or 
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tenofovir concentrations compared with those not taking a boosting agent at any study visit. In Cohort 2, 
participants taking a boosted antiretroviral regimen had higher tenofovir-diphosphate concentrations at 
baseline (before ledipasvir/sofosbuvir). The geometric mean (CV%) tenofovirdiphosphate concentrations 
prior to the addition of ledipasvir/sofosbuvir, were 1912 (29) and 1279 (32) for boosted versus unboosted 
regimens, respectively (p= 0.005). However, this was not observed at subsequent visits and rather, 
participants not taking a boosting agent actually had numerically (though not statistically) higher 
tenofovir-diphosphate concentrations.   
Renal Function 
The mean (SD) creatinine clearance (CLcr)  in Cohort 1 participants was 125.4 mL/min (24) at study entry 
and 117.7 mL/min (20) at week 12 of sofosbuvir+ribavirin treatment, p=0.18. The mean (SD) CLcr in 
Cohort 2 participants was 107.5 mL/min (16) at study entry and 99.8 mL/min (18) at week 8 of 
ledipasvir/sofosbuvir treatment, p=0.01. Two participants, both on tenofovir disoproxil fumarate plus a 
boosting agent in Cohort 2, had an increase in serum creatinine >0.4 mg/dL (confirmed within 2 weeks), 
which was a protocol-defined renal toxicity. However, neither participant required a dose reduction of 





In our investigations using drug concentrations to assess antiretroviral adherence in HIV-infected men 
treated for acute HCV, we identified an unexpected increase in cellular tenofovir-diphosphate 
concentrations with both sofosbuvir+ribavirin and to a much larger extent with ledipasvir/sofosbuvir. The 
interaction was not observed in plasma for sofosbuvir+ribavirin and was observed with 
ledipasvir/sofosbuvir, but at a much smaller magnitude compared with the effect on tenofovir-
diphosphate in dried blood spots. We believe this finding suggests the presence of a previously 
undescribed drug-drug interaction between tenofovir disoproxil fumarate and sofosbuvir.    
The mechanism for this interaction is unclear, but given the increase in tenofovir-diphosphate 
concentrations occurred with both sofosbuvir+ribavirin and ledipasvir/sofosbuvir suggests sofosbuvir is 
perpetrating this interaction. However, the interaction occurred at  a much larger extent in those who 
received ledipasvir in addition to sofosbuvir, so ledipasvir is also a significant contributor to this 
interaction. Whether the contribution is via a direct effect of ledipasvir on tenofovir or tenofovir 
disoproxil fumarate (perhaps through inhibition of P-glycoprotein or breast cancer resistance protein) or 
the result of ledipasvir causing an increase in sofosbuvir AUC, which has been observed in prior studies45-
47, is unknown. In healthy volunteers, sofosbuvir increases the maximum concentration of tenofovir in 
plasma by 25% with no change in AUC.48 Ledipasivr/sofosbuvir increases tenofovir plasma 
concentrations by 30-80% depending on the concomitant antiretrovirals.44, 49  
There are several potential mechanisms for the sofosbuvir-mediated increase in tenofovir diphosphate. A 
study in Caco-2 monolayers found that tenofovir disoproxil fumarate recovery (from the apical to 
basolateral membrane) was increased in the presence of sofosbuvir.47 Recent work suggests sofosbuvir 
inhibits carboxylesterase-2 (CES2).50 Tenofovir disoproxil fumarate is converted to tenofovir by two 
separate ester hydrolysis steps.33 Carboxylesterases are involved in this conversion of tenofovir disoproxil 
to tenofovir.51, 52 Carboxylesterase enzymes are expressed in liver, small intestine, kidneys, lungs, plasma 
and other cell types.53 Thus, sofosbuvir-inhibition of carboxylesterase-2 could result in greater prodrug 
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delivery and increased cellular uptake. Other potential mechanisms include alterations in drug 
phosphorylation or dephosphorylation or changes in cellular uptake or efflux.  
In terms of potential alterations in phosphorylation, it is possible that sofosbuvir (or its intracellular 
metabolites) enhance phosphorylation of tenofovir or inhibit tenofovir-diphosphate dephosphorylation 
through upregulation or downregulation of the involved kinases or phosphatases. The effect of sofosbuvir 
on enzymes responsible for tenofovir phosphorylation (e.g., adenylate kinase 1&2, pyruvate kinase, 
creatine kinase) or tenofovir-diphosphate dephosphorylation (e.g., 5′-nucleotidases) 54-58 has not been 
evaluated to our knowledge.  
In terms of the potential for sofosbuvir to increase cellular uptake of tenofovir-disoproxil fumarate or 
tenofovir, tenofovir is a substrate for the uptake transporter, organic anion transporter (OAT1) and single 
nucleotide polymorphisms (SNPs) in the gene that encodes OAT1 (SLC22A6) have been associated with 
increased tenofovir-diphosphate concentrations.59 Tenofovir-diphosphate concentrations also may be 
increased in individuals with variant polymorphisms in the genes encoding the equilibrative nucleoside 
(ENT) transporters.60 The potential for sofosbuvir (or its metabolites) to induce OAT1, ENT1, or other 
uptake transporters has not been evaluated to our knowledge. In terms of the potential for sofosbuvir to 
block cellular efflux, sofosbuvir does not inhibit P-gp, breast cancer resistance protein (BCRP), multidrug 
resistance protein 2 (MRP2), or bile salt export pump. Ledipasvir does not inhibit MRP 2 or 4, but does 
inhibit intestinal P-gp and BCRP. As evidence of its effect on P-gp and BCRP, ledipasvir increases 
sofosbuvir (a P-gp and BCRP substrate) AUC and Cmax by 2.3- and 2.2-fold, respectively45-47 and this 
may explain why the effect of ledipasvir/sofosbuvir on tenofovir-diphosphate is greater than that observed 
with sofosuvir+ribavirin, as more tenofovir disoproxil fumarate may cross the gut barrier and reach the 
portal blood if intestinal P-gp and/or BCRP are inhibited.  
In addition to uncovering the potential mechanism for this interaction, it is important to determine its 
clinical relevance. Chronic tenofovir disoproxil fumarate use can result in proximal tubular damage and 
acute and chronic kidney injury.61, 62 Some studies suggest these toxicities are concentration-dependent 
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(i.e., higher plasma tenofovir or intracellular tenofovir-diphosphate concentrations are associated with a 
greater risk for toxicity).63-65  Tenofovir-diphosphate concentrations would be difficult to measure in renal 
proximal tubule cells, but if tenofovir- diphosphate concentrations were also increased by sofosbuvir in 
this cell type, this could theoretically lead to a higher risk of renal toxicity. We did not find a large decline 
in estimated CLcr overall in our cohorts or in any individual participant, but sofosbuvir dosing was for a 
relatively short period of time, 8 to 12 weeks. Longer treatment may require closer monitoring. SWIFT-C 
participants also had normal renal function at baseline (Table I), so we cannot determine whether the 
interaction would result in renal toxicity in individuals with impaired renal function.  
An important factor to consider for this drug-drug interaction, is that HCV therapy is finite. Thus, this 
interaction may not have serious clinical implications for HIV co-infected individuals, but there may be 
consequences for other nucleotide analogs which may require longer durations of treatment. In addition, 
the implications of this interaction in the context of the new tenofovir prodrug, tenofovir alafenamide, 
which has 5 to 7-fold higher tenofovir-diphosphate concentrations in PBMCs66, is also unknown. These 
data also raise the question of which form of the nucleos(t)ide analog (the prodrug, parent drug, or 
triphosphate) should be evaluated in drug-drug interaction studies. 
In summary, this study uncovered an unexpected drug-drug interaction between tenofovir disoproxil 
fumarate and sofosbuvir and ledipasvir at the cellular level. The much higher levels of tenofovir-
diphosphate were not associated with large declines in CLcr in these participants with good baseline renal 
function, however this interaction precludes using tenofovir diphosphate in dried blood spots to assess 
adherence during sofosbuvir-based HCV treatments pending further study. Additional research is needed 
to determine the mechanism for this interaction and the potential clinical implications.  
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 Cohort 1 (N=15) Cohort 2 (N=22) 







     Hispanic, N (%) 11 (73) 
 
6   (27) 
 
     White, N (%) 4   (27) 18 (73) 
Baseline CLcr (mL/min): mean + SD 125.4 + 23.4 107.5 + 15.7  
Age (years): mean + SD 44.3 + 9.5 44.4 + 8.8 
 
Weight (kg): mean + SD 76.5 + 10.3 76.9 + 9.6 
 
Antiretroviral Regimen, N (%)  
     NNRTI 7 (47) 8 (36) 
     Integrase 5 (33) 11 (50) 
     Boosted 6 (40) 9 (41) 
          COBI 3 (50) 4 (44) 











Figure 1a: Geometric mean (%CV) tenofovir-diphosphate (TFV-DP in fmol/punch) concentrations in 
dried blood spot samples at study entry (before starting SOFOSBUVIR+RIBAVIRIN), after 12 weeks of 
SOFOSBUVIR+RIBAVIRIN treatment, and 12 weeks after completing SOFOSBUVIR+RIBAVIRIN 
treatment (EOT+12). Concentrations at week 12 of SOFOSBUVIR+RIBAVIRIN treatment were 
compared with entry using a paired t-test.  
Figure 1b: Geometric mean (%CV) tenofovir-diphosphate (TFV-DP in fmol/106 cells) concentrations in 
PBMC samples at study entry (before starting SOFOSBUVIR+RIBAVIRIN), after 12 weeks of 
SOFOSBUVIR+RIBAVIRIN treatment, and 12 weeks after completing SOFOSBUVIR+RIBAVIRIN 
treatment (EOT+12). Concentrations at week 12 of SOFOSBUVIR+RIBAVIRIN treatment were 
compared with entry using a paired t-test. 
Figure 1c: Geometric mean (%CV) tenofovir (TFV in ng/mL) concentrations in plasma samples at study 
entry (before starting SOFOSBUVIR+RIBAVIRIN), after 12 weeks of SOFOSBUVIR+RIBAVIRIN 
treatment, and 12 weeks after completing SOFOSBUVIR+RIBAVIRIN treatment (EOT+12). The 
tenofovir concentrations were similar to historical data and unchanged across visits, p=0.83. 
Figure 2a: Geometric mean (%CV) tenofovir-diphosphate (TFV-DP in fmol/punch) concentrations in 
dried blood spot samples at study entry (before starting ledipasvir/sofosbuvir), Weeks 1, 2, 4 and 8 of 
ledipasvir/sofosbuvir treatment, and 2, 4, 8 and 12 weeks after completing ledipasvir/sofosbuvir treatment 
(EOT+2, EOT+4, EOT+8 and EOT+12). Concentrations of tenofovir-diphosphate during 
ledipasvir/sofosbuvir treatment were compared with entry using a paired t-test. 
Figure 2b: Geometric mean (%CV) tenofovir (TFV in ng/mL) concentrations in plasma samples at study 
entry (before starting ledipasvir/sofosbuvir), after 8 weeks of ledipasvir/sofosbuvir treatment, and 12 
weeks after completing ledipasvir/sofosbuvir treatment (EOT+12). The tenofovir concentrations were 






















ACCEPTED MANUSCRIPT AIM 2 
J Antimicrob Chemother. 2019 [Accepted] 
Increased tenofovir-monoester concentrations in patients receiving tenofovir disoproxil fumarate 
with ledipasvir/sofosbuvir 
 
Kristina M. BROOKS1, Jose R. CASTILLO-MANCILLA2, Joshua BLUM3, Ryan HUNTLEY1, 
Samantha MAWHINNEY4, Keisha ALEXANDER1, Becky Jo KERR1, Lucas ELLISON1, Lane R. 
BUSHMAN1, Christine E. MACBRAYNE1†, Peter L. ANDERSON1 and Jennifer J. KISER1* 
 
1Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and 
Pharmaceutical Sciences, Aurora, CO, USA; 2Department of Medicine, University of Colorado School of 
Medicine, Aurora, CO, USA; 3Denver Health, Denver, CO, USA; 4Department of Biostatistics and 
Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 
Aurora, CO, USA 
 
*Corresponding author. University of Colorado Skaggs School of Pharmacy and Pharmaceutical 
Sciences, 12850 E Montview Blvd, V20-C238, Aurora, CO 80045, USA. Tel: +1 (303) 724 6131; Fax: 
+1 (303) 724 6135; E-mail: jennifer.kiser@ucdenver.edu 
†Present address: Children’s Hospital Colorado, Aurora, Colorado, USA. 
 
Running head: Tenofovir-monoester with ledipasvir/sofosbuvir  
191 
SYNOPSIS 
Background: Intracellular tenofovir-diphosphate concentrations are markedly increased in HIV/HCV co-
infected individuals receiving tenofovir disoproxil fumarate (TDF) with sofosbuvir-containing treatment. 
Sofosbuvir may inhibit the hydrolysis of TDF to tenofovir, resulting in increased concentrations of the 
disoproxil or monoester forms, which may augment cell loading. We sought to quantify tenofovir 
disoproxil and monoester concentrations in individuals receiving TDF with and without 
ledipasvir/sofosbuvir. 
Methods: HIV/HCV co-infected participants receiving TDF-based therapy were sampled pre-dose, and 1 
and 4 h post-dose prior to and 4 weeks after initiating ledipasvir/sofosbuvir. Tenofovir-disoproxil was not 
detectable. Tenofovir-monoester in plasma and tenofovir-diphosphate in PBMC and dried blood spots 
(DBS) were quantified using LC-MS/MS. Geometric mean ratios (week 4 versus baseline) and 95% CIs 
were generated for the pharmacokinetic parameters. P values reflect paired t-tests. 
Results: Ten participants had complete data. At baseline, geometric mean (95% CI) tenofovir-monoester 
plasma concentrations at 1 and 4 h post-dose were 97.4 ng/mL (33.0–287.5) and 0.74 ng/mL (0.27–2.06), 
respectively. With ledipasvir/sofosbuvir, tenofovir-monoester concentrations at 4 h post-dose were 5.02-
fold higher (95% CI 1.40–18.05; P=0.019), but not significantly different 1 h post-dose (1.72-fold higher, 
95% CI 0.25–11.78; P=0.54), possibly due to absorption variability. Tenofovir-diphosphate in PBMCs 
and DBS were increased 2.80-fold (95% CI 1.71–4.57; P=0.001) and 7.31-fold (95% CI 4.47–11.95; 
P<0.0001), respectively after 4 weeks of ledipasvir/sofosbuvir. 
Conclusions: Tenofovir-monoester concentrations were increased in individuals receiving TDF with 
ledipasvir/sofosbuvir, consistent with inhibition of TDF hydrolysis. Additional studies are needed to 
determine the clinical relevance of this interaction.  
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Introduction 
There are an estimated 2.3 million individuals living with HIV and HCV worldwide.1 Persons living with 
HIV/HCV coinfection are at an increased risk for multiple liver-related morbidities in comparison with 
HCV monoinfection.2 Thus, HCV treatment is critical to improve health outcomes in this population. 
Several direct-acting antiviral (DAA) combinations are approved for HCV treatment, many of which only 
require once-daily dosing for as little as 8 weeks of therapy. Despite the short treatment duration for 
HCV, HIV requires lifelong therapy and should not be interrupted during the course of HCV treatment.3 
Thus, drug–drug interactions between DAAs and antiretroviral medications are of concern.  
Both sofosbuvir and tenofovir are key components of multiple recommended HCV and HIV 
treatment regimens, respectively, and have a low potential for causing or being susceptible to significant 
drug–drug interactions. However, we recently found that intracellular concentrations of tenofovir-
diphosphate were significantly increased in individuals with HIV/HCV co-infection taking tenofovir 
disoproxil fumarate (TDF) in combination with sofosbuvir-containing HCV treatment.4 Tenofovir-
diphosphate concentrations in dried blood spot (DBS) samples were increased 4.3-fold after 12 weeks of 
sofosbuvir/ribavirin and 17.8-fold after 8 weeks of ledipasvir/sofosbuvir treatment, whereas tenofovir 
concentrations in plasma appeared unchanged with sofosbuvir/ribavirin, and were only 2.1-fold higher 
with ledipasvir/sofosbuvir. The mechanisms behind this drug–drug interaction are unclear.  
Tenofovir-disoproxil is a prodrug initially hydrolysed to tenofovir-monoester and subsequently to 
tenofovir (Figure 1). Tenofovir is then phosphorylated by host enzymes to the active moiety, tenofovir-
diphosphate. Early in vitro studies indicated that carboxylesterases were responsible for the initial 
hydrolysis of tenofovir-disoproxil to tenofovir-monoester, and the monoester was then converted into 
tenofovir by phosphodiesterases.5 Recent work by Shen et al.6,7 suggests that sofosbuvir reduces TDF 
hydrolysis via inhibition of carboxylesterase 2 (CES2). However, clinical/pharmacokinetic data to support 
this proposed drug–drug interaction are not available, and there are variable data on the clinical 
significance of drug–drug interactions via carboxylesterases.8 Prior studies suggested that TDF 
conversion through tenofovir-monoester was rapid, resulting in tenofovir as the only detectable 
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circulating moiety in the plasma.9 However, Nye et al.10 recently found a metabolite presumed to be 
tenofovir-monoester while developing an LC-MS/MS method for tenofovir, emtricitabine, and efavirenz, 
which was detected in plasma in ‘considerable quantities’ up to 4 h post-dose.   
Tenofovir-monoester is more lipophilic than tenofovir,10 and thus may contribute to blood cell 
loading in individuals similarly to tenofovir-disoproxil. Higher tenofovir-disoproxil and/or tenofovir-
monoester concentrations may result from inhibition of TDF hydrolysis with the concomitant use of 
sofosbuvir-containing therapy, which could lead to enhanced blood cell loading. This may explain the 
several-fold increased levels of intracellular tenofovir-diphosphate in persons receiving this combination. 
Thus, we sought to determine whether tenofovir-disoproxil or tenofovir-monoester were quantifiable in 
individuals with HIV/HCV co-infection receiving TDF, and whether concentrations of these moieties 
were increased following the initiation of ledipasvir/sofosbuvir treatment.   
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Patients and methods 
This was a single-centre study conducted at the University of Colorado Anschutz Medical Campus 
(NCT02588287). This study was approved by the Colorado Multiple Institutional Review Board. All 
participants provided written informed consent. Eligible participants included persons living with 
HIV/HCV between 18–60 years of age on TDF in combination with a ritonavir-boosted HIV PI as part of 
standard care for at least 30 days prior to initiating ledipasvir/sofosbuvir treatment. Key exclusion criteria 
included women currently or planning to become pregnant, an estimated glomerular filtration rate (eGFR) 
<60 mL/min/1.73 m2, and any medical, social, or mental health issue(s) that could interfere with study 
participation or study outcomes. Enrolment began in December 2015, with the last follow-up visit in 
September 2016. 
Pharmacokinetic assessments were performed prior to (baseline) and 4 weeks after initiating 
ledipasvir/sofosbuvir treatment. All participants received a standardized meal (macro-controlled 600 
calorie meal consisting of 15% protein, 35% fat, and 50% carbohydrates) and study medications were 
administered under directly observed therapy at both pharmacokinetic assessments. Blood samples for 
pharmacokinetic analysis were obtained at pre-dose (time 0), and 1 and 4 h post-dose. DBS and PBMCs 
were processed from the time 0 sample, and plasma was collected at all aforementioned timepoints. 
Tenofovir disoproxil was not detectable in plasma and thus could not be quantified. Tenofovir-monoester 
in plasma was quantified using a novel UPLC-MS method.11 This method was linear over a range of 0.1 
to 500 ng/mL using a 1/concentration2 weighted calibration curve. Samples exceeding the upper limit of 
quantification were diluted and reanalysed. Tenofovir in plasma and intracellular tenofovir-diphosphate in 
PBMCs and DBS were quantified using validated LC-MS/MS methods as previously described.12,13 
Statistical analyses were performed in Stata/IC (v15.1). Pharmacokinetic data were log-transformed to 




Twelve participants were enrolled, of whom 10 had data available at baseline and week 4 for comparison. 
Of the two participants who did not complete the week 4 visit, one did not start ledipasvir/sofosbuvir 
therapy and the other had poor adherence to antiretroviral therapy and was removed from study. Of the 10 
participants who completed baseline and week 4, 8 were male and 2 were female, and 30% were white, 
40% were black, and 30% were Hispanic/Latino. Mean (SD) age, weight, and eGFR were 48.2 (10.4) 
years, 72.1 (14.3) kg, and 98.7 (29.9) mL/min/1.73 m2, respectively. Three participants received ritonavir-
boosted atazanavir and seven received ritonavir-boosted darunavir. The majority of participants were 
HCV genotype 1a (70%), two were genotype 1b, and one was mixed genotype 1a+1b. 
 
Pharmacokinetic results 
At baseline, geometric mean (95% CI) tenofovir-monoester plasma concentrations at 1 and 4 h post-dose 
were 97.4 ng/mL (33.0–287.5) and 0.74 ng/mL (0.27–2.06), respectively (see Figure 2). Following the 
initiation of ledipasvir/sofosbuvir, these increased to 167.8 ng/mL (45.8–615.3) and 3.73 ng/mL (2.34–
5.97), respectively. Tenofovir-monoester concentrations at 1 h post-dose were higher but not significantly 
different between study visits, likely due to sampling variability during the absorption phase (GMR 1.72, 
95% CI 0.25–11.78; P=0.54). However, tenofovir-monoester concentrations at 4 h post-dose were 5.02-
fold higher (95% CI 1.40–18.05; P=0.019) with ledipasvir/sofosbuvir. Tenofovir-monoester was not 
detectable pre-dose at baseline or week 4. Plasma concentrations of tenofovir at time 0 (pre-dose), 1, and 
4 h post-dose were increased 1.34-fold (95% CI 1.09–1.65; P=0.011), 1.83-fold (95% CI 0.51–6.54; 
P=0.31), and 1.43-fold (95% CI 1.29–1.58, P<0.0001), respectively, between week 4 versus baseline. 
Tenofovir-diphosphate concentrations in PBMCs and DBS with ledipasvir/sofosbuvir increased by 2.80-
fold (95% CI 1.71–4.57; P=0.001) and 7.31-fold (95% CI 4.47–11.95; P<0.0001), respectively after 4 
weeks.   
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Discussion 
This study demonstrated that tenofovir-monoester was quantifiable in plasma among persons with 
HIV/HCV coinfection receiving TDF-based therapy. Furthermore, concentrations of this moiety were 
increased following the initiation of ledipasvir/sofosbuvir treatment, potentially explaining the drug–drug 
interaction that was previously discovered in individuals on sofosbuvir-based therapy in combination with 
TDF. These results contradict prior literature suggesting tenofovir-monoester was not detectable in the 
plasma of humans taking TDF14,15 and extends the work of Nye and colleagues,10 which identified a 
compound with a mass-to-charge ratio corresponding in elemental composition to tenofovir-monoester.  
 Initial studies on the pharmacology of TDF reported its conversion to tenofovir as rapid and 
spontaneous, resulting in no detectable tenofovir-monoester in plasma.9 However, in conjunction with the 
joint analyses published along within this brief report, Brooks et al. demonstrated tenofovir-monoester 
exhibits quantifiable pharmacokinetics in vivo following a single TDF/emtricitabine dose.11 Baseline 
tenofovir-monoester measured at 1 and 4 h post-dose in this study were higher than those quantified in the 
healthy volunteer study, where geometric mean concentrations at the same timepoints were ~39 ng/mL 
and 0.17 ng/mL, respectively. These differences may be driven in part by differences in fasted versus fed 
state15 and the concomitant use of PIs.16,17 Thus, tenofovir-monoester exhibits quantifiable 
pharmacokinetics in vivo. Tenofovir-monoester is more lipophilic than tenofovir, and was shown to cross 
from the apical to basolateral side in Caco-2 cells, whereas tenofovir transfer was not detected.18 
Therefore, elevated tenofovir-monoester levels may enhance cellular delivery of tenofovir and 
subsequently increase intracellular concentrations of the active tenofovir-diphosphate form. The ~5-fold 
increase in tenofovir-monoester at 4 h post-dose was higher than the concomitant elevation of tenofovir in 
plasma (~1.5-fold), but comparable to the 7.3-fold and 2.8-fold higher tenofovir-diphosphate 
concentrations in DBS and PBMCs, respectively.  
Sofosbuvir was previously shown to increase TDF recovery through an unidentified mechanism 
in Caco-2 cells.19 Shen et al.6,7 demonstrated that sofosbuvir inhibited TDF hydrolysis via inhibition of 
CES2 in liver and kidney microsomes, and in intestinal and liver homogenates of mice treated with 
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sofosbuvir.7 CES2 is highly expressed in the intestinal tract,8 and thus CES2 inhibition could result in 
enhanced delivery of the disoproxil and monoester forms in portal blood. Unfortunately, tenofovir 
disoproxil is unstable in human plasma and was not quantifiable in this study (data not shown). However, 
tenofovir-monoester was quantifiable. Tenofovir-monoester is more lipophilic than tenofovir and has 
been shown to transfer across Caco-2 cell layers, whereas tenofovir transfer was not detected.18 Therefore, 
elevated tenofovir-monoester levels may enhance cellular delivery and subsequently increase intracellular 
concentrations of the active tenofovir-diphosphate form. Our findings are consistent with the hypothesis 
that sofosbuvir-mediated inhibition of TDF hydrolysis contributes to the mechanism for higher 
intracellular tenofovir-diphosphate concentrations observed in persons taking these therapies 
concomitantly. 
In addition to our hypothesis above, other drug–drug interaction mechanisms may also contribute 
to increased concentrations of tenofovir-monoester and tenofovir-diphosphate during sofosbuvir-based 
therapy. CES2 may not exclusively convert TDF to the monoester form, and other carboxylesterase 
subtypes, esterases, and lipases have been implicated in TDF hydrolysis.20 Boosted PIs also inhibit 
various drug transporters, including P-glycoprotein, and carboxylesterases.16,17 Concomitant PIs in our 
study were consistent between baseline and week 4 in all participants. While sofosbuvir does not inhibit 
common efflux transporters, such as P-glycoprotein, breast cancer resistance protein (BCRP), or MDR-
associated proteins,21 ledipasvir does inhibit P-glycoprotein and BCRP, for which both sofosbuvir and 
tenofovir-disoproxil are substrates. Ledipasvir increases the AUC of sofosbuvir by 130%19 and tenofovir 
by ~40%–98%,21 depending on the concomitant antiretroviral administered. These AUC increases were 
concurrent with increases in peak concentrations, suggesting inhibition of first-pass metabolism. The 
magnitude of increase in intracellular tenofovir-diphosphate concentrations in red blood cells was 
markedly higher with the combination of ledipasvir/sofosbuvir versus sofosbuvir with ribavirin in 
previous studies [17.8-fold (95% CI 12.77–24.86) versus 4.3-fold (95% CI 2.46–7.67), respectively].4 
Collectively, a combination of drug–drug interactions from PIs, inhibition of CES2 by sofosbuvir, and 
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drug efflux transporters by ledipasvir may result in elevated tenofovir-disoproxil and tenofovir-
monoester, driving blood cell loading of tenofovir-diphosphate in this and the prior study.4   
Our findings raise new questions about the importance of interactions occurring at the level of 
nucleotide prodrug conversion to the cellular pharmacology of this class of drugs. Enhanced delivery of 
the disoproxil or monoester forms could lead to enhanced antiviral activity, particularly within the liver. 
However, renal proximal tubule damage has been associated with higher tenofovir exposures,22 which 
brings into question the role that tenofovir-monoester may play in these toxicities if increased delivery of 
the monoester form is contributing to circulating tenofovir levels in the blood. The magnitude of increase 
in tenofovir-diphosphate PBMC concentrations in our study is similar to the ~2.4–7-fold increases 
observed with tenofovir alafenamide (TAF)-containing therapy.23,24 More research is needed to examine 
potential relationships between intracellular tenofovir-diphosphate concentrations and treatment-related 
toxicities. Tenofovir-diphosphate concentrations in DBS are used to determine cumulative medication 
adherence to tenofovir-based therapies owing to the long half-life of tenofovir-diphosphate in this cell 
type,25,26 which can be altered by concomitant antiretroviral medications in persons living with HIV.27 
The magnitude of tenofovir-diphosphate increase that occurs with sofosbuvir-containing regimens 
precludes the ability to use this measure for adherence interpretations. However, the active anabolite of 
sofosbuvir, 007-triphosphate, is quantifiable in DBS and could alternatively serve as a direct measure of 
cumulative DAA adherence in persons on sofosbuvir-containing therapy.28 
 There are limitations to this study. First, a limited sampling strategy was used as the original 
focus of the study was to measure changes in plasma tenofovir concentrations, but tenofovir-monoester 
peaks at 0.5 h post-dose and has a half-life of ~0.44 h.11 Thus, true peak concentrations of tenofovir-
monoester were likely missed and AUC calculations were not possible. Additionally, this was a small 
sample size and two different participants had low tenofovir-monoester concentrations at 1 h post-dose 
compared with the rest of the study participants, one at baseline and the other 4 weeks after initiating 
ledipasvir/sofosbuvir. All participants received a standardized breakfast and took an observed dose of 
study medication during the pharmacokinetic assessments. The mechanisms behind these observations are 
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unclear, but could be attributed in part to delays in absorption. Tenofovir-diphosphate in DBS is also 
influenced by cumulative adherence to tenofovir disoproxil fumarate. Two participants had DBS levels 
that were below the threshold of 1250 fmol/punch, which has been identified as a cut-off for levels 
associated with seven doses per week in persons on pre-exposure prophylaxis (PrEP).25,28 Overall DBS 
concentrations measured at baseline in our study were comparable to those measured in virologically 
suppressed persons living with HIV on boosted PI therapy [2344 (95% CI 1460–3761) versus 1890 (95% 
CI 1704–2095) fmol/punch, respectively].27  
In summary, this study revealed increased concentrations of tenofovir-monoester following the initiation 
of ledipasvir/sofosbuvir in persons living with HIV and HCV. These findings are consistent with elevated 
tenofovir-monoester resulting from inhibition of TDF hydrolysis by sofosbuvir, resulting in enhanced cell 
loading by the disoproxil or monoester forms, and thus higher intracellular tenofovir-diphosphate 
concentrations with concomitant use. Further research is needed to characterize the pharmacokinetic 
profile of tenofovir-monoester and its potential relevance to cell loading in humans, and establish the 
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FIGURES & FIGURE LEGENDS 
Figure 1. Overview of tenofovir disoproxil fumarate (TDF) hydrolysis and proposed drug–drug 
interaction mechanism between TDF and sofosbuvir. Dashed lines indicate hypothetical mechanism of 
inhibition of TDF hydrolysis by sofosbuvir. CES, carboxylesterase; SOF, sofosbuvir; TFV-monoester, 
tenofovir-monoester; TFV, tenofovir; TFV-MP, tenofovir-monophosphate; TFV-DP, tenofovir-
diphosphate.  
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Figure 2. Geometric mean (95% CI) plasma tenofovir-monoester concentrations at baseline and after 4 
weeks of ledipasvir/sofosbuvir (Week 4) at (a) 1 h post-dose and (b) 4 h post-dose. Intracellular tenofovir-
diphosphate concentrations in (c) PBMCs and (d) DBS were also significantly increased at week 4 in 

























































APPENDIX E  
TFV-DP QUANTIFICATION IN DBS AND PBMC 
DBS, Plasma and PBMC Isolation from a Single Tube 
4-mL whole blood samples were collected in K2 EDTA Vacutainer tubes from a single 
blood draw in order to obtain dried blood spots (DBS), plasma, and peripheral blood 
mononuclear cells (PBMCs). A 25μL pipette is used to spot the whole blood on Whatman 
Protein Saver Cards #903. Five spots are placed on the cards and cards allowed to dry for a 
minimum of 3 hours and a maximum of 24 hours. After drying, the cover flap is closed and the 
card is placed in a low gas-permeability plastic bag with a humidity indicator and desiccant pack 
to reduce humidity. The card is stored at -20°C or -80°C until analysis.  
 
Figure 20. Whatman #903 protein saver card with dried blood spots used for measuring TFV-DP 
 
The whole blood remaining in the K2 EDTA tube after obtaining DBS is inverted several 
times then centrifuged at 1200g for 10 minutes at 4°C. 1.5mL of plasma is then transferred to a 
labeled microcentrifuge tube and stored at -80°C until analysis.  
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Blood remaining in the K2 EDTA tube is used for PBMC isolation as described in the 
following steps: 
A) Ficoll Spin 
 
1) Label a 15 ml centrifuge tube and add 4 ml of lymphocyte separation medium (LSM). 
2) Label a second 15 ml centrifuge tube that will be used for collection of PBMC. 
3) Estimate the volume of remaining blood after obtaining plasma. 
4) Add approximately equal volume of phosphate buffered saline (PBS) to the blood tube and cap. 
5) Invert gently several times to mix the blood sample. 
6) Load the blood samples slowly, layering the blood onto the LSM from step 1. 
7) Centrifuge at approximately 1800 x g for 20 minutes at ambient with no brake or very low brake 
setting on the centrifuge. 
8) After spin, a PBMC buffy layer should be visible just above the LSM layer.  Carefully remove the 
PBMC buffy layer into the corresponding labeled 15mL centrifuge tube labeled in step 2 using a 
plastic disposable pipet.  
9) Discard the blood collection tube appropriately, consistent with local regulation. 
 
B) PBMC  Process 
 
1) Add a volume of PBS equal to the total volume contained in the tube (from step 8) to aid in washing 
cells. 
2) Mix gently by inversion and spin at 4°C (±1°C) at 400xg for 10 minutes. 
3) Carefully remove/discard most supernatant of the PBS without disturbing the cell pellet. 
4) Add 2 ml of ACK lysing buffer and gently re-suspend the cells.  Incubate at room Temp for 5 minutes 
for RBC lysis. 
5) Add 4mL of PBS buffer to dilute the ACK lysing buffer. 
6) Spin the 15mL centrifuge tube for 10 minutes at 400xg and 4°C (±1°C) to pellet the cells. 
7) Carefully remove/discard PBS supernatant without disturbing the cell pellet. 
8) Add 5 ml of PBS and gently suspend the cells with pipet and record the exact volume of the 
suspension (±0.1mL). 
9) Determine an accurate PBMC cell count with a hemocytometer. (Our lab uses the Countess automated 
cell counter to perform PBMC cell counting.) 
 
Note: during cell counting, cell samples should be kept on crushed ice.  
 
10) Spin tube for 10 minutes at 400xg and 4°C (±1°C) to pellet the cells.  Remove and discard all but 1ml 
of the remaining supernatant (PBS).  Suspend the cells and place into a 2.0 ml microcentrifuge tube. 
Wash the original tube w/0.5 ml PBS and transfer the wash to the same 2.0 ml microcentrifuge tube to 
ensure minimum possible cell loss.  
11) Spin cells for 5 minutes at 400xg in microfuge at 4°C (±1°C) if temperature control is available for 
microfuge, if unavailable the spin may be done at ambient (18-25°C).  Remove ALL OF THE 
SUPERNATANT (PBS) without disturbing the pellet.   
12) Suspend the cells in 500µL of COLD (4°C or colder) 70% methanol/30% water.   
13) Lyse cells by pipetting several times to ensure the cell pellet has been disrupted. 




TFV-DP Quantification in PBMCs 
Waters QMA strong anion exchange solid-phase extraction (SPE) cartridges were used to 
separate tenofovir, TFV-MP, and TFV-DP fractions, with each fraction collected into a separate 
tube. This extraction included cartridge preparation (1 × 2.0 ml UP water, 1 × 1.5 ml 1 M KCl, 
and 1 × 2 ml 5 mM KCl), followed by sample addition and separation of the anabolites using a 
potassium chloride concentration gradient (MP, 5 ml × 75 mM KCl; DP, 7 ml × 90 mM KCl; TP, 
2 ml × 1 M KCl). Each fraction was dephosphorylated to parent tenofovir using acid 
phosphatase, which was allowed to incubate for 30 min at 37°C. Following dephosphorylation, 
internal standard (20 μl) was added to all samples except the blank without internal standard 
sample followed by the addition of working standard solutions (20 μl) to the extracted blank 
cellular lysate samples designated for standard samples. The Strata-X SPE column was prepared 
with three washes (1 × 2.0 ml methanol and 2 × 2.0 ml 15mM ammonium acetate) followed by 
sample application, which consisted of the entire fraction collected during the strong anion 
exchange solid phase extraction. Cartridges were subsequently washed (1 × 2.0 ml ammonium 
acetate), followed by cartridge drying. The second and final wash was with 0.5mL 
dichloromethane followed by sample drying. Analytes were then eluted (2 × 0.5 ml methanol). 
Samples were dried at 40°C for 25 min under nitrogen in a Zymark TurboVap (Zymark Corp., 
Hopkinton, MA, USA) and were then reconstituted using 100 μl ultrapure water. The sample was 
vortex mixed and transferred to a 150-μl low volume insert, and 30 μl was injected onto the 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. 
Samples were analyzed by LC-MS/MS. The high-pressure liquid chromatography 
(HPLC) system consisted of a Thermo Scientific Accela pump (San Jose, CA, USA), an 
Eppendorf CH-30/CH-50 heater/controller (Hauppauge, NY, USA), and a CTC Analytics HTC 
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PAL autosampler (Zwingen, Switzerland) equipped with a 100-μl sample syringe and a 50-μl 
PEEK sample loop. A Thermo Scientific TSQ Vantage triple quadrupole mass spectrometer 
coupled with a HESI II probe was used for detection. Data were captured with Xcalibur 2.2 
SP1.48 software.  
A Synergi Polar RP 2.5 μM, 100A, 2.0 x 100mm analytical column (Phenomenex, 
Torrance, CA, USA) was used for chromatographic separations. The mobile phase consisted of 
2% acetonitrile and 0.1% formic acid in ultrapure water at an isocratic flow of 250 μl/min. The 
column was maintained at 40°C, and the sample temperature was maintained at 20°C. Each 
injection was followed by a strong and weak needle wash (0.1% formic acid in 50% acetonitrile–
50% ultrapure water and 10% methanol–90% ultrapure water, respectively). 
The MS/MS source was operated in positive mode, with the detector in simultaneous 
reaction monitoring (SRM) ionization mode. The spray voltage was 3500 V, vaporizer 
temperature was 380°C, sheath gas (nitrogen) was 40 arbitrary units, auxiliary gas (nitrogen) was 
5 arbitrary units, capillary temperature was 225°C, chromatography filter peak width was 20.0 s, 
collision gas (argon) pressure was 1.0 millitorr, S lens was 46 V, experiment type SRM (HSRM) 
peak width Q1: 0.2 FWHM, Q3: 0.7 FWHM, scan width was 0.002 m/z, scan time was 0.600 s, 
and centroid data type was collected. The run time was 8 min. Parent/product transitions were 
288.044 to 176.108 for tenofovir and 293.044 to 181.108 for tenofovir internal standard.  The 
lower limit of quantification was 2.5 femtomoles per sample. The quantifiable linear range for 
tenofovir diphosphate was 2.5–2000 fmol per sample.  
TFV-DP Quantification in DBS 
Dried blood spots contain a significant amount of red blood cells. A method for 
measuring TFV-DP in DBS has been developed and validated in our laboratory and used in 
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multiple clinical studies of TDF and emtricitabine for HIV prevention. The long half-life of 
TFV-DP in DBS (17 days) allows for measuring long-term adherence or cumulative drug dosing, 
similar to a hemoglobin A1C for assessing glucose control. A 3mm punch is extracted into a 





TFV-DP IN DBS IN THOSE SWITCHING FROM TDF TO TAF 
TFV-DP Concentrations (fmol/punch) in DBS in the Participants in ACTG 5327 that Switched 
from TDF to TAF. A 3mm punch was assayed. Values in Yellow Reflect Those Excluded from 
Analyses Based on Site/Participant Reported Date for Switch from TDF to TAF. 
Study Visit Participant 1 Participant 2 Participant 3 
0.00 Ent 2481.332708 2211.298 2310.055 
Weeks After Initiating LDV/SOF 
1.00 Wk 3773.90323 4531.552 6941.239 
2.00 Wk 12572.28807 6937.177 7175.295 
4.00 Wk 13225.14693 11887.74 4086.988 
8.00 Wk 17981.21357 19245.99 1302.209 
After Stopping LDV/SOF 
2.00 Pos 8313.370529 10612.09 924.0367 
4.00 Pos 5772.855628 5357.056 322.7964 
8.00 Pos 3219.148538 3691.869 185.925 
12.00 Pos no sample 2594.96 203.7619 
 
 
